O-heyteroaryl, o-alkylheteroaryl, o-alkenylheteroaryl and o-alkynylheteroaryl macrolides
12 claims: 11 independent, 1 dependent
- 1IŠRADIMO APIBRĖŽTIS 1. Junginys, turintis formulę I:arba jo farmaciniu požiūriu priimtina druska, kurioje R 1 yra: (1) heteroarilas;
- 2(2) pakeistas heteroarilas, kuriame yra pakaitai X, Y ir Z;
- 3(3) heteroaril-C 1 _ 10 -alkilas;
- 4(4) pakeistas heteroaril-C 1 _ 10 -alkiias, kuriame heteroarilo grupėje yra pakaitai X, Y ir Z ir alkilo fragmentas gali būti pakeistas vienu arba daugiau pakaitų, kurie parinkti iš:(a) hidroksilo, (b) oksoc/rupės, (c) C^g-alkoksigrupės, UI! IBIU: I! .1 II 11:11 1.1Λ .I. 225 (d) aril-C 1 _ 3 -alkoksigrupės, (e) pakeistos arilC 1 _ 3 -alkoksigrupės, kurioje arilo grupėje yra pakaitai X, Y ir Z, (f) nepakeista arba pakeista ariloksigrupė, kurioje arilo grupėje yra pakaitai X, Y ir Z, (g) -OCO-C^g-aikilas, (h) -NR R , kai R ir R' nepriklausomai vienas nuo kito yra pasirinktinai (i) vandenilis, (ii) pakeistas arba nepakeistas C 1 . 10 -alkilas, turintis vieną ar daugiau pakaitų, tarp kurių pasirinktinai : (a 1 ) arilas, nepakeistas arba pakeistas X, Y, Z, (b 1 ) heteroarilas, nepakeistas arba pakeistas X, Y, Z, (C) -OH, (d') C^g-aikoksigrupė, (e') -CO 2 H, (f') -CO 2 -C 1 _ 6 -alkilas, (g') -C 3 .. 7 -cikloalkilas ir (h') -OR 11 , (iii) C 3 _ 10 -alkenilas, nepakeistas arba pakeistas vienu ar keliais pakaitais, tarp kurių pasirinktinai: (a') arilas, nepakeistas arba pakeistas X, Y, Z, (b') heteroarilas, nepakeistas arba pakeistas X, Y, Z, (c') -OH, (d' ) Cg.g-alkoksigrupė, UBUI. J. I 226 (e') -CO 2 H, (f) -CO 2 -C 1 _ 6 -alkilas, (g') -C 3 _ 7 -cikloalkilas ir (h') -OR 11 , 6 7 (iv) arba kai R , R ir N atomas, prie kurio jie prijungti, sudaro nepakeistą arba pakeistą 3-7 narių heterocikliną žiedą, kurio sudėtyje gali būti vienas arba du papildomi heteroatomai nepriklausomai vienas nuo kito parinkti iš grupės, sudarytos iš O, S(O) p , NR 14 , kai R 14 yra vandenilis arba C 1 _ 6 -alkilas, nepakeistas arba pakeistas fenilu, p lygus 0, 1 arba 2, (i) -NR 6 CO-C 1 _ 6 -alkil-R 7 , kuriame R 6 ir R 7 reikšmės apibrėžtos aukščiau, (j) -NR 6 CO 2 -C 1 _ 6 -alkil-R 7 , (k) -NR 6 CO-NR 6 R 7 , (l) -oconr 6 r 7 , (m) -COOR 6 , (n) -CHO, (o) arilas, (p) pakeistas arilas, kuriame yra pakaitai X, Y ir Z, (q) -OR 11 , ir (r) -S (O) p -C 1 _ 6 -alkilas;
- 5(5) heteroaril-C 1 _ 10 -alkilas, kuriame vienas arba keli anglies atomai pakeisti grupe pasirinktina iš:-NR 6 -, -0-, -S(O) p -, -CO 2 , -O 2 C-, -CONR 6 -, -NR 6 CO-, -NR 6 CONR 7 -;
- 6(6) pakeistas heteroaril-C 1 _ 10 -alkilas, kuriame vienas arba keli alkiliniai anglies atomai pakeisti grupe pasirinktinai iš:-NR 6 -, -0-, -S(O) p -, -CO 2 , -0 2 C-, -CONR 6 -, -NR b CO, -NR 6 CONR 7 -, heteroarilo grupė ι ικιι ιιι.ιι ι ι ι χι ω n ι 227 pakeista X, Y ir Z, o alkilo pakeista vienu arba keliais rinktinai, tarp jų: grupė gali būti pakaitais pasi(a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (D (m) (n) (o) (P) (g) (r)
- 7(7)
- 8(8) hidroksilas, oksogrupė, C 1 _ 6 -alkoksigrupė, aril-C 1 _ 3 -alkoksigrupė, pakeista arilC 1 _ 3 -alkoksigrupė, kurioje arilo grupėje yra pakaitai X, Y ir Z, nepakeista arba pakeista ariloksigrupė, kurioje arilo grupėje yra pakaitai X, Y ir Z, -OCO-C^g-alkilas, -NR 6 R 7 , kai R 6 ir R 7 turi aukščiau apibrėžtas reikšmes, -NR 6 CO-C 1 _ 6 -alkil-R 7 , -NR 6 CO 2 -C 1 _ 6 -alkil-R 7 , -nr 6 co-nr s r 7 , -oconr 6 r 7 , -COOR 6 , -CHO, arilas, pakeistas arilas, kuriame yra pakaitai X, Y ir Z, -OR 11 , ir -S (O) p-Cį-g-alkilas; heteroaril-C 3 . 10 -alkenilas, kuriame alkenilas turi nuo vienos iki keturių dvigubų jungčių; heteroaril-C 3 _ 10 -alkenilas, kuriame alkenilas turi nuo vienos iki keturių dvigubų jungčių ir kai vienas arba keli alkiliniai anglies atomai pakeisti I U:! I 228 grupe pasirinktinai iš: -NR 0 -, -0-, -S(O) p -, -CO 2 , -O 2 C-, -CONR 6 -, -NR S CO-, -NR 6 CONR 7 -;
- 9(9) pakeistas heteroaril-C 3 _ 10 -alkenilas, kuriame alkenilas turi nuo vienos iki keturių dvigubų jungčių ir kai vienas arba keli alkiliniai anglies atomai gali būti pakeisti grupe pasirinktinai iš:-NR 6 -, -0-, -S (O) p -, -CO 2 , -O 2 C-, -CONR 6 -, -NR 6 CO-, -NR°CONR 7 -, heteroarilinė grupė pakeista X, Y ir Z, o alkilo grupė gali būti pakeista vienu arba keliais pakaitais pasirinktinai, tarp jų: (a) hidroksidas, (b) oksogrupė, (c) Cj.g-alkoksigrupė, (d) aril-C 1 _ 3 -alkoksigrupė, (e) pakeista arilC 1 _ 3 -alkoksigrupė, kurioje arilo gruėje yra pakaitai X, Y ir Z, (f) nepakeista arba pakeista ariloksigrupė, kurioje arilo grupėje yra pakaitai X, Y ir Z, (g) -OCO-Ci-g-alkilas, (h) -NR S R 7 , kuriame R 6 ir R 7 reikšmės apibrėžtos aukščiau, (i) -NR°CO-C 1 _g-alkilas, kuriame R 6 reikšmės apibrėžtos aukščiau, (j) -NR 6 CO 2 -C 1 _ 6 -alkilas, (k) -nr 6 co-nr 6 r 7 , (l) -OCONR 6 R 7 , (m) -COOR 6 , (n) -CHO, (o) arilas, (p) pakeistas arilas, kuriame yra pakaitai X, Y ir Z, (q) -OR 11 , ir I III II I uiu .i! ι .ι ..ι;· υι.ι 229 (r) -S (O) p-C^g-alkilas;R 2 gali būti pasirinktinai: iui.ii iiuui ii ι i jnui 230 (k) -CHO, (i) fenilas, (m) pakeistas fenilas, turintis pakaitus X, Y ir Z, (n) 1- arba 2-naftilas, (c) pakeistas 1- arba 2-naftilas, turintis pakaitus X, Y, Z, (p) bifenilas, (q) pakeistas bifenilas, turintis pakaitus X, Y, Z, (r) -OR 11 , ir (s) S (O) p-Ci.g-alkilas;
- 10(11) C 3 _ 10 -alkenilas;
- 11(12) pakeistas C 3 _ 10 -alkenilas, turintis pasirinktinai vieną ar daugiau pakaitų, tarp jų:(a) hidroksilas, (b) oksogrupė, (c) C^g-alkoksigrupe, (d) fenil-C 1 _ 3 -alkoksigrupė, (e) pakeista fenil-C : . 3 -alkoksigrupė, kurioje fenilo grupėje yra pakaitai X, Y ir Z, (f) -OCO-C^g-alkiias, (g) -NR 6 R', kuriame R 6 ir R 7 turi aukščiau apibrėžtas reikšmes, (h) -NR 6 CO-C 1 _ 6 -alkilas, kuriame R 6 reikšmės apibrėžtos aukščiau, (i) -COOR 6 , kuriame R 6 reikšmės apibrėžtos aukščiau, (j) -CHO, (k) fenilas, (l) pakeistas fenilas, turintis pakaitus X, Y ir Z, (m) 1- arba 2-naftilas, I III t ! LKBIIK Ii I II ūmini 231 I.«11 m .ii .i i .imu !. 232 (q) -OR 11 , ir (r) -S (0) p-C^g-alkilas;
- 12(15) -R 11 ; R 3 yra vandenilis, hidroksilas, OR 11 arba C^g-alkoksigrupė; R 4 yra vandenilis arba R 3 ir R 4 kartu sudaro dvigubą jungtį; R 5 yra metilas, etilas, ptopilas arba alilas; R 10 yra vandenilis, hidroksigrupė, OR 11 arba fluoras; R 1 pasirinktinai gali būti :(a) -PO(OH)O M + , kai M + yra teigiamo krūvio neorganinis arba organinis jonas, (b) -SO 3 'M + , (c) -CO(CH 2 )qCO 2 M + , kai q lygus 1-3, ir (d) -CO-C 1 _ 6 -alkil-NR 6 R 7 , kuriame R 6 ir R 7 turi aukščiau apibrėžtas reikšmes ir alkilinę grupė nepakeista arba pakeista vienu arba keliais pakaitais pasirinktinai, tarp jų: (i) hidroksilas, (ii) C 1 . e -alkoksigrupė, (iii) -NR 16 R 17 , kuriame R 16 ir R 17 nepriklausomai vienas nuo kito gali būti pasirinktinai: (a') vandenilis, ir (b ' ) C 3 _ 6 -alkiias, (iv) -COOR 6 , kuriame R 6 reikšmės apibrėžtos aukščiau, (v) fenilas, (vi) pakeistas fenilas, turintis pakaitus X, Y ir Z, ιιιιικ Ji i i .iLig ui 233 (vii) heteroarilas, (viii) -SH, ir (ix) -S-Cį-g-alkilas ;W yra O arba (H, OH) ;X, Y ir Z nepriklausomai vienas nuo kito yra pasirinktinai : (a) vandenilis, (b) C^jo-alkilas, nepakeistas arba pakeistas vienu ar keliais pakaitais, tarp kurių pasirinktinai: (i) arilas, (ii) pakeistas arilas, turintis pakaitus X', Y' ir Z', (iii) heteroarilas, (iv) pakeistas heteroarilas, turintis pakaitus X', Y' ir Z ' , (v) nepakeistas arba pakeistas ariloksiradikalas, turintis arilo grupėje pakaitus X', Y' ir Z', (vi) -OR 6 , (vii) -OR 11 , (viii) -OCOR S , (ix) -OCO 2 R 6 , (x) -NR S R 7 , (xi) -CHO, (xii) -NR 6 CO-C : _ 6 -alkil-R 7 , (xiii) -NR 6 CO 2 -C ,_ 6 -alkil-R 7 , (xiv) -NR 6 CONR 6 R ? , (XV) -oconr 5 r\ (xvi) -CONR 6 R 7 , ιιιυι 234 (c) y.^-alkilas, kai vienas arba keli alkiliniai anglies atomai pakeisti grupe pasirinktinai iš: -NR 6 -, -0-, -S (O) p -, -CO 2 , -O 2 C-, -CONR 6 -, -NR 6 CO-, -NR 6 CONR 7 -, -CO-, -CH(OH)-, alkenilas arba alkinilas ir alkilas gali būti nepakeistas arba pakeistas vienu ar keliais pakaitais pasirinktinai, tarp jų: I.UIIK !;.1 II Jhll UI· 235 (i) -SR 8 , kai R 8 vandenilis, C^g-alkilas, trifluormetilas arba fenilas, (j) -SOR 8 , (k) -SO 2 R 8 , (l) -conr 6 r 7 , (m) R 9 O(CH 2 ) m -, kai R 9 yra vandenilis, C^g-alkilas, hidroksi-C 2 _ 3 -alkilas, -CF 3 , fenilas, R 11 arba naftilas ir m lygu 0, 1, 2 arba 3, (n) -CH (OR 12 ) (OR 13 ) , kai R 12 ir R 13 yra C 1 _ 3 -alkilas arba kartu sudaro etilinį ar propilinį tiltelį, (o) R 9 COO (CH 2 ) m ~, kuriame R 9 ir m reikšmės apibrėžtos aukščiau, (p) R 9 OCO (CH 2 ) n,-, kuriame R 9 ir m reikšmės apibrėžtos aukščiau, ir (q) -R 11 ;arba bet kurie du iš X, Y, Z gali būti sujungti norint sudaryti sotų žiedą, turintį 5, 6 arba 7 atomus, tarp šio žiedo atomų yra 1 arba 2 deguonies atomai, likusieji atomai yra anglies, X', Y' ir Z' nepriklausomai vienas nuo kito yra pasirinktinai : (a) vandenilis, (b) C^-alkilas, (c) C 2 _ 6 -alkenilas, (d) halogenas, 6 7 6 7 (e) (CH 2 ) m -NRR , kuriame R , R ir m reikšmės apibrėžtos aukščiau, (f) -CN, (g) -cho, imu . i i i.mi.ui 236 brėžtos aukščiau, J 1 (o) R CO(CH 2 ) m -, kuriame R ir m reikšmės apibrėžtos aukščiau, II 9 9 (p) R CO(CH 2 ) m -, kuriame R ir m reikšmės apibrėžtos aukščiau, ir (g) -R 11 ;n yra 1 arba 2. 2. Junginys pagal 1 punktą, besiskiriantis tuo, kad jame absoliuti konfigūracija Formulėje I yra apibrėžta Formule III: III ιι·!ΐ,ιι, .. I 1 ΙίΙΙΙΙ.';,;! LT 3533 Β 237 3. Junginys pagal 1 punktą, besiskiriantis tuo, kad jame heteroarilas yra pasirenkamas iš grupės, i, kurios sudėti, įeina: (Pirimidinas) (Pirazinas) lllll 238 X (Izochinolinas) X (Chinoksalinas) kai Q yra -N(X)-, -O arba -S-. 4. Junginys pagal 3 punktą, besiskiriantis tuo, kad jame heteroarilas yra parenkamas iš grupės, į kurios sudėtį įeina: I «1,1 U-l ιιι» m ·;Ί 1 .11 EB [,! . 239 MISI lllllllli I! .III lt I litui, :i 1.1 i 240 kuriame X reikšmės apibrėžtos 1 punkte i ui ai 241 5. Junginys pagal 1 punktą, besiskiriantis tuo, kad heteroarilas yra: R 2 yra pasirinktinai: (1) vandenilis, (2) metilas, (3) etilas, (4) propilas, (5) alilas, (6) R 11 , (7) -C 2 - 3 alkil-OH;ir (8) C 2 _ 3 alkil--OR 11 ;R 3 yra pasirinktinai: (1) vandenilis, (2) hidroksigrupė, (3) OR 11 , arba R 3 ir R 4 kartu sudaro dvigubą jungtį;R 10 yra vandenilis, hidroksigrupė, fluoras arba OR 11 ;W yra 0;ir n lygu 2. llll 11111«! JI Iii II IJIIUII .1 11,1 242 6. Junginys, kuris parinktas iš grupės, kurioje yra: 17-Eti1-1,14-dihidroksi-12-[ 2'-(4''-(2-furanil)metoksi3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(2-furanil)metoksi3' '-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'- (4' '-hidroksi-3' '-(2furanil)-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l,14-dihidroksi-12-[ 2' -(4' '-(2-tiofen)-metoksi3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2' -(4' '-(2-tiofen)-metoksi3' '-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4' '-(3-tiofen)-metoksi3' '-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-hidroksi-3''-(2tiofen)-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa~4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;1 111 ιΝ Ιλ·Ι· '1 Ί II. .11111.111 243 17-Etil-l,14-dihidroksi~12-[ 2'-(4''-hidroksi-3'’ — (3 — tiofen)-metoksicikloheksil)-1'-metilvinil] -23,25-dime toksi-13,19,21,27-tetrametii-ll,28-dioksa~4-azatricikio-[ 22.3.1. O 4,9 ] oktakoz-lS-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2’-(4’(2-tiofen)oksi-3’’metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-i1,28-dioksa-4-azatriciklo [ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2’—(4''-(2-benzotienil)oksi-3 ' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12—[ 2'-(4''-(5-indolil)oksi3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2’—(4''-(5-indolil)oksi3' '-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2 , 3,10,16-tetraonas;17-Eti1-1,14,20-trihidroksi-12-[ 2'-(4''-(5-indolil)oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,20-dihidroksi-12-[ 2' — (4’'-(5-indolil)oksi3''-metoksicikloheksil)-1'-metilvinil]-23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l-hidroksi-12-[ 2'-(4''-(5-indolil)oksi-3''metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksiI III I Ullllllll .11 III II Lllll!. I 1..I.I 244 13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2' — (4’ '-(5-indolil)oksi3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2 ' - (4 ''-(5-indolil)oksi3''-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14,20-trihidroksi-12-[ 2'- (4' '-(5-indolil)oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l 3, 19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,20-dihidroksi-12-[ 2'-(4''-(5-indolil)oksi3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3, 10, 16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'- (4' '-(5-indolil)oksi3' '-etoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2, 3,10, 16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''-(5-indolil)oksi3' '-etoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Alil-l-hidroksi-12-[ 2'- (4 ' '-(5-indolil)oksi-3''metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-ll,2S-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;1 Illi »J 245 17-Eti1-1,14-dihidroksi-12-[ 2 ' - (4 ' '-(l-N-metil-5indolil)-oksi-3' '-metoksicikloheksil)-1’-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2, 3,10, 16-tetraonas;17-Etii-l,14-dihidroksi-12-[ 2'-(4''-(l-N-metil-5-indolil)-oksi-3’ '-hidroksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l,14,20-trihidroksi-12-[ 2'-(4' l-N-metil-5indoIii)-oksi-3' '-metoksicikloheksil)-!'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Eti1-1,14,20-trihidroksi-12-[ 2'-(4''-(l-N-metil-5indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa~4azatrici klo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l,20-dihidroksi-12-[ 2'- (4' '-(l-N-metil-5-indolil)-oksi-3 ' '-metoksicikloheksil·)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,2 8-dioksa-4-azatriciklo-[ 22'. 3.1. O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l,20-dihidroksi-12-[ 2'-(4' '-(l-N-metil-5-indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'- (4' '-(l-N-metil-5-indo1i1)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25ιιιι ΙΙΙΙΙΜΙΙ! I! ,ΙΙί ,11 I„H I IJ J 246 dimetoksi-13,19,21,27-tetrametil-ll,2 8-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14,2 0-trihidroksi-12-[ 2’- (4 ' '-(l-N-metil-5indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3, 10, 16-tetraonas;17-Ali1-1,20-dihidroksi-12-[ 2’-(4''-(l-N-metil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l-hidroksi-12-[ 2’—(4''-(l-N-metil-5-indolil)oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.0 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Eti1-1,14-dihidroksi-12-[ 2'-(4''-(l-N-metil-5-indolil)-oksi-3' '-etoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21 ,.27-tetrametil-l 1,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Ali1-1,14-dihidroksi-12-[ 2'- (4' '-(l-N-metil-5-indolil)-oksi-3''-etoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2' -(4' '-(l-N-etil-5-indo1i1)-oksi-3' '-etoksicikloheksil)-1'-metilvinil] -23,2 5dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l-hidroksi-12-[ 2'-(4''-(l-N-etil-5-indolil)oksi-3' '-metoksicikloheksil)-1'-metilvinil] -2 3,2 5-dime1 Ml JI J UHIKI JI .1 1 I III Ll·· J! 247 toksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2, 3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2’-(4’'-(l-N-metil-5-indolil)-oksi-3''-aliloksicikloheksil)-1'-metilvinil]-23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3, 10, 16-tetraonas;17-Etil-l-hidroksi-12-[ 2'-(4''-(l-N-metil-5-indolil)oksi-3''-aliloksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2, 3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(1-N-metii-5-indolil) -oksi-3''-n-propiloksicikloheksil)-1'-metilvinil] 23.25- dimetoksi-13,19,21,27-tetrametil-ll, 28-dioksa-4azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l-hidroksi-12-[ 2’-(4''-(l-N-metil-5-indolil)oksi-3' '-n-propiloksicikloheksil)-1'-metilvinil]-23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(1-N-metil-5-indolil)-oksi-3''-i-propiloksicikloheksil)-1'-metilvinil] 23.25- dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.0 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4'’-(l-N-etil-5-indo111)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14,20-trihidroksi-12-[ 2'- (4''-(l-N-etil-5indoIii)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] ιιιι IUIUK L! ,11 11 J JIUIj , I 248 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10, 16-tetraonas ;17-Etil-l,2 0-dihidroksi-12-[ 2 ’ — (4 ’'-(l-N-etil-5-indolil)-oksi-3 ' '-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-etil-5-indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] -2 3, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2, 3,10, 16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-etil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14,20-trihidroksi-12-[ 2'-(4''-(l-N-etil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.0 4 ' 9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Alil-l,20-dihidroksi-12-[ 2’—(4’'-(l-N-etil-5-indolil) -oksi-3 ' '-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Ali1-1,14-dihidroksi-12-[ 2'- (4''-(l-N-etil-5-indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil]-23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l-hidroksi-12-[ 2'- (4''- (l-N-etil-5-indolil)-oksi-3 ' '-metoksicikloheksil)-1'-metilvinil] -23,25-dime1 IIU 3) ŪMUI ·!;Ί 1 DU D'I. 249 toksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3, 10, 16-tetraonas;17-Alil-l-hidroksi-12-[ 2’-(4'(1-N-etil-5-indolii)oksi-3' '-metoksicikloheksil)-1'-metilvinil] -2 3,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2’ — (4' '-(1-N-etil-5-indolil)-oksi-3' '-etoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-l 3, 19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-propil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l,14,20-trihidroksi-12-[ 2'-(4''-(l-N-propil-5indolii)-oksi-3' '-metoksicikloheksil)-1’-metilvinil] 23,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,20-dihidroksi-12-[ 2'-(4' '-(l-N-propil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-l 3, 19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2, 3, 10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-propil-5-indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-l3,19,21,27-tetrametil-ll, 28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l, 14,20-trihidroksi--12-[ 2 ' - (4 ' ' - (1 -N-propil-5indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4I 1)11 IUIMI IS iii J UB.IIIJ 250 azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-1,20-dihidroksi-12-[ 2’-(4'’-(l-N-propil-5-indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-l3,19,21,27-tetrametil-ll,18-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-propil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.0 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14,20-trihidroksi-12-[ 2'-(4''-(l-N-propil-5indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] 2 3,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Alil-l,20-dihidroksi-12-[ 2'-(4'’-(l-N-propil-5-indolil) -oksi-3’'-metoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-propil-5-indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3, 10, 16-tetraonas;17-Etil-l-hidroksi-12-[ 2'-(4''-(l-N-propil-5-indolil) oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Ali1-1-hidroksi-12-[ 2’-(4''-(l-N-propil-5-indolil) oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dii iu i UUD i;ii 1 .1 .IMI. U* 251 metoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3, 10, 16-tetraonas;17-Eti 1-1,14-dihidroksi-12-[ 2’-(4''-(l-N-propil-5-indolil)-oksi-3''-etoksicikloheksil)-1'-metilvinil] -2 3,2 5dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2, 3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2' — (4''-(l-N-propil-5-indolil)-oksi-3''-etoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Eti1-1,14-dihidroksi-12-[ 2'- (4' '- (l-N-alil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2, 3,10, 16-tetraonas;17-Etil-l,14,20-trihidroksi-12-[ 2'-(4''-(l-N-alil-5indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l,20-dihidroksi-12-[ 2'-(4’'-(l-N-alil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23, 25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-alil-5-indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14,20-trihidroksi-12-[ 2’—(4''-(l-N-alil-5-indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] -23, I III I imiaiš n iii. i UBU . 1 l ll 252 25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10, 16-tetraonas ;17-Etil-l,20-dihidroksi-12-[ 2’-(4' '-(l-N-alil-5-indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''-(L-N-alil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14,20-trihidroksi-12-[ 2'-(4’'-(l-N-alil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,20-dihidroksi-12-[ 2'-(4''-(l-N-alil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -2 3,2 5dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'- (4' '- (l-N-alil-5-indolil)-oksi-3' '-hidroksicikloheksil)-i'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2, 3,10,16-tetraonas;17-Etil-l-hidroksi-12-[ 2'-(4''-(l-N-alil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-1-hidroksi-12-[ 2 ' - (4 ' '-(l-N-alil-5-indolil)-oksi-3 ' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2, 3,10,16-tetraonas;1 »1 44 UBO I r I1U, IIIU 253 17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-alil-5-indolil)-oksi-3''-etoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''- (l-N-alil-5-indolil)-oksi-3''-etoksicikloheksil)-1'-metilvinil] -2 3,2 5dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'—(4''-(l-N-2-hidroksietil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16- tetraonas;17- Etil-l,14,20-trihidroksi-12-[ 2' — (4''-(l-N-2-hidroksietii-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametil-ll, 28dioksa-4-azatriciklo-[ 22.3.1.0 4,9 ] oktakoz-18-en-2,3,10, 16- tetraonas;17- Etil-l,20-dihidroksi-12-[ 2'—(4'’-(l-N-2-hidroksietil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametil-ll, 28dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16- tetraonas;17- Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-2-hidroksietil-5-indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametil-ll, 2 8dioksa-4-azatriciklo-[ 22.3.1.0 4 ' 9 ] oktakoz-18-en-2,3,10, 16- tetraonas;17- Eti1-1,14,20-trihidroksi-12-[ 2' -(4' '-(l-N-2-hidroksietil-5-indolil) -oksi-3''-hidroksicikloheksil)-1'-metilvinil] -23,2 5-dimetoksi-13,19,21,27-tetrametil-ll,28IIIIL , 11111«! Ji ;IL I J.JIBJ;254 dioksa-4-azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2,3,10, 16- tetraonas;17- Etil-l,2 0-dihidroksi-12-[ 2 ’ - (4 ’’ - (1-N-2-hidroksietil-5-indolil)-oksi-3’’-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3, 10,16tetraonas ;17-Alil-l,14-dihidroksi-12-[ 2’-(4’’-(1-N-2-hidroksietil-5-indolil)-oksi-3’’-metoksicikloheksil)-1’-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2,3,10,16tetraonas ;17-Alil-l,14-dihidroksi-12-[ 2’—(4’'-(1-N-hidroksietil5-indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16tetraonas ;17-Eti1-1,14-dihidroksi-12-[ 2'-(4''-(l-N-benzil-5-indoiii)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -2 3, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Eti1-1,14,20-trihidroksi-12-[ 2'- (4' '-(l-N-benzil-5indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l,20-dihidroksi-12-[ 2 ' - (4' '-(l-N-benzil-5-indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -2 3, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] ok.takoz-18-en-2,3, 10, 16-tetraonas;I 1IU ELI IUHD Ϊ: !l 1 .1!« 1,113 255 17-Etil-l,14-dihidroksi-12-[ 2'- (4 ' '-(l-N-benzil-5-indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14,20-trihidroksi-12-[ 2’-(4''-(l-N-benzil-5indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l,20-dihidroksi-12-[ 2'-(4' '-(l-N-benzil-5-indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.0 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4' '-(l-N-benzil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23, 25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,14,20-trihidroksi-12-[ 2’—(4’'-(l-N-benzil-5indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l,20-dihidroksi-12-[ 2'- (4' '- (1-N-benzi1-5-indo iii)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] -2 3, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3, 10, 16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'- (4 ' '-(l-N-benzil-5-indolil)-oksi-3''-hidroksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2, 3,10,16-tetraonas;1111 256 17-Etil-l-hidroksi-12-[ 2' — (4’'-{l-N-benzil-5-indolil)oksi-3’’-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3, 10,16-tetraonas;17-Alil-l-hidroksi-12-[ 2 1 -(4’’-(l-N-benzil-5-indolil)oksi-3' '-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-benzil-5-indolil)-oksi-3' '-etoksicikloheksil)-1'-metilvinil] -23,25dime toks i-13, 19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.0 4,9 ] oktakoz-18-en-2,3, 10,16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-benzil-5-indolil)-oksi-3''-etoksicikloheksil)-1'-metilvinil] -23,25dime toks i-13, 19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, Ιβ-t-etraonas;17-Etil-l,14-dihidroksi-12-[ 2'—(4’'-(l-N-ciklopropil-5indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2, 3,10,16-tetraonas ;17-Etil-l,14-dihidroksi-12-[ 2' — (4’ ' - (l-N-ciklopropil-5indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2, 3,10,16-tetraonas ;17-Ali1-1,14-dihidroksi-12-[ 2’ — (4’'-(l-N-ciklopropil-5indolil)-oksi-3' '-metoksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2, 3,10,16-tetraonas ;257 17-Alil-l,14-dihidroksi-12-[ 2'- (4' '-(l-N-ciklopropil-5indolil)-oksi-3' '-hidroksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas ;17-Etil-l,14-dihidroksi-12-[ 2'- (4' '-(l-N-ciklopropil-5indolil)-oksi-3' '-etoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Alil-l,14-dihidroksi-12-[ 2'-(4''-(l-N-ciklopropil-5indolil)-oksi-3' '-etoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l-hidroksi-12-[ 2'- (4''-(l-N-ciklopropil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25dime to ksi-13, 19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Alil-l-hidroksi-12-[ 2'-(4''-(l-N-ciklopropil-5-indolil)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l-hidroksi-12-[ 2'-(4' '-metoksi-N-triptofanilkarbonil-metoksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3, 10, 16tetraonas ;17-Etil-l-hidroksi-12-[ 2'-(4''-(3-indolil)etilaminokarbonil-metoksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.0 4,9 ] oktakoz-18-en-2,3, 10,16tetraonas ;lllil . IIHIIII! JI Jll III ILIIIIIJ. IU I 258 17-Etil-l,14-dihidroksi-12-[ 2'- (4' '-1-(3-hidroksipropil)-indolil-5-il)-oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametil-ll,28dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16- tetraonas;17- Etil-l,14-dihidroksi-12-[ 2'-(3''-hidroksi-4''-(1hidroksietilindol-5-il)-oksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2, 3,10,16tetraonas ;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-(1-hidroksietilindol-6-il)oksi-3''-metoksicikloheksil)-1'-metilvinil] 23,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3, 10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'- (4' '-(l-metilindol-6il)oksi-3''-metoksicikloheksil)-1'-metilvinil]-23,25dimetoksi-l 3 , 19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2’—(4’'-(1-dibenzilfosfonoksi-etilindol-5-il)oksi-3''-metoksicikloheksil)-1'metilvinil] -2 3,25-dimetoksi-l3,19,21,27-tetrametil-ll, 28-dioksa-4-azatricik.lo-[ 22.3.1.0 4,9 ] oktakoz-18-en-2,3, 10,16-tetraonas;17-Eti1-1,14-dihidroksi-12-[ 2'-(4''-(1-fosfonoksi-etilindol-5-il)oksi-3''-metoksicikloheksil)-1'-metilvinil] -2 3,25-dimetoksi-l3,19,21,27-tetrametil-ll,28-dioksa-4-azatricii lo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2, 3,10,16tetraono mcnokalio druska;17-Etil-l,14-dihidroksi-12-[ 2 1 —(4’'-(1-(N,N-dimetilgliciloksi)etilindol-5-il)oksi-3''-metoksicikloheksil)-1'I Ui ELI 259 metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametilll, 28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4' '-(1-sukciniloksietilindol-5-il)oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16- tetraonas;17- Etil-l,14-dihidroksi-12-[ 2'-(4''-(l-metil-3-fenilindolil-5-il)oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16tetraonas ;17-Etil-l,14-dihidroksi-12-[ 2'-(4' '-(l-metil-3-(2-hidroksietil)-indol-5-il)oksi-3''-metoksicikloheksil)-1' metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll, 28-dioksa-4-azatriciklo-[ 22.3.1.0 4 ' 9 ] oktakoz-18-en-2,3, 10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'- (4' '-(1,3-dimetilindol5-il)oksi-3' ’-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4 ' 9 ] oktakoz-18-en-2, 3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'- (4' '-(9'-metilkarbazol3'-ii)oksi-3''-metoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2' - (4' '- ( (2' '' '- (3'''''dietilaminopropioniloksi)etil)indol-5'''-ii)oksi-3''metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;ιιιι ΙΙΙίΙΙΙΙί Ii .III III I llllll, ,1,1,1 J 260 17-Etil-l,14-dihidroksi-12-[ 2 '- (4' '-( (2'’''- (3’''''dimetilaminopropioniloksi)etil)indol-5''’-il)oksi-3'' metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2’-(4’ '-( (2' ’ ' '-(3' ' ' ' 'aminopropioniloksi)etil)indol-5'''-ii)oksi-3''-metoksicikloheksil) -1'-metilvinil] -23,25-dimetoksi-l3,19,21, 27-tetrametil-ll, 28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2’-(4 ,, -((2’'’'-(3' ,,, 'benziloksikarbonil-2'''''-benziloksikarbonilaminopropioniloksi)etil)indol-5'’'-il)oksi-3''-metoksicikloheksil) -1'-metilvinil] -2 3,25-dimetoksi-13,19,21,27tetrametil-ll, 28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-1,14-dihidroksi-12-[ 2'-(4''-((2''''-(aspartiloksi)etil)indol-5'''-il)oksi-3''-metoksicikloheksil)1'-metilvinil] -23,25-dimetoksi-l3,19,21,27-tetrametilll, 28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4’ '-((2’'''-(1' ' ' ' 'imidazolilkarboniloksi)etil)indol-5'''-ii)oksi-3''metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-ll, 28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4''-((2''''-(l'''''piperazinkarboniloksi)etil)indol-5'''-ii)oksi-3''metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;261 17-Etil-l,14-dihidroksi-12-[ 2’-(4 IT -(l’''-(2’’’’(2 ' ' ' ' '-hidroksi)etilaminokarboniloksi)etil)indol-5'''ii)oksi-3''-metoksicikloheksil)-1'-metilvinil] -23,25dimetoksi-13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2'-(4’'- (1’'’- (2 '''’-(izopropi1aminokarboniloksi)etil)indol-5''’-il)oksi-3''-metoksicikloheksil ) -1'-metilvinil] -23,25-dimetoksi13.19.21.27- tetrametil-ll,28-dioksa-4-azhtriciklo[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l, 14-dihidroksi-12-[ 2^(4^-(1^-(2-^(1'''''-piperidinkarboniloksi)etil)indol-5'''-ii)oksi3''-metoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi13.19.21.27- tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.0 4 ' 9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l, 14-dihidroksi-12-[ 2^(4^-(1^^(2^^(11 i * ι i-morfolinkarboniloksi)etil)indol-5'''-ii)oksi3''-metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l, 14-dihidroksi-12-[ 2'-(4''-(l’'’-(2'’'’(difenilaminokarboniloksi)etil)indol-5'''-ii)oksi-3''metoksicikloheksil)-1'-metilvinil] -23,25-dimetoksi13,19,21, 27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10, 16-tetraonas;17-Etil-l, 14-dihidroksi-12-[ 2--(4^-(1^^(2^^(dietilaminokarboniloksi)etil)indol-5'''-ii)oksi-3''metoksicikloheksil)-1'-metilvinil] -23, 25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3, 10,16-tetraonas;lllll· llhlllll .11 .III II J.II1BI, I 11 262 17-Etil-l,14-dihidroksi-12-[ 2’-(4 TT -(l’’’-(2’’ ,T (metansulfoniloksietil)indol-5'''-ii)oksi-3''-metoksicikloheksil) -1'-metilvinil] -23,25-dimetoksi13,19,21,27-tetrametil-ll,28-dioksa-4-azatriciklo[ 22.3.1.O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2 '- (4' '- (1' ''- (2 ' ' ' ' azidoetil)indol-5'''-ii)oksi-3''-metoksicikloheksil)1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametilll, 28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en2,3,10,16-tetraonas;17-Etil-l,14-dihidroksi-12-[ 2 '-(4'’-(1'''-(2 ''''-aminoetil)indol-5'''-ii)oksi-3''-metoksicikloheksil)-1'metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametilll, 28-dioksa-4-azatriciklo-[ 22.3.1.O 4 ' 9 ] oktakoz-18-en2,3,10,16-tetraonas;17-Etil-l, 14-dihidroksi-12-[ 2’-(4-(l ’-t-butildimetilsililoksietoksietilindol-5'''-ii)oksi-3’'-metoksicikloheksil) -1'-metilvinil]-23,25-dimetoksi-l3,19,21, 27-tetrametil-ll, 28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz-18-en-2,3,10,16-tetraonas;17-Etil-l, 14-dihidroksi-12-[ 2^(4^-(1^ '-hidroksietoksietilindol-5''’-il)oksi-3''-metoksicikloheksil)1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametilll, 28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz-18-en2,3,10,16-tetraonas;17- Etil-l,14-dihidroksi-12-[ 2'-(3''-metoksi-4' '- (1'’'(1''''-oksoprop-3'''’-il)indol-5''’-il)oksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-11,28-dioksa-4-azatriciklo-[ 22.3.1.O 4,9 ] oktakoz18- en-2,3,10,16-tetraonas;ir i nu ii.i 1UIUI1 Ji ii lt Lili L! .11,1 263 17-Etil-l,14-dihidroksi-12-[ 2'-(3''-metoksi-4''-(1''' (1'''’-karboksiet-2''''-ii)indol-5'’'-ii)oksicikloheksil)-1'-metilvinil] -23,25-dimetoksi-13,19,21,27-tetrametil-ll, 28-dioksa-4-azatriciklo-[ 22.3.1. O 4,9 ] oktakoz5 18-en-2,3,10,16-tetraonas;arba jų farmaciniu požiūriu priimtina druska. 7. Farmacinė kompozicija, besiskirianti 10 tuo, kad ą jos sudėtą ąeina farmacinis nešiklis ir terapiškai efektyvus kiekis junginio pagal 1 punktą. 8. Junginio pagal 1 punktą panaudojimas gaminti vaistus, kurie skirti imunoreguliacinių sutrikimų gydymui. 9. Junginio pagal 1 punktą panaudojimas gaminti vaistus, kurie skirti atsparumo transplantacijai gydymui. 10. Junginio pagal 1 punktą panaudojimas gaminti vais20 tus, kurie skirti uždegiminių ir hiperproliferatyvinių odos susirgimų gydymui arba ant odos pasireiškiančių su imunine sistema susijusių susirgimų gydymui.
Independent claims12
2,098 paragraphs in 182 sections, as filed
The present invention describes Ο-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylacrolides useful in the treatment of mammals for autoimmune diseases (such as juvenile diabetes mellitus, multiple sclerosis and rheumatoid arthritis), immunodepression, to prevent rejection of transplanted foreign organs (for example, bone marrow transplantation, heart and xenograft transplantation), also useful in the treatment of locally inflammatory and hyperproliferative skin conditions and skin-related immune-related disorders (such as psoriasis, atopic dermatitis, contact dermatitis, and other eczema dermatitis, seborrheic dermatitis, lichen erythema, vesicular, bullous, , urticaria, angioedema, angina, erythema, cutaneous euzinophilia, blistering alopecia, male alopecia, senile alopecia, reversible obstructive airway disease, particularly asthma, alopecia, lymph and blood vessel inflammation, cytomegalovirus infection, multiple drug resistance, idiopathic thrombocytopenic pink rash, Behcet syndrome, conjunctivitis, Crohn's disease, Mooren's ulcer, uveitis lesion associated with ischemic disease. In addition, some of the compounds of the present invention may have antagonistic properties and may therefore be adapted to eliminate the activity of other immunosuppressive agents and / or to reduce their toxicity.
More particularly, the present invention describes compounds of the general formula I:
I II I I I I I
<img file="LT3533B_D0001.tif" />
in which R<sub>1F</sub> R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>10</sub>, W and n are defined below.
The present invention also describes a pharmaceutical composition containing the compounds and a method of using these compounds and other agents for the treatment and prophylaxis of certain disorders, disorders, diseases and conditions.
Fijisawa United States, European and Japanese Patents and Applications (U.S. Pat. Nos. 4, 894, 366, 1990, EPO 0, 184, 162, and PBJ Nos. 63-17884) and publications (J. Am.
Chem. Soc., 1987, 109, 5031 ir J Antibiotics 1987, £0
1249) 17-allyl-1, 14-dihydroxy-12- [2 '- (4' 'hydroxy-3' '- methoxy-cyclohexyl) -1'-methylvinyl] -23,
25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22. 3. 1. O<sup>4,9</sup>] Oktakoz 18 en 2, 3, 10, 16tetraoną (FR-900 506), (CF-506), (The 679, 934) with 17 ethyl,
14-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- methoxycyclohexyl) -1' -methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27tetramethyl-1,11, 28-dioxa- 4-azatricyclo- [22. 3. 1.-0<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone (FR-900520) 'and related compounds which are the starting materials for the synthesis of the described compounds. Synthesis of said starting material (FR-900506) has been recently described (J. Am. Chem. Soc., 1989, iii, 1157). Sandoz's European Patent Application (EPO No. 0 356 399) describes stereoisomers FR-900506 and their derivatives in position 17. Fison
I
<td>firms</td><td>in applications</td><td>3 European</td><td>and</td><td>WIPG patents</td><td>(EPO</td>
<td>No. 0</td><td>323,042) and</td><td colspan="2">WO 89/05304)</td><td>various are described</td><td>FR-</td>
<td> 900506</td><td>FR-900520 ir</td><td>similar</td><td colspan="3">compounds. Sandoz pads-</td>
This European Patent (EPO 0 437 680) describes chlorine, bromine, iodine and azide derivatives of FR900506, FR-900520 and the like. Merck's European Patent Application (EPO No. 0 428 365) describes various amino acids of FR-900506, FR900520 and similar compounds. Fujisawa's patent application (GB 2 245 891-A) describes various derivatives of FR-900506 having a heterocyclic group.
U.S. Pat. No. 4,929,611, 1990, U.S. Pat. No. 4,956,352, 1990, and U.S. Pat. No. 45, 110, 811, 1992, describe the use of FK-506-type compounds in overcoming the body's resistance to organ transplantation. Sandoz's European Patent Application (EPO No. 0 315 978) describes the use of FR-900506 and related compounds for the topical treatment of inflammatory and hyperproliferative skin disorders and of the skin immune system. Fisons patent application WIPO patent (WO 91/04025) describes the use of various derivatives of FR-900506 for the treatment of immunodepression. Fison's patent application WIPO patent (WO 90/14826) describes the use of FR-900506 and related compounds for the treatment of immunodepression and the treatment of reversible obstructive airways diseases, particularly asthma. Fujisawa's European Patent Application (EPO 0 423 714) describes the use of FK-506 and related compounds for the treatment of baldness. various studies have demonstrated the efficacy of FK-506 in the treatment of a variety of diseases such as rheumatoid arthritis (C. Arita et al., Clinical Exp. Immunol. 82: 456-461, 1990; N. Inamura et al., Clin. Immunol. Immunopathol, 1988, 46, 82-90), initial diabetes (N. Murase, et al., Diabetes, 1990, 39, 1584-86; N. Murase, et al., Lancet, 1990, 336, 373-74), posterior uveitis, (H. Kawashima, Invest. Ophtalmoi. Vis. Sci., 29, 1265-71, 1988), liver lesions associated with ischemic disease (M. Sakr, et ai., Life Sci., 1990, 47, 687-91), alern
Gentle encephalomyelitis (K. Deguchi, et al., Brain Nerve, 1990, 42, 391-97), glomerulonephritis (J. McCauley, et al., Lancet, 1990, 335,674), systemic lupus erythematosus (K. Takabayashi, et al. al., Clin. Immunol. Immunopathol. 1989, 51, 110-117), 110-117), multiple drug resistance (M. Naito, et al., Cancer Chemother. Pharmacol. blood vessel inflammation (WO 91/17754), cytomegalovirus infection (GB no. 2 247 620A) and idiopathic thrombocytopenic rash and Basedov's disease (WO 91/19495).
Immune regulatory disorders have been shown to occur in a variety of autoimmune diseases and chronic inflammations, including systemic lupus, chronic rheumatoid arthritis, type I and type II diabetes, intestinal inflammation, biliary cirrhosis, uveitis, multiple sclerosis, and other conditions such as C; disease, ulcerative colitis, bullous bullous, sarcoidosis, psoriasis, ichthyosis, and Graves ophthalmopathy. Although the pathogenesis of each of these conditions may be different, they have in common the development of multiple autoantibodies and self-reactive lymphocytes. Such auto-reactivity may, in part, lead to the loss of homeostatic control, which allows the immune system to function normally.
Similarly, after bone marrow or organ transplantation, host lymphocytes recognize foreign tissue antigens and start producing antibodies, which triggers a rejection reaction.
One end result of the autoimmune or rejection process is tissue destruction caused by inflammatory cells and substances released by the cells. The principle of the action of anti-inflammatory agents, such as NSAIDs (non-steroidal anti-inflammatory drugs) and corticosteroids, is based on these substances.
II, or their secretion, but has no effect on the immune nature of the disease. On the other hand, cytotoxic agents, such as cyclophosphamide, act so nonspecifically that they block both the normal and autoimmune responses. In fact, patients treated with such non-specific immunosuppressants are likely to die from both the infection and the autoimmune disease they are suffering from.
Ciclosporin A, approved in 1983 by the US FDA (Food and Drug Administration), is currently a major drug used to prevent organ transplant rejection. It works by suppressing the body's immune system, which prevents it from mobilizing a huge arsenal of natural protective agents that reject the foreign protein of the transplanted organ. Although cyclosporin A is effective in combating transplant rejection, it is toxic to the kidneys and causes some undesirable side effects such as kidney problems, abnormal liver function and gastrointestinal discomfort.
Newer, safer drugs with fewer side effects are constantly being sought in this area.
Tricyclic, 23-membered macrolide immunosuppressant - tacrolimus, FR-90D506, FK-506,
Ii ii I ii ll 1.1. I
<img file="LT3533B_D0002.tif" />
(17-allyl-1,4-dihydroxy-12- [2 '- (4' '- hydroxy-3''methoxy-cyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11-28-dioxa-4-azatricyclo [22.3.1.<sup>4,9</sup>] octacozo-18-en-2, 3, 10, 16-tetraone) and similar compounds isolated and described by Tanaka, Kuroda and collaborators from Fujisawa Pharmaceutical Co. (Japan); J, Am. Chem. Soc., 1987, 109, 5031 and
U.S. Pat. No. 4,894,366, 1990), have been shown to exhibit particularly high immunosuppressive activity. U.S. Pat. No. 4,929,611 to Fujisawa, 1990, U.S. Pat.
No. 4,956,352, 1990 and U.S. Pat. No. 45 110 811, 1992) describes the use of FK-506-type compounds in overcoming organ transplant resistance. In particular, FR-900506 is reported to be 100-fold more potent than cephalosporin in suppressing the immune system in vitro (J. Antibiotics 1987, '40, '1256). In addition, these compounds are known to have local activity in the treatment of inflammatory and hyperproliferative skin disorders and skin immune responses (EPO No. 0 315 978).
Compound FK-506 and related compounds may be useful in the treatment of obstructive airways diseases, particularly asthma (WO 90/14826), male-type or senile-type alopecia (EPO No. 0 423 714), rheumatoid arthritis (C. Arita, et al. al., Clinical Exp. Immunol., 82, 1990,
II II II kk
456-461; Inamura N., et al., Clin. Immunol. Immunopathol. 1988, 46, 82-90) for initial diabetes (N. Murase, et al., Diabetes, 1990, 39, 1584-86; N. Murase, et al., Lancet, posterior uveitis, H. Kawashima, Vis. Sci. 1988,
1990, 336 373-74),
Invest. Ophtalmol
29, Liver lesions associated with ischemic disease et al., Life Sci., 47, 687-91 (1990),
1265-71), (M. Sakr, alerginio encefalomielito (K. Deguchi, et ai., Brain Nerve, 1990, 42, 391-97), glomerulonefrito (J. McCauley, et ai.,
Lancet, 1990, 335,674), systemic lupus erythematosus (K. Tabaa 1. Clin. Immunol. Immunopathol. 198 9, 51
110-117), multiple drug resistance kayashi, et 110-117), (M. Naito, et al., Cancer Chemother. Pharmacol., 1992, Inflammatory cytomegalovirus infections of the lymph and blood vessels (GB No. 2 (WO
195-200), 91/17754) ,
247 620A) and idiopathic thrombocytopenic rash and Basedov's disease (WO 91/19495).
A. Purpose of the Invention
The novel compound of this invention (or a pharmaceutically acceptable salt thereof) has the structural formula I:
-i 2
<img file="LT3533B_D0003.tif" />
ch<sub>3</sub>o and<sub>3</sub> in which
R<sup>1</sup> is:
(1) heteroaryl;
(2) substituted heteroaryl substituted with X, Y and Z;
(3) heteroaril-C<sub>1</sub>_<sub>10</sub>-alkyl;
(4) substituted heteroaryl-C 1-4 alkyl wherein the heteroaryl group is substituted with X, Y, and Z and the alkyl moiety may be substituted with one or more substituents selected from:
(a) hydroxyl, (b) oxo, (c) yg-alkoxy, (d) arylC<sub>1</sub>_<sub>3</sub>-alkoxy groups (e) substituted with arylC<sub>1</sub>_<sub>3</sub>-alkoxy group in which the aryl group is substituted with X, Y and Z, (f) unsubstituted or substituted aryloxy group in which the aryl group is substituted by X, Y and Z, (g) -OCO-C 1-6 alkyl, (h) -NR R wherein R and R independently of one another are optionally (i) hydrogen, (ii) substituted or unsubstituted C 1-6<sub>10</sub>, having one or more substituents, optionally including:
(a ') aryl, unsubstituted or substituted with X, Y, Z, (b') heteroaryl, unsubstituted or substituted with X,
Y, Z, (C) -OH,
II I,, ι j (d ') Vg-alkoxyigroup, (e') -CO<sub>2</sub>H, (f ') -CO<sub>2</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl, (g ') -C<sub>3</sub>_<sub>7</sub>-cycloalkyl and (h ') -OR<sup>11</sup>(Iii) 100<sub>3</sub>_<sub>10</sub>-alkenyl, unsubstituted or substituted by one or more substituents, optionally:
(a ') aryl, unsubstituted or substituted with X, Y, Z, (b') heteroaryl, unsubstituted or substituted with X,
Y, Z, (C) -OH, (d ') Ci.g-alkoxide, (e') -CO<sub>2</sub>H, (f ') -CO<sub>2</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl, (g ') -C<sub>3</sub>_<sub>7</sub>-cycloalkyl and (h ') -OR<sup>11</sup>,
7 (iv) or when the R, R and N atom to which they are attached form an unsubstituted or substituted 3- to 7-membered heterocyclic ring which may contain one or two additional heteroatoms independently selected from the group consisting of O, S (O)<sub>p</sub>, NO<sup>14</sup>, kai R.<sup>14</sup> is hydrogen or C -._<sub>6</sub>-alkyl, unsubstituted or substituted with phenyl, p = 0, 1 or 2, for example morpholine, thiomorpholine, piperidine or piperazine, (i) -NR<sup>6</sup>-CO<sub>1</sub>_<sub>6</sub>-alkyl-R<sup>7</sup>, kai R.<sup>6</sup> and R<sup>7</sup> the meanings are defined above, (j) -NR<sup>6</sup>CO<sub>2</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl-R<sup>7</sup>, (k) -NR<sup>6</sup>-CO-NR<sup>6</sup>R<sup>7</sup>, (l) -OCONRYR<sup>7</sup>, (m) -COOR<sup>6</sup>,
I u (n) (o) (p) (q) (r) (5)
-CHO, aryl, substituted heteroaryl substituted with X, Y and Z,
-OR<sup>11</sup>, and
-S (O) <sub>p</sub>-C<sub>1</sub>.<sub>6</sub>-alkyl;
heteroaril-C<sub>1</sub>_<sub>10</sub>-alkyl, where one or more carbon atoms are replaced by a group optionally selected from: NR<sup>6</sup>-, -o-, -S (O) <sub>p</sub>-, -CO<sub>2</sub>, -O<sub>2</sub>C-, -CONR<sup>6</sup>-, -NR<sup>6</sup>CO ~, no<sup>6</sup>conr<sup>7</sup>-, · (6) substituted heteroaryl-C<sub>1</sub>_<sub>10</sub>-alkyl, where one or more alkyl carbon atoms are optionally substituted with: -NR -, - Ο -, -S (O)<sub>p</sub>-, -CO<sub>2</sub>, heteroarylinė
-CONR<sup>6</sup>-, -NR<sup>6</sup>CO-,
-No<sup>6</sup>conr<sup>7</sup>groups
-O<sub>2</sub>C- is substituted with X, Y and Z, and the alkyl group may be substituted with one or more substituents optionally including:
(a) (b) (c) (d) (e) (f) (g) (h) (i) hidroksilas, oksogrupė,
C<sub>1</sub>_<sub>6</sub>-alkoxy, Ari lC<sub>1</sub>_<sub>3</sub>-al any group substituted with arylC<sub>1</sub>.<sub>3</sub>-the alkoxy group in which the aryl group is substituted with X, Y and Z, the unsubstituted or substituted aryloxy group in which the aryl group is substituted by X, Y and Z,
-OCO-C !_<sub>6</sub>-alkyl,
-NR<sup>6</sup>R<sup>7</sup>, kai R.<sup>6</sup> and R<sup>7</sup> have the meanings defined above,
-NR<sup>6</sup>CO -C<sub>1</sub>_<sub>6</sub>-alkyl-R<sup>7</sup>, kai R.<sup>6</sup> and R<sup>7</sup> meanings are defined above, t I. I ii 1.1, ι J u
<td>(j)</td><td>-NR<sup>6</sup>CO<sub>2</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl-R<sup>7</sup>,</td><td></td><td></td>
<td>(k)</td><td>-No<sup>6</sup>-CO-NR<sup>6</sup>r<sup>7</sup>,</td><td></td><td></td>
<td>(D</td><td>-oconr<sup>6</sup>r<sup>7</sup>,</td><td></td><td></td>
<td>(m)</td><td>-COOR<sup>6</sup>,</td><td></td><td></td>
<td>(n)</td><td>-FOR,</td><td></td><td></td>
<td>(O)</td><td>arilas,</td><td></td><td></td>
<td>(P)</td><td>substituted aryl in which</td><td>is a substituent X,</td><td>And go Z,</td>
<td>(q)</td><td>-OR<sup>11</sup>, and</td><td></td><td></td>
<td>(r)</td><td>-S (O) p C 1-6 alkyl;</td><td></td><td></td>
<td> (7)</td><td>heteroaril-C<sub>3</sub>_<sub>10</sub>-alkenilas, one to four doubles</td><td>kai alkenilas connections;</td><td>has since</td>
<td> (8)</td><td>heteroaril-C<sub>3</sub>_<sub>10</sub>-alkenilas,</td><td>kai alkenilas</td><td>has since</td>
one to four double bonds and when one or more alkyl carbon atoms are replaced by a group optionally selected from: -NR<sup>6</sup>-, -0-, -S(O)<sub>p</sub>~, -CO<sub>2</sub>, -O<sub>2</sub>C-,
-CONR<sup>6</sup>-, -NR<sup>6</sup>CO-, -NR<sup>6</sup>CONR<sup>7</sup>-;
(9) substituted heteroaryl-C<sub>3</sub>_<sub>10</sub>-alkenics where alkenyl has one to four double bonds and when one or more alkyl carbon atoms are replaced by a group optionally selected from: -NR<sup>6</sup>-, -0-, -S(O)<sub>p</sub>-, -CO<sub>2</sub>,
-O<sub>2</sub>C—, -CONR<sup>6</sup>-, -NR<sup>6</sup>CO-, -NR<sup>6</sup>CONR<sup>7</sup>-, the heteroaryl group is substituted with X, Y and Z, and the alkyl group may be substituted with one or more substituents optionally including:
(a) hydroxyl, (b) oxogroup, (c) Vg-alkoxygroup, (d) aryl-C<sub>1</sub>_<sub>3</sub>-alkoxy, (e) substituted with arylC<sub>1</sub>_<sub>3</sub>-Alkoxy group in which the aryl group is substituted with X, Y and Z,
I.Uil 1 m III
I I illll'll·!
(f) an unsubstituted or substituted aryloxy group in which the aryl group is substituted with X, Y and Z, (g) -OCO-C 1-4 alkyl, (h) -NR R where R and R are as defined above for (i) -NR<sup>6</sup>CO -C<sub>1</sub>_<sub>6</sub>-alkyl wherein R<sup>6</sup> the meanings are defined above, (j) -NR<sup>6</sup>CO<sub>2</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl, (k) -NR<sup>6</sup>CO-NR<sup>6</sup>R<sup>7</sup>, (l) -OCONR<sup>6</sup>R<sup>7</sup>, (m) -COOR<sup>6</sup>, (n) -CHO, (o) aryl, (p) substituted aryl substituted with X, Y and Z, (q) -OR<sup>U</sup>, and (r) -S (O) p-C 1-8 alkyl;
R may be optionally:
(1) R<sup>1</sup> meanings;
(2) hydrogen;
(3) phenyl;
(4) substituted phenyl substituted with X, Y, Z;
(5) 1- or 2-naphthyl;
(6) substituted 1- or 2-naphthyl substituted with X, Y, Z;
(7) bifenilas;
(8) substituted biphenyl substituted with X, Y, Z;
(9) C<sub>1</sub>_<sub>ic</sub>-alkyl;
(10) replaced by C<sub>1</sub>_<sub>10</sub>-alkyl optionally substituted with one or more substituents, including:
I
<td></td><td>(a)</td><td>hydroxilas,</td>
<td></td><td>(b)</td><td>oxo group,</td>
<td></td><td>(c)</td><td>C <sub>x</sub>_<sub>6</sub>what a group,</td>
<td></td><td>(d)</td><td>ar i l-C<sub>1</sub>_<sub>3</sub>-al ko ksigrupė,</td>
<td> 5</td><td>(e)</td><td>substituted arylC<sub>1</sub>_<sub>3</sub>-Alkoxy group in which the aryl group is substituted with X, Y and Z,</td>
<td></td><td>(f)</td><td>an unsubstituted or substituted aryloxy group in which the aryl group contains X, Y and Z,</td>
<td></td><td>(g)</td><td>-OCO-CYg-al kilas,</td>
<td> 10</td><td>(h)</td><td>6 7 6 7 -NR R where R and R are as defined above meanings,</td>
<td></td><td>(i)</td><td>-NR<sup>6</sup>CO -C<sub>1</sub>_<sub>6</sub>-alkyl-R 'wherein R<sup>6</sup> and R<sup>7</sup> meanings are defined above,</td>
<td></td><td>(j)</td><td>-COOR, where R values are as defined above,</td>
<td> 15</td><td>(k)</td><td>-FOR,</td>
<td></td><td>(D</td><td>phenyl,</td>
<td></td><td>(m)</td><td>substituted phenyl substituted with X, Y and Z,</td>
<td></td><td>(n)</td><td>1- or 2-naphthyl,</td>
<td></td><td>(O)</td><td>substituted 1- or 2-naphthyl substituted with X,</td>
<td> 20</td><td></td><td>Y with</td>
<td></td><td>(P)</td><td>bifenilas,</td>
<td></td><td>(q)</td><td>substituted biphenyl substituted with X, Y, Z,</td>
<td></td><td>(r)</td><td>OR<sup>11</sup>, and</td>
<td></td><td>(s)</td><td>-S (O) p C 1-4 alkyl;</td>
<td> 25</td><td></td><td> -</td>
<td></td><td> (11)</td><td>C<sub>3</sub>.<sub>10</sub>-alkenilas;</td>
<td></td><td> (12)</td><td>replaced by C<sub>3</sub>_<sub>10</sub>-alkenyl optionally containing one or more substituents, including:</td>
<td></td><td>(a)</td><td>hydroxilas,</td>
<td> 30</td><td>(b)</td><td>oxo group,</td>
<td></td><td>(c)</td><td>. C ,_<sub>6</sub>-ai ko ksigrupė,</td>
(d) phenyl-C 1-4 -alkoxy, (e) substituted-phenyl-C<sub>1</sub>_<sub>3</sub>-alkoxy, wherein the phenyl group is substituted with X, Y and Z, (f) -OCO-C 1-6 -alkyl,
7 6 7 (g) -NR R where R and R are as defined above, (h) -NR<sup>6</sup>CO -C<sub>1</sub>_<sub>6</sub>-alkyl wherein R<sup>6</sup> values as defined above, (i) -COOR where R values are as defined above, (j) -CHO, (k) phenyl, (l) substituted phenyl substituted with X, Y and Z, (m) 1- or 2-naphthyl , (n) substituted 1- or 2-naphthyl substituted with X, Y and Z, (o) biphenyl, (p) substituted biphenyl substituted with X, Y and Z, (q) -OR<sup>11</sup>, and (r) -S (O) p-C 1-8 alkyl;
(13) C<sub>3</sub>_<sub>10</sub>-alkinilas;
(14) replaced by C<sub>3</sub>_<sub>10</sub>-alkynyl optionally substituted with one or more substituents including:
(a) hydroxylase, (b) oxogroup, (c) C 1-6 alkoxygroup, (d) phenyl-C<sub>1</sub>_<sub>3</sub>-alkoxy, (e) substituted with phenyl-C<sub>1</sub>_<sub>3</sub>- an alkoxy group in which the phenyl group is substituted with X, Y and Z, (f) -OCO-C 1-8 -alkyl,
Lt
R<sup>7</sup> has the meaning given above when the values of R are defined by (g) -NR<sup>6</sup>R<sup>7</sup>, kai R.<sup>6</sup> and values, (h) -NR<sup>6</sup>CO -C<sub>1</sub>_<sub>6</sub>-alkyl, above, (i) -COOR<sup>6</sup>, kai R.<sup>6</sup> the values are defined above, (j) -CHO, (k) phenyl, (l) substituted phenyl substituted with X, Y and Z, (m) 1- or 2-naphthyl, (n) substituted 1- or 2-naphthyl, X, Y and Z, (o) biphenyl, (p) substituted biphenyl, substituted with X, Y and Z, (q) -OR<sup>11</sup>, ir (r) -S (O) <sub>p</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl;
(15) -R<sup>11</sup>;
11
R is hydrogen, hydroxy, OR or C / g-alkoxy;
R<sup>4</sup> is hydrogen or R<sup>3</sup> and R<sup>4</sup> together form a double bond;
R<sup>5</sup> is methyl, ethyl, propyl or allyl;
R<sup>10</sup> is hydrogen, hydroxy, OR<sup>11</sup> or fluorine;
R<sup>11</sup> optional:
(a) -PO(OH)O M<sup>+</sup>, kai M.<sup>+</sup> is a positively charged inorganic or organic ion,
-so<sub>3</sub>, ”M<sup>+</sup>, (b) (C) (d) (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix)
-CO (CH<sub>2</sub>) <sub>q</sub>CO<sub>2</sub><sup>_</sup>M<sup>+</sup>, when q equals 1-3, and
-CO-C<sub>1</sub>_<sub>6</sub>alkyl-NR<sup>6</sup>R<sup>7</sup>, in which R<sup>6</sup> and R<sup>7</sup> has the meanings defined above and the alkyl group may be substituted with one or more substituents optionally including:
hydroxilas,
CX<sub>6</sub>-alkoksigrupė,
-NR<sup>lu</sup>R<sup>17</sup>, kai R.<sup>16</sup> and R<sup>17</sup> independently of each other may be optional:
(a ') hydrogen, and (b') C 1-8 alkyl,
-COOR<sup>5</sup>, kai R.<sup>6</sup> the values defined above, phenyl, substituted phenyl substituted with X, Y and Z, heteroaryl,
-SH, go
-S-C<sub>1</sub>_<sub>6</sub>-alkyl;
W is O or (H, OH);
X, Y and Z are independently selected from:
(a) hydrogen, (b) C<sub>1</sub>_<sub>10</sub>-alkyl, unsubstituted or substituted by one or more substituents, optionally:
(i) aryl, (ii) substituted aryl substituted with X ', Y' and
Z ', (iii) heteroaryl, (iv) substituted heteroaryl substituted with X', Y 'and Z', (v) unsubstituted or substituted aryloxy radical substituted with X ', Y' and Z ', (vi) - OR<sup>6</sup>, (vii) -OR<sup>11</sup>, (viii) -OCOR<sup>6</sup>, (ix) -OCO<sub>2</sub>R<sup>6</sup>, (x) -NR<sup>6</sup>R<sup>7</sup>, (xi) -CHO, (xii) -NR<sup>6</sup>CO -C<sub>1</sub>.<sub>6</sub>-alkyl-R<sup>7</sup>, (xiii) -NR<sup>6</sup>CO<sub>2</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl-R<sup>7</sup>, (xiv) -NR<sup>6</sup>CONR<sup>6</sup>R<sup>7</sup>, (xv) -OCONR<sup>e</sup>R<sup>7</sup>, (xvi) -CONR<sup>6</sup>R<sup>7</sup>, (c) C,_<sub>10</sub>-alkyl, where one or more alkyl carbon atoms are replaced by a group optionally selected from: -NR<sup>6</sup>-, -0-, -S (O) <sub>p</sub>-, -CO<sub>2</sub>, -O<sub>2</sub>C-, -CONR<sup>6</sup>-, -NR<sup>6</sup>CO-,
-NR<sup>6</sup>CONR<sup>7</sup>-, -CO-, -CH (OH) -, alkenyl or alkynyl and alkyl may be unsubstituted or substituted with one or more substituents optionally including:
(i) aryl, (ii) substituted aryl substituted with X ', Y' and Z ', (iii) heteroaryl,
I III I 31 III ll I i ui «ι mum t
<td>(iv)</td><td>substituted heteroaryl substituted with X ', Y' and Z ',</td>
<td>(v)</td><td>unsubstituted or substituted aryloxy radical, substituted with X ', Y' and Z 'in the aryl group,</td>
<td>(we)</td><td>-OR<sup>6</sup>,</td>
<td>(vii)</td><td>-OR<sup>11</sup>,</td>
<td>(viii)</td><td>-OCOR<sup>6</sup>,</td>
<td>(ix)</td><td>-hollow<sub>2</sub>r<sup>6</sup>,</td>
<td>(X)</td><td>-No<sup>6</sup>r<sup>7</sup>,</td>
<td>(xi)</td><td>-FOR,</td>
<td>(xii)</td><td>-AcO-C/g-alkil-R<sup>7</sup>,</td>
<td>(xiii)</td><td>-NR<sup>6</sup>CO<sub>2</sub>-C<sub>1</sub>_<sub>6</sub>-alkyl-R<sup>7</sup>,</td>
<td>(xiv)</td><td>-No<sup>6</sup>conr<sup>6</sup>r<sup>7</sup>,</td>
<td>(xv)</td><td>-oconr<sup>6</sup>r<sup>7</sup>,</td>
<td>(xvi)</td><td>-conr<sup>6</sup>r<sup>7</sup>,</td>
<td>(d)</td><td>halogen,</td>
<td>(e)</td><td>-No<sup>6</sup>r<sup>7</sup>,</td>
<td>(f)</td><td>-CN,</td>
<td>(g)</td><td>-FOR,</td>
<td>(h)</td><td>- cf<sub>3</sub>,</td>
<td>(i)</td><td>8 8 -SR when R is hydrogen, C1-4 alkyl, trifluoromethyl- thyl or phenyl,</td>
<td>(j)</td><td>-ROW<sup>8</sup>,</td>
<td>(k)</td><td>-so<sub>2</sub>r<sup>8</sup>,</td>
<td>(D</td><td>-conr<sup>6</sup>r<sup>7</sup>,</td>
<td>(m)</td><td>R<sup>9</sup>O(CH2)m-, kur R<sup>9</sup> is hydrogen, C / g-alkyl, hydroxy-C2-3-alkyl, -CF<sub>3</sub>, phenyl, R<sup>11</sup> or petroleum br and m is equal to 0, 1, 2 or 3,</td>
<td>(n)</td><td>-CH (OR<sup>12</sup>) (OR<sup>13</sup>), kai R.<sup>12</sup> and R<sup>13</sup> is C<sub>1</sub>.<sub>3</sub>-alkyl or together form an ethylene or propylene bridge,</td>
II 11
O
<td>(O)</td><td>R<sup>9</sup>CO (CH<sub>2</sub>)<sub>m</sub>-, when</td><td>R<sup>9</sup></td><td>and M</td><td>meanings</td><td>defined</td>
<td>(P)</td><td>above, 0 9 f ROC(CH<sub>2</sub>)<sub>m</sub>-, when</td><td>R<sup>9</sup></td><td>and M</td><td>meanings</td><td>defined</td>
<td>(q) or</td><td>above, and -R<sup>11</sup>; any two of X,</td><td>Y,</td><td>From the gala</td><td colspan="2">to be connected in order to</td>
to form a saturated ring containing 5, 6 or 7 atoms, there being 1 or 2 oxygen atoms between the atoms of the ring, the remaining atoms being carbon, for example dioxolanyl or dioxanyl;
X ', Y' and Z 'independently of one another are optionally:
(a) hydrogen, (b) C<sub>1</sub>_<sub>7</sub>-alkiias, (c) C<sub>2</sub>_<sub>6</sub>-alkenyl, (d) halogen, (e) {CH<sub>2</sub>)<sub>m</sub>-NR R where R, R and m are as defined above, (f) -CN, (g) -cho, (h) -CF<sub>3</sub>, (i) -SR<sup>8</sup>, kai R.<sup>3</sup> hydrogen, C<sub>1</sub>_<sub>6</sub>-alkyl, trifluoromethyl or phenyl, (j) -SOR wherein R is as defined above, (k) -SO<sub>2</sub>R, wherein the values of R are as defined above, (l) -CONR<sup>6</sup>R<sup>7</sup>, where R<sup>6</sup> and R<sup>7</sup> the values are defined above, (m) R<sup>9</sup>O (CH<sub>2</sub>)<sub>m</sub>- where R<sup>9</sup> and the values of m are defined above, m ui; mum (n) -CH (OR<sup>12</sup>) (OR<sup>13</sup>) where R<sup>12</sup> and R<sup>13</sup> meanings are defined above,
O
II (o) R<sup>9</sup>CO (CH<sub>2</sub>) <sub>m</sub>- where R<sup>9</sup> and the values of m are defined above,
O
II (p) R<sup>9</sup>OC (CH<sub>2</sub>) <sub>m</sub>- where R<sup>9</sup> and the values of m are defined above, and (q) -R<sup>11</sup>;
n is 1 or 2.
The compounds of the present invention have asymmetric centers and the present invention includes all optical isomers and mixtures thereof.
In addition, carbon-carbon double bonded compounds can exist in Z and E forms, so that all isomeric forms of these compounds are included in the present invention.
In the case where any variable (eg alkyl, aryl, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>in</sup>, X, Y, Z, and 1.1.) Occurs more than once in any of the variables or in Formula 1, its value in each case is independent of its value in any other case.
The term alkyl, as used herein, includes alkylating groups having a defined number of carbon atoms which in configuration are straight, branched, or cyclic. Examples of alkyl include methyl, ethyl, propyl, isopropyl, butyl, secondary and tertiary butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like. AlL1 coke is an alkyl group of a specified number of carbon atoms attached through an oxygen bridge such as methoxy, ethoxy, propoxy, butoxy and pentoxy. The term alkenyl includes a hydrocarbon chain of the indicated number of carbon atoms, linear or branched and containing at least one unsaturated bond which may be anywhere on the chain, such as ethenyl, propenyl, butenyl, pentenyl, dimethylpentyl, and the like, and includes E and Z forms, when present; the term heteroarylalkyl includes heteroaryl groups as defined herein and attached through a straight or branched alkyl chain of 1 to 10 carbon atoms. The term halogen as used in the present invention means fluorine, chlorine, bromine or iodine.
It will be understood by those skilled in the art that pharmaceutically acceptable salts include, but are not limited to, salts of inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide and nitrate, or salts of organic acid such as malate, maleate, fumarate, tartrate, succinate, acetate, lactate, methanesulfonate, p-toluenesulfonate or palmoate, salicylate or stearate. Similarly, pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (especially ammonium salts with amines of formula HNR).<sup>S</sup>R<sup>7</sup>) .
The heteroaryl group includes, as used in the present invention, acridine, carbazole, cinnoline, dibenzofuran, dibenzothiophene, quinoxaline, pyrazole, indole, benzotriazole, furan, benzofuran, quinoline, isoquinoline, pyrazine, pyridine, pyridine, to change or not to change.
I III I II II I I I I I IUU1
In the compounds of Formula 1, any heteroaryl or carbon atom (if any) in the heteroaryl group may be replaced by X, Y and Z, but the compounds in which the nitrogen atom has been replaced by some X, Y and Z may be relatively unstable and absent. more appropriate than others.
The term heteroaryl, as used in the present invention, includes the following heteroaromatic groups which may be substituted at X, Y and Z at the indicated positions when Q is -N (X) -, -O-, -S-, -SO- or -SO<sub>2</sub>-:
x.
X.
Y v
X (Piridazinas) (Piridinas)
<img file="LT3533B_D0004.tif" />
Y z \ nJ (Pyrimidines) (Pyrazines)
<img file="LT3533B_D0005.tif" />
<img file="LT3533B_D0006.tif" />
X (Cinolines)
<img file="LT3533B_D0007.tif" />
<img file="LT3533B_D0008.tif" />
1, there is ί .11 3; T 1 3 3 Ιϊ'Iii f t
The aryl or aromatic groups may be phenyl or naphthyl, unsubstituted or substituted with 1-3 radicals independently selected from the group consisting of alkyl, alkenyl, halogen, carboxyl, CHO, amino, monoalkylamino, dialkylaminoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethyl, amide, monoalkylamide, dialkylamide, hydroxy, hydroxyalkyl, R<sup>11</sup> O-alkilas, alkoksi-, alkoksialkilas, formamidas, formami10 doalkilas, alkil-CO<sub>2</sub>-, alkyl-CO<sub>2</sub>-alkyl, carboxyl, acyl-CO<sub>2</sub>H, alkyl-O<sub>2</sub>C, alkyl-O<sub>2</sub>C-alkyl and OR<sup>U</sup>.
Compounds of formula I are more preferably heteroaryls selected from the group consisting of:
<img file="LT3533B_D0009.tif" />
X
X
<img file="LT3533B_D0010.tif" />
and
L il JI miimn: ii m where X values are defined above.
In the compound of formula 1, the following values are more suitable:
R<sup>2</sup> is:
<td> (1)</td><td>hydrogen,</td>
<td> (2)</td><td>methyl,</td>
<td> (3)</td><td>etilas</td>
<td> (4)</td><td>propilas,</td>
<td> (5)</td><td>lips,</td>
<td> (6)</td><td>R<sup>11</sup>,</td>
<td> (7)</td><td>C<sub>2</sub>_<sub>3</sub>-alkil-OH,</td>
<td> (8)</td><td>C<sub>2</sub>.<sub>3</sub>-alkyl-R<sup>11</sup>;</td>
<td colspan="2"> _ 2</td>
<td>R</td><td>is:</td>
<td>(D</td><td>hydrogen,</td>
<td> (2)</td><td>hydroxy,</td>
<td> (3)</td><td>-OR<sup>11</sup>,</td>
R<sup>3</sup> and R<sup>4</sup> together form a double bond;
R<sup>10</sup> is hydrogen, hydroxy, fluorine or -OR<sup>U</sup>;
W is O; and n equals 2.
In one example of the present invention, heteroaryl is an indole, which is represented by the following formulas:
I ίΙ
<img file="LT3533B_D0011.tif" />
defined above when X, Y and Z have values.
More preferred examples of the present invention include:
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (2-furanyl) methoxy-3' '- methoxy-cyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13 , 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. ON<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (2-furanyl) methoxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19 , 21, 27-Tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- (2-furanyl) -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1];
O<sup>4</sup>'<sup>9</sup>] octacos-18-en-2, 3, 10, 16-tet17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- (2-thiophene) -methoxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo- [22.3.1.0 raonas;
4,9.
octacos-18-en-2, 3, 10, 16-tet17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- (2-thiophene) -methoxy-3' '-hydroxycyclohexyl) - 1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
I ui ί ji ιι jif ui .ki »i«.
17-Ethyl-1, 14-dihydroxy-12- [2 '(4' '- (3-thiophene) -methoxy3' '-hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo-L 22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- (2thiophene) -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxsa-4-azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- (3-thiophene) -methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13, 19,21,27-Tetramethyl-11,18-dioxa-4-azatricyclo [22.3.1.0<sup>4</sup>'<sup>9</sup>] octacose-18-en-2,3,10, 16-tetraonas
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (2-thiophene) oxy3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (2-benzothienyl) oxy -3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19 , 21, 27-Tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (5-indolyl) oxy3' '- methoxycyclohexyl) 1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (5-indolyl) oxy3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (5-indolyl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25I Ll Ll Ii I ! L II III .. Lili dimethoxy-13, 19, 21, 27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (5-indolyl) oxy3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (5-indolyl) oxy-3' '- methoxycyclohexyl) -1' -methylvinyl) -23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (5-indolyl) oxy3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '(4' '- (5-indolyl) oxy3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11-28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1, 14, 20-trihydroxy-12- [2 '- (4 (5-indolyl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19. 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-l, 20-dihydroxy-12- [2'- (4 '' (5-indolyl) oxy3 '' -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11-28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
standing ί um
17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' - (5-indolyl) oxy3 '' - ethoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27 -tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4</sup>’<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (5-indolyl) oxy3' '- ethoxycyclohexyl) -1'-methylvinyl] -23 ,. 25-dimethoxy13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1-hydroxy-12- [2 '- (4' '- (5-indolyl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1N-methyl-5-indolyl) -oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4, 20-trihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11-28-diLT 3533 B oxa-4-azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25 -Dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,2,2-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '-hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1.0<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-2- [2'- (4 '' - (1N-methyl-5-indolyl) oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13 , 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4-azaLT 3533 B tricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- ethoxycyclohexyl) -1'-methylvinyl] -23, 25 dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- ethoxycyclohexyl) -1'-methylvinyl] -23, 25 dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '(1N-ethyl-5-indolyl) -oxy-3' '- ethoxycyclohexyl) -1'-methylvinyl] -23, 25dimethoxy-13 , 19, 21, 27-tetramethyl-11, 28-dioxa-4azatriciclo- [22. 3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16tetraonas;
17-Allyl-1-hydroxy-12- [2 '- (4' '- (1 N-ethyl-5-indolyl) -oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- allyloxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Etil-l-hidroksi-12- [2 '- (4' '- (lN-metil-5-indolil) oksi-3' '- aliloksicikloheksil) -1'-metilvinil] -23, 25-dimetoksi-13 , 19, 21, 27-tetrametil-ll, 28-dioksa-4ι II II i II 2 1 1 Μ Ι.Ι1Η I.
LT 3533 Β azatricyclo- [22.3.1. ON<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- propyloxycyclohexyl) -1'-methylvinyl] -23.
25-dimethoxy-1,3, 19, 21, 27-tetramethyl-1,1, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-12- [2<sup>1</sup> -(4<sup>1</sup>'- (1N-methyl-5-indolyl) oxy-3' '- propyloxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- 1-propyloxycyclohexyl) -1'-methylvinyl] 23, 25 -Dimethoxy-13, 19, 21, 27-tetramethyl-11,18-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1N-ethyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-14,20-trihydroxy-12- [2 '- (4' '- (1N-ethyl-5indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy -13, 19, 21, 27-tetramethyl-ll, 28dioxsa-4-azatriciclo- [22.3.1.0<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-ethyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxa-4ΙΙΙ, Ι II UI .1 I II III K mini azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-ethyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '(4' '- (1N-ethyl-5-indolyl) -oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-28-en-2, 3, 10, 16-tetraonas;
17-Allyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1 N-ethyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25- dimethoxy-1,3, 19, 21, 27-tetramethyl-11,28 dioxa-4-azatricyclo- [22.3. 1. O<sup>4,9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Allyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-ethyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '(4' '- (1N-ethyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (1N-ethyl-5-indolyl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13 , 19, 21, 27-tetramethyl-11, 28-dioxa-4I Π ii Iii ii: i ii. utn and azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1-hydroxy-12- [2 '- (4' '- (1N-ethyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo-t 22.3.1.O<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-ethyl-5-indolyl) -oxy-3' '- ethoxycyclohexyl) -1'-methyvinyl] -23, 25 dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '(1N-propyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1-N-propyl5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25 -Dimethoxy-13, 19, 21, 27-tetramethyl-11,28 dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2'- (4 '' - (1N-propyl-5-indolyl) -oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23,25 dimethoxy- 13,19,21,27-tetramethyl-1,11-28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2,3,10,16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1N-propyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl [-23,25-dimethoxy -13,19,21,27-tetramethyl-1,11-28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octacose-18-en-2,3,10,16-tetraonas;
m ι i m
17-Ethyl-1, 14,20-trihydroxy-12- [2 '- (4' '- (1N-propyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl (-1'-methylvinyl] 23,25-dimethoxy -13,19,21,27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1.O<sup>4,9</sup>] octacose-18-en-2,3,10,16-tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-propyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-propyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1-N-propyl5-indolyl-oxy-3' '- methoxycyclohexyl) -1'methylvinyl] 23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11 dioxa-4-azatricyclo-f 22.3.1.<sup>4,9</sup>] octave-18-in-2, 3, 10,
16-tetraonas;
17-Allyl-1,2-dihydroxy-12- [2 '- (4' '(1N-propyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Alil-l, 14-dihidroksi-12- [2 '- (4' '- (lN-propil-5-indolil) -oksi-3' '-hidroksicikloheksil) -1'-metilvinil] -23,
25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, tetraonas;
10, 16LT 3533 B
17-Ethyl-1-hydroxy-12- [2'- (4 '' - (1N-propyl-5-indolyl) oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13 , 19, 21, 27-Tetramethyl-1,1, 28-dioxa-4-azatricyclo © 22.3.1.O<sup>4,9</sup>] oktkoz-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1-hydroxy-12- [2 '- (4' '- (1N-propyl-5-indolyl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13 , 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- (1 N-propyl-5-indolyl) -oxy-3' '- texicyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas,
17-Alil-l, 14-dihidroksi-12- [2 '- (4' '- (lN-propil-5-indolil) -oksi-3' '- etoksicikloheksil) -1'-metilvinil] -23,
25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo-f 22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-allyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14, 20-trihydroxy-12- [2 '(4' '- (1N-allyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3, 10,
16-tetraonas;
17-Ethyl-l, 20-dihydroxy-12- [2 '- (4' '- (1 N-allyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tet5 raonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-allyl-5-indolyl) -oxy-3' '-hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-410 azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14, 20-trihydroxy-12- [2 '- (4- (1 N-allyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] 15 23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17- Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-allyl-5-indo20 III) -oxy-3' '-hydroxycyclohexyl) -1'-methylvinyl] -23,
25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1_. Oh<sup>4,9</sup>] o«ktakoz-18-en-2, 3, 10, 16-tetraonas ;
17-Allyl-1,4-dihydroxy-12- [2- '(4' '- (1N-allyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Alil-l, 14, 20-trihidroksi-12- [2 '- (4' '- (lN-alil-5indolil) -oksi-3' '- metoksicikloheksil) -1<sup>1</sup>-methylvinyl] 23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3, 10,
16-tetraonas;
I NO
17-Allyl-1,2-dihydroxy-12- [2'- (4 '' - (1N-allyl-5-indolyl) -oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23, 25 -dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Alil-l, 14-dihidroksi-12- [2 '- (4' '- (lN-alil-5-indolil) -oksi-3' '- hidroksicikloheksil) -1'-metilvinil] -23, 25- dimetoksi-13, 19, 21, 27-tetrametil-ll, 28-dioksa-4azatriciklo- [22.3.1. O<sup>4,9</sup>] cktakoz-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-12- [2'- (4 '' - (1N-allyl-5-indolyl) -oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1-hydroxy-12- [2 '- (4' '- (1N-allyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1.0<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1 N-allyl-5-indolyl) -oxy-3' '-ethoxycyclohexyl) -1'-methylvinyl] -23, 25 dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-14-dihydroxy-12- [2 '(4'<sup>1</sup> - (1N-Allyl-5-indolyl) -oxyl-3 '' -ethoxycyclohexyl) -1'-methylvinyl] -23, 25 dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3 .1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' - (1N-2-hydroxyethyl-5-indolyl) -oxy-3 '' - methoxyciclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Ethyl-1,14,20-trihydroxy-12- [2 '- (4' <sup>1</sup> - (1N-2-hydroxyethyl-5-indolyl) -oxy-3 '' - methoxycyclohexyl) -1'methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl11,28-dioxa-4-azatricyclo - [22.3.1. Oh<sup>4,9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (1-N-2-hydroxyethyl-5-indolyl) -oxy-3' '- methoxyciclohexyl) -1'-methylvinyl] - 23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1. ABOUT<sup>4,9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Ethyl-l ,. 14-dihydroxy-12- [2 '- (4' '- (1N-2-hydroxyethyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Ethyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1N-2-hydroxyethyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'methylvinyl] -23 , 25-dimethoxy-13, 19, 21, 27-tetramethyl11,28-dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2'- (4 '' - (1N-2-hydroxyethyl-5-indolyl) -oxy-3 '' - hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1. ABOUT<sup>4,9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-2-hydroxyethyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23. 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1-N-hydroxyethyl 5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28 dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octave-18-in-2, 3, 10,
26-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-benzyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,12-dioxa-4azatricyclo- [22.3.1.0<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4, 20-trihydroxy-12- [2 '- (4' '- (1-N-benzyl5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25 -Dimethoxy-13, 19, 21, 27-tetramethyl-11,18-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17- Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-benzyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23,
25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1N-benzyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1-N-benzyl 5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23. 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,12LT 3533 B dioxa-4-azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1,2-dihydroxy-12- [2 '- (4' '- (1N-benzyl-5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-benzyl-5-indolyl) -oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,12-dioxa-4azatricyclo- [22.3.1.0<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1, 14, 20-trihydroxy-12- [2 '- (4' '- (1-N-benzyl 5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25 -Dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17- Allyl-l, 20-dihydroxy-12- [2 '- (4' '- (1N-benzyl-5-ynyl) -oxy-3' '- methoxycyclohexyl) -1'methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-14-dihydroxy-12- [2 '- (4' '- (1N-benzyl-5-indolyl) -oxy-3' '-hydroxycyclohexyl) -1<sup>1</sup>-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (1N-benzyl-5-indolyl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13 , 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4-azaLT 3533 B tricyclo- [22.3.1. θ '*'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1-hydroxy-12- [2 '(4' '- (1N-benzyl-5-indolyl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricylchlo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (1N-benzyl-5-indolyl) -oxy-3 '' - ethoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-benzyl-5-indolyl) -oxy-3' '-ethoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1, O<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-N-cyclopropyl5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy -13,19,21,27-Tetramethyl-1,11-28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] Oct-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-N-cyclopropyl5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28 dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1-N-cyclopropyl5-indolyl) -oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy -13, 19, 21, 27-tetramethyl-11, 28-diΙ.ΚΙ I. J. UI .1 II III .Hl «..
oxa-4-aza-tricyclo [22.3.1. O<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3, 10,
16-tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1-N-cyclopropyl5-indolyl) -oxy-3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, 21, 27-tetramethyl-11,28 dioxa-4-azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (1N-cyclopropylS-indolyl) -oxy-3 '' - ethoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy-13 , 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Allyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-cyclopropylS-indolyl) -oxy-3' '- ethoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy-13 , 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] Oct-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (1N-cyclopropyl-5-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. ON<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Allyl-1-hydroxy-12- [2 '- (4' '- (1N-cyclopropyl-S-indolyl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. ON<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (1-N-tryptophanyl-carbonyl-methoxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23,
25-dimethoxy-13, 19, 21, 27-tetramethyl-ll, 28-dioxy-4I Ii ll iii ,; ι ii u azatriciklo interview- [22.3.1. O<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1-hydroxy-12- [2 '- 4' '- (3-indolyl) ethylamino-carbonyl-methoxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy-13,19 , 21, 27-Tetramethyl-11,12-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octave-18-in-2, 3, 10,
16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2 '- (4<sup>1</sup> '- (3-hydroxypropyl) -indol-5-yl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2'- (3 '' - hydroxy-4 '' - (1-hydroxyethylindol-5-yl) -oxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy -13, 19, 21, 27-tetramethyl-11, 28-dioxa-4-azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-hydroxyethylindol-6-yl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy- 13, 1,9, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. ON<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17- Ethyl-1, '14-dihydroxy-12- [2' - (4 '' - (1-methylindole-6yl) oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-11, 28-dioxa-4-azatriciklo © 22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
The 17 Ethyl, 14 dihidroksi-12 [2 - (4 '- (the dibenzilfosfonoksi-etilindol-5-) OKSI 3' - metoksicikloheksil) -1-metilvinil] -23, 25- dimetoksi 13, 19, 21, 27 tetrametilLT 3533 B
11, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-phosphonoxy-ethylindol-5-yl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25 -dimethoxy-13, 19, 21, 27-tetramethyl-11, 28dioxsa-4-azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraon monocal salt;
The Ethyl 17-, 14 dihidroksi-12 [2 - (4 '- (1- (N, N-OKSI dimetilglicil) etilindol-5-) OKSI 3' - metoksicikloheksil) -1 ' -metilvinil] -23> 25 dimetoksi 13, 19, 21, 27tetrametil ll, 28 dioksa 4-azatriciklo- [22.3.1. O<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1-succinyloxyethylindol-5-yl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy- 13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octave-18-in-2, 3,
10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1-methyl-3-phenylindol-5-yl) oxy-3' '- methoxycyclohexyl) -1' -methylvinyl] 23, 25-dimethoxy-l37 19, 21, 27-tetramethyl-l l, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas;
17- Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-methyl-3- (2-hydroxyethyl) -indol-5-yl) oxy-3' '- methoxycyclohexyl) -1 'methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl11, 28-dioxsa-4-azatriciclo- [22.3.1.O<sup>4,9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1, 3-dimethylindol5-yl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,
25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4I II azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (9'-methylcarbazol3'-ii) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy -13, 19, 21, 27-Tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4 ”- ((2 - (3' -diethylaminopropionyloxy) ethyl) indole-5 '' '- ii) oxy-3' '- methoxyciclohexyl) - 1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxsa-4-azatriciclo [22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' - ((2 '' '' - (3 '' '' '- dimethylaminopropionyloxy) ethyl) indol-5' '' - yl) oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,17-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- ((2' '' - (3 '' '' 'aminopropionyloxy) ethyl) indole-5' '' - ii) - oxy-3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxsa-4-azatriciclo [22.3.1.0<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- ((2' '' '- (3' '' 'benzyloxycarbonyl-2' '' '- benzyloxycarbonylamino-propionyloxy) ethyl ) indole-5 '' - ii) oxy-3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27 tetramethyl-1,1, 28-dioxa-4-azatricyclo- [ 22.3.1.O<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- ((2' '' - (aspartyloxy) ethyl) indol-5 '' -yl) oxy-3 '' - methoxycyclohexyl 1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetraIII I II III
II methyl-11,28-dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] octakoz18-en-2, 3, 10, 16-tetraonas:
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- ((2' '' '- (1<sup>1</sup> '' '' -imidazolylcarbonyloxy) ethyl) indol-5 '' - yl) oxy-3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11 , 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' - ((2- (1 '' 'piperazinecarbonyloxy) ethyl) indole-5' '' - ii) oxy-3 '' - methoxycyclohexyl ) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,. 14-dihydroxy-12- [2'- (4 '' - (1 '' '- (2' '' '(2' '' '- hydroxy) ethylaminocarbonyloxy) ethyl) indole-5' '' yl) oxy -3 '' - methoxycyclohexyl) -1'-methylvinyl] -23, 25dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxa-4azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '- (isopropylaminocarbonyloxy) ethyl) indol-5' '-yl) oxy- 3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4</sup>’<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2 '- (4- (1' - (2 (1 '' '' '- piperidinecarbonyloxy) ethyl) indole-5' '' - ii) oxy 3 '' - methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1' - (2 (1 '' '' -morpholincarbonyloxy) ethyl) indole-5 '' '- ii) oxy
3 '' -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - (diphenylaminocarbonyloxy) ethyl) indole-5 '' '- ii) oxy- 3''-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Etil-l, 14-dihidroksi-l2- (2 '- (4' '- (l'<sup>,</sup>'- (2' '' '- (diethylaminocarbonyloxy) ethyl) indole-5' '' - ii) oxy-3 '' - methoxycyclohexyl) -1 '-methyl vinyl] -23,25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1' - (2 '' '- (methanesulfonyloxyethyl) indole-5' '- ii) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21,
27-Tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - (azidoethyl) indole-5 '' '- ii) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas;
17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - (aminoethyl) indole-5 '' '- ii) oxy-3' 'methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl, 28-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1' '- t-butyldimethyl-silyloxyethoxyethyl) indol-5' '-yl) oxy-3' '- methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19,
IIII E .1 III - I II IIIIIILIUl
21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1' '-hydroxyethoxy-ethyl) indol-5' '-yl) oxy-3' '- methoxycyclohexyl) 1' -methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas;
17-Ethyl-1,4-dihydroxy-12- [2 '- (3' '-methoxy-4' '- (1' '' (1 '' '- oxoprop-3' '' - ii) indole -5 '' '- ii) oxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27 tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone; and
17-Ethyl-1,. 14-dihydroxy-12- [2 '- (3' '- methoxy-4' (1 '' '' - carboxyethyl-2 '' '' - ii) indole-5 '' '- ii) oxycyclohexyl) -1' -methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27 tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas.
Compounds of the present invention include compounds of formula X, XI, XII and XIII:
<img file="LT3533B_D0012.tif" />
II,
<img file="LT3533B_D0013.tif" />
<img file="LT3533B_D0014.tif" />
<img file="LT3533B_D0015.tif" />
innm i t
<img file="LT3533B_D0016.tif" />
XII
<img file="LT3533B_D0017.tif" />
AND<sub>3</sub> ch<sub>3</sub>O
. Ii
II III imm,
<img file="LT3533B_D0018.tif" />
XIII kai R.<sup>ba</sup> the values of H and R 'are selected from the following substituent groups:
<td>R<sup>6</sup></td><td>R<sup>7</sup></td><td>R<sup>2</sup></td><td>R<sup>3</sup></td><td>R<sup>5</sup></td>
<td>phenyl</td><td>phenyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>phenyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>benzil</td><td>H .</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-H; NCO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-Cl-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-HO<sub>?</sub>C-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-H, NCO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-l!O-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
I UI
UI
<td>3-Cl-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>phenyl</td><td>phenyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>phenyl</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-Cl-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-H<sub>2</sub>NCO-benz ii</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
i — pt
- TT — Tx
<td>2-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>H</td>
<td>phenyl</td><td>phenyl</td><td>ch<sub>3</sub></td><td>OH</td>
<td>phenyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4-HO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4-Cl-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3-HO-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3-Cl-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3-pyridyl</td><td>H'</td><td>ch<sub>3</sub></td><td>OH</td>
<td>2-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>4-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>3-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>2-piridilmetil</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>CH<sub>3</sub></td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>(CH<sub>3</sub>)<sub>2</sub>CH</td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>OH</td>
etil alil alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil Alil
<td>HIGH<sub>2</sub>CH<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>high<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>(CH<sub>3</sub>) <sub>2</sub>ch</td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ho<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>eeil</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>high<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
<td>(CH<sub>3</sub>) <sub>2</sub>ch</td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>H</td><td>OH</td><td>ethyl</td>
m: ii you! I. I 11. ί t
<td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>H</td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub>ch<sub>2</sub></td><td>H</td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>high<sub>2</sub>ch<sub>2</sub></td><td>H</td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch</td><td>2 HIGH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub></td><td>H</td><td>OH</td><td>ethyl</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>and<sub>2</sub>ch<sub>2</sub>-</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>-</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>and<sub>2</sub>ch<sub>2</sub>-</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>-</td><td>H</td><td>OH</td><td>ethyl</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>and<sub>2</sub>ch<sub>2</sub>-</td><td>H</td><td>OH</td><td>ethyl</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>-</td><td>H</td><td> OH</td><td>ethyl</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>and<sub>2</sub>ch<sub>2</sub>-</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>-</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>and<sub>2</sub>ch<sub>2</sub>-</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>-</td><td>H</td><td>OH</td><td>alil</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>and<sub>2</sub>ch<sub>2</sub>-</td><td>H</td><td>OH</td><td>alil</td>
<td></td><td>-ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub>-</td><td>H</td><td>OH</td><td>alil</td>
The compounds of formula XIV, XV, XVI and XVII include, but are not limited to, compounds of the invention:
I illll III III i ui. , J.;
<img file="LT3533B_D0019.tif" />
XIV <sup>11111 1 iu</sup> 1 1 '[, K! I.
<img file="LT3533B_D0020.tif" />
T Tm<sup>-</sup> t t | illll III 11 (j I j 1 ·· J ··<sup>1</sup>
<img file="LT3533B_D0021.tif" />
ch<sub>3</sub>O
I IIINIHE
<img file="LT3533B_D0022.tif" />
ch<sub>3</sub>o and<sub>3</sub>
I 1131 III II ,1 I I I1L L· L
<td>kai R.<sup>6a</sup> are H or selected from such</td><td>CH<sub>3</sub>, O alternate</td><td>R<sup>2</sup>, R<sup>3</sup>, groups:</td><td>R<sup>5</sup> and R<sup>6</sup></td><td>meanings</td>
<td>R<sup>6</sup></td><td></td><td>R<sup>2</sup></td><td>R<sup>3</sup></td><td>R<sup>5</sup></td>
<td>H</td><td></td><td>CH<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>2</sub>= chch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>(CH<sub>3</sub>)<sub>2</sub>CH</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>phenyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-pyridyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-pyridyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-pyridyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-piridilmetil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-piridilmetil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-piridilmetil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-Cl-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
is
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>CH<sub>3</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>pub<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>2</sub>= chch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>(CH<sub>3</sub>) <sub>2</sub>ch</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>phenyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-pyridyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-pyridyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-pyridyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
I III! III III ! I I I 1. K·I
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>' ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>CH<sub>3</sub>CH;,</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>ch<sub>2</sub>= chch<sub>2</sub></td><td> ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>(CH<sub>3</sub>) <sub>2</sub>ch</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
i, h. i. iii iii
I 1 HUDD
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>phenyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-pyridyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-pyridyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-pyridyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil '</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
In enemy III .11; lf I i ajBii
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
Compounds of the present invention include compounds of formula XVIII, XIX, XX and XXI:
<sup>1 III11</sup>' <sup>1</sup> “ll 11 I I, III: Hll;
R<sup>a</sup>
<img file="LT3533B_D0023.tif" />
XVIII ch<sub>3</sub>O
III III III
I I ,111,1,11
OH
<img file="LT3533B_D0024.tif" />
AND,
CH<sub>3</sub>O
JOHN I 1111 YES
YOU'LL LIFE
<img file="LT3533B_D0025.tif" />
no m ui: ι ii
<img file="LT3533B_D0026.tif" />
ch<sub>3</sub>o and<sub>3</sub>
I .01 I 1111 III
<td rowspan="2">kai R.<sup>or</sup> are H or selected from such</td><td rowspan="2">CH<sub>3</sub>, O alternate</td><td colspan="3"> 71</td>
<td>R, R<sup>2</sup>, R<sup>3 </sup>groups:</td><td>and R<sup>5</sup></td><td>meanings</td>
<td>R<sup>a</sup></td><td></td><td>R<sup>2</sup></td><td>R<sup>3</sup></td><td>R<sup>5</sup></td>
<td>ch<sub>3</sub></td><td></td><td>CH<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>2</sub>= chch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>(CH<sub>3</sub>)<sub>2</sub>CH</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>(CH<sub>3</sub>) <sub>2</sub>ch<sub>2</sub></td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>phenyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-pyridyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-pyridyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-pyridyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-piridilmetil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-piridilmetil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-piridilmetil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C0benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-Cl-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-HO<sub>2</sub>C-benzil</td><td></td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
I Iii III 11
Π i IH, ii. L · !:
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>oh</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>čh<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch,=chch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>(CH<sub>3</sub>)<sub>2</sub>CH</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>(CH<sub>3</sub>) <sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>phenyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-pyridyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-pyridyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-pyridyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-piridiĮmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
), BEAUTIFUL. I 1111 III
I 1 HlM'.ll.t
<td>benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>ch<sub>3</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>ch<sub>2</sub>= chch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>ch<sub>3</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>(CH<sub>3</sub>) <sub>2</sub>ch</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>ho<sub>2</sub>cch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>h<sub>2</sub>ncoch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>high<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>high<sub>2</sub>ch<sub>2</sub>ch<sub>2</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
I 1119 III 11 l I <sup>!</sup>, lll.l·.·!',
<td>(CH<sub>3</sub>)'<sub>2</sub>CH<sub>2</sub></td><td>CH<sub>3</sub></td><td>OH</td><td>alil</td>
<td>phenyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-pyridyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-pyridyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-pyridyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-pyrdilmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
1111 “I, I, e;
Compounds of the present invention include compounds of formula XVIII:
<img file="LT3533B_D0027.tif" />
t rii ri ii n Trr · m iii: i H * 1.1111
LT 3533 Β
<td>kai X, R , R ir R alternate groups:</td><td>values are selected</td><td>from</td><td>such</td>
<td>X</td><td>R<sup>2</sup></td><td>R<sup>3</sup></td><td>R<sup>5</sup></td>
<td>1-imidazolilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-imidazolilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-Oxazolylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>5-tetrazolilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-R<sup>11</sup>0-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-R<sup>n</sup>0-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
to go—
LUJI
1111 III
II 111111111
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-R<sup>n</sup>0-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-(4-piridil)-imidazol-2-ίlmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (3-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (2-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-phenylimidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (4-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (4-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-(4-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (4-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (4-R<sup>xl</sup>0-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (4-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (4- (CH<sub>3</sub>) <sub>2</sub>N-fenil) -imidazol-2- ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (3-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (3-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (3-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (3-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-(3-R<sup>n</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (3-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (3- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (2-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-(2-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3-(2-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (2-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (2-R<sup>1:L</sup>0-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (2-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>3- (2- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>ethyl</td>
<td>1-imidazolilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-imidazolilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-Oxazolylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>5-tetrazolilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-R<sup>U</sup>0-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-R<sup>n</sup>0-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-ben'zil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
, H4
III III
I t llllli U HE
<td>2-HO<sub>2</sub>C-benzil 2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub>ch<sub>3</sub></td><td>H H</td><td>ethyl ethyl</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-R<sup>n</sup>0-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (4-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (2-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-phenylimidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (4-H0<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (4-H<sub>2</sub>NC0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (4-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (4-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-(4-R<sup>in</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (4-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-(4-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3-R<sup>11</sup>0-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (3- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (2-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-(2-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-(2-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
I IIII .11! . (I; if I iltiniai;
<td>3- (2-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3-(2-R<sup>n</sup>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (2-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>3- (2-CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>ethyl</td>
<td>1-imidazolilmetil</td><td>h</td><td>H</td><td>ethyl</td>
<td>2-imidazolilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-Thiazolylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-Thiazolylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-Oxazolylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>5-tetrazolilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>4-piridilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-piridilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-piridilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>4-HO-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>4-R<sup>11</sup>O-benzyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>4-Cl-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-HO-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-R<sup>1:L</sup>O-benzyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-Cl-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>H</td><td>ethyl</td>
·1
1111 «I
11i. ! 1
<td>2-HO<sub>2</sub>C-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-HO-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-R<sup>n</sup>0-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>2-Cl-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (4-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (3-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (2-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-phenylimidazol-2-ylmethyl</td><td>H-</td><td>H</td><td>ethyl</td>
<td>3- (4-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-(4-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (4-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (4-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (4-R<sup>11</sup>0-phenyl) -mylidazole-2-ilmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (4-Cl-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (4- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (3-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-(3-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-(3-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (3-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (3-R<sup>xl</sup>0-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (3-Cl-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (3- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (2-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (2-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (2-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
i II ·. lll II .iii ', Ι 1..1.11.
<td>3- (2-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>H</td><td>ethyl</td>
<td>3-(2-R<sup>n</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (2-Cl-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>3- (2- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>H</td><td>ethyl</td>
<td>1-imidazolilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-imidazolilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-Oxazolylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>5-tetrazolilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-piridilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-R<sup>in</sup>0-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-RX-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-R<sup>in</sup>0-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (4-pyridyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (3-pyridyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (2-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-phenylimidazol-2-ylmethyl</td><td>ch<sub>3</sub>.</td><td>OH</td><td>alil</td>
<td>3- (4-H0<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (4-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetii</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (4-CH<sub>3</sub>O-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (4-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-(4-R<sup>in</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (4-Cl-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-(4-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (3-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (3-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (3-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (3-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (3-R<sup>xl</sup>0-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (3-Cl-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-(3-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (2-HO<sub>2</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (2-H<sub>;</sub>NC0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (2-CH<sub>3</sub>O-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
i IMI III II 'I l II', Lili
<td>3- (2-HO-fenil) imidazol-2-ilmetil</td><td>CH<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-(2-R<sup>n</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3- (2-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>3-(2-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>OH</td><td>alil</td>
<td>1-imidazolilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-imidazolilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-Thiazolylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-Oxazolylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>5-te t razolilmet.il</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>4-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-piridilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>4-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil ·</td>
<td>4-R<sup>11</sup>0-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>4-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-HO<sub>2</sub>C-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-R<sup>n</sup>0-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil ·</td>
I liW
III HI l ϊ Hliu.i · !.
<td>2-HO<sub>2</sub>C-benzil</td><td>CH<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-HO-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-R<sup>in</sup>0-benzil.</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2-Cl-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (4-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (3-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (2-pyridyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-phenylimidazole-2-ylmethyl</td><td>ch<sub>3</sub>.</td><td>H</td><td>alil</td>
<td>3- (4-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (4-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (4-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (4-HO-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-(4-R<sup>in</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (4-Cl-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-(4-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (3-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (3-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-(3-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (3-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-(3-R<sup>n</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (3-Cl-phenyl) -imidazole-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-(3-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (2-H0<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (2-H<sub>2</sub>NC0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (2-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H '</td><td>alil</td>
i, aa u, iii, 1 I.11. J. 11
<td>3- (2-HO-fenil) imidazol-2-ilmetil</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-(2-R<sup>n</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3- (2-Cl-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>3-(2-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>ch<sub>3</sub></td><td>H</td><td>alil</td>
<td>1-imidazolilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>2-imidazolilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-Thiazolylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>2-Thiazolylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>2-Oxazolylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>5-tetrazolilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>4-piridiImetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-piridilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>2-piridilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>4-HO<sub>2</sub>C-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>H</td><td>OH</td><td>alil</td>
<td>4-HO-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>4-R<sup>11</sup>0-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>4-Cl-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-h0<sub>2</sub>C-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-H<sub>2</sub>NCO-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-CH<sub>3</sub>O-benzyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3-HO-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-R<sup>i:i</sup>O-benzyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3-Cl-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>OH</td><td>alil</td>
· ie, M 91 3 tt ΊΚ 1000
<td>2-HO<sub>2</sub>C-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>H</td><td>OH</td><td>alil</td>
<td>2-HO-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>2-Yo-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>2-Cl-benzil·</td><td>H</td><td>OH</td><td>alil</td>
<td>2-(CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (4-piridil) -mida'ZOl-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (3-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (2-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3-phenylimidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (4-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (4-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (4-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (4-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-(4-R<sup>n</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (4-Cl-fenil) -i'midazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-(4-(CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (3-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (3-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (3-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (3-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-(3-R<sup>n</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (3-Cl-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (3- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (2-HO<sub>2</sub>C-fenel)-imidazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (2-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-(2-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
ii m ii l 1 III!, i; !
<td>3- (2-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>OH</td><td>alil</td>
<td>3-(2-R<sup>in</sup>0-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (2-Cl-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>3- (2- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>OH</td><td>alil</td>
<td>1-imidazolilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>2-imidazolilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>3-Thiazolylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>2-Thiazolylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>2-Oxazolylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>5-tetrazolilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>4-piridilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>3-piridilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>2-piridilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>benzil</td><td>H</td><td>H</td><td>alil</td>
<td>4-h0<sub>2</sub>C-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>4-H<sub>2</sub>NCO-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>4-CH<sub>3</sub>O-benzyl</td><td>H</td><td>H</td><td>alil</td>
<td>4-HO-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>4-R<sup>U</sup>0-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>4-Cl-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>4- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3-h0<sub>2</sub>C-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3-H<sub>2</sub>NC0-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3-CH<sub>3</sub>0-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3-H0-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3-R<sup>11</sup>0-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3-Cl-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>H</td><td>alil</td>
I III III II IIH 1111111.1
<td>2-HO<sub>2</sub>C-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>2-H<sub>2</sub>NCO-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>2-CH<sub>3</sub>O-benzyl</td><td>H</td><td>H</td><td>alil</td>
<td>2-HO-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>2-R<sup>in</sup>0-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>2-Cl-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>2- (CH<sub>3</sub>) <sub>2</sub>N-benzil</td><td>H</td><td>H</td><td>alil</td>
<td>3- (4-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (3-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (2-pyridyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3-phenylimidazole-2-ylmethyl ·</td><td>H .</td><td>H</td><td>alil</td>
<td>3- (4-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (4-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>3-(4-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (4-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>3-(4-R<sup>n</sup>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (4-Cl-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (4- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (3-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (3-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>3- (3-CH<sub>3</sub>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (3-HO-fenil) imidazol-2-ilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>3-(3-R<sup>n</sup>O-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (3-Cl-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (3- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (2-HO<sub>2</sub>C-phenyl) -imidazol-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
<td>3- (2-H<sub>2</sub>NCO-fenil) -imidazol-2-ilmetil</td><td>H</td><td>H</td><td>alil</td>
<td>3- (2-CH, O-phenyl) -imidazole-2-ylmethyl</td><td>H</td><td>H</td><td>alil</td>
· Ι BU II II Iii. Lili
3- (2-HO-fenil) imidazol-2-ilmetil
3- (2-R<sup>xl</sup>O-phenyl) -imidazole-2-ylmethyl 3- (2-Cl-phenyl) -imidazole-2-ylmethyl 3- (2- (CH<sub>3</sub>) <sub>2</sub>N-phenyl) -imidazole-2-ylmethyl
HH alil
HH alil
HH alil
HH alil
B. SYNTHESIS OF COMPOUNDS
The starting materials for the synthesis of the compounds of the present invention are represented by Formula II:
<img file="LT3533B_D0028.tif" />
wherein E is hydrogen or methyl;
W is O or (H, OH);
R<sup>3</sup> is hydrogen, hydroxy or C<sub>1</sub>_<sub>6</sub>-alkoksiradikalas; R<sup>4</sup> is hydrogen, or R<sup>3</sup> and R<sup>4</sup> together form a double bond;
R<sup>5</sup> is methyl, ethyl, propyl, or allyl; and n is equal to 1 or 2.
The preparation and characterization of compounds of formula II are described in the literature (see U.S. Pat. No. 4,894,366, 1990,016; U.S. Pat. No. 4,929,611, May 29, 1990; U.S. Pat.
I Iii lll III 'Ii Iii: H · .L pat. Nr. 3 244 592,; EPO Nr. 0 323 042,; EPO Nr. 0 356 399,; PBJ 63-17884; J.Am. Chem. Soc., 1987, 109, 5031;
J. Antibiotics, 1987, 40, 1249; J. Antibiotics, 1988,
41(11), 1592; ir J. Antibiotics, 1992, 4 5 (1), 118).
Both bio-enzymatic and synthetic methods are described. A synthetic route for the preparation of compounds of formula II may include modifications of this route as described in J.Am. Chem. Soc., 11, 1157 (1989).
Biological fermentation and subsequent synthetic modification is currently the most suitable method for the preparation of compounds of formula II. Organisms belonging to the genus Streptomyces, such as Streptomyces tsukubaensis, No. 9993 and Streptomyces hygroscopicus, var. ascomycetis, no. No. 14891, when incorporated into an aqueous nutrient medium, produces the desired compounds in amounts that can be isolated. The nutrient medium contains assimilated sources of carbon and nitrogen, more suitable for aerobic conditions.
Fermentation produces four compounds of formula II:
(A), 4 when methyl, hydroxy, R<sup>4</sup> is hydrogen, R<sup>5</sup> is allyl and
1 to 2; droxyl <equals 2; hydroxy equal to 1.
is O, R is n is 2
<td>(B)</td><td>kai</td><td>E is methyl, W</td><td>is 0,</td><td>R<sup>3</sup></td><td>is hi-</td>
<td>, R<sup>4</sup></td><td>is</td><td>hydrogen, R<sup>5</sup> is</td><td>etilas</td><td>and</td><td>n is 2</td>
<td>(C)</td><td>kai</td><td>E is methyl, W</td><td>is 0,</td><td>R<sup>3</sup></td><td>is hi-</td>
<td>, R<sup>4</sup></td><td>is</td><td>hydrogen, R<sup>5</sup> is</td><td>methyl</td><td>and</td><td>n is 2</td>
<td>and</td><td>(D)</td><td>when E is methyl,</td><td>W is</td><td> 0,</td><td>— 3 R is</td>
5 hydroxy, R is hydrogen, R is allyl and n is
Freeze-dried isolated Streptomyces tsukubaensis, no. Example 9993 was deposited with Fermentation Research Institute, Agency of Industrial Science and Technology (No. 1-3, Higashi 1-chcme, Yatabemachi Tsukuba-gun, Ibaraki Prefecture, Japan), Deposit No. FERM P-7886 (date of deposit: 5.10.1984), thereafter deposited on 19.10.1985 with the new deposit no. FERM BP-927.
Using the four compounds produced by the above fermentation process, it is easy to prepare the remaining compounds of formula II,<sup>5 </sup>may be readily reduced to propyl by methods known in the art, such as, for example, U.S. Pat. No. 4,894,366 Hydroxy group R<sup>3</sup> the radical may be protected by methods well known in the art, such as described in EPO No. 0 323 042. Similarly, the hydroxy group on the C-4 radical may be protected. In addition, the hydroxy group R<sup>3 </sup>the radical may be reduced to hydrogen or eliminated to form a double bond to R<sup>4</sup> (These methods are described in U.S. Pat. No. 4,894,366, EPO No. 0 323 042, EPO No. 0 413 532). The carbonyl group in the radical W can be reduced to the alcohol using the methods described in EPO no. 0 323 042 or EPO
No. 0 445 975.
The resulting methyl in the E radical may be replaced by hydrogen or demethylated and then properly protected if necessary. Such demethylation of compounds wherein E is methyl may be accomplished by a demethylation reaction using compounds of formula II as a nutrient medium. For example, Compound A, described above in Formula II, can be demethylated at E using the microorganism Actinomycetales ATCC No. No. 53771 (U.S. Pat. 4 981 792) or using the microorganism Streptomyces tsukubaensis, No. 9993 (described in EPO No. 0 353 678). Similarly, Compound B, as defined above in Formula II, can be demethylated at E using the microorganism Actinoplanacete sp. No. 53771 (EPO No. 0 349 061). In addition, a compound of formula II wherein E is H, W is O, R<sup>3</sup> is a hydroxy group of 4, R is hydrogen, R is ethyl and n | II III || I iu ii. UBUI equal to 2 can be synthesized directly by fermentation using a mutant microorganism Streptomyces hygroscopicus sup. ascomyceticus, no. 53855 (This microorganism is a blocked mutant of Streptomyces hygroscopicus sup. Ascomyceticus, # 14891
EPO No. 0 388 152). Similarly, (a compound of formula II is described wherein E is H, W is O, R is hydroxy, R<sup>4</sup> is hydrogen, R<sup>5</sup> is methyl and n equals 2, can be synthesized simply by fermentation using a mutant microorganism Streptomyces hygroscopicus (this microorganism is sup. ascomyceticus, (described in EPO No. 0 388 Sup. ascomyceticus, No. 53855.
153). The hydroxy group at C-3 may be protected using similar methods to protecting the hydroxyl groups at R<sup>3</sup> and / or C-4 as described, for example, in U.S. Pat. No. 4,894,366.
Suitable hydroxyl protecting groups are well known, for example, methylthiomethyl, ethylthiomethyl; tripartite yarn, such as trimethylsilyl, triethylsilyl, tri-butylsilyl, tri-i-propylsilyl, t-butyldimethylsilyl, tri-t-butylsilyl, methyldiphenylsilyl, ethyldiphenylsilyl, t-butyldiphenylsilyl and the like; acrylics such as acetyl, pivaloylbenzoyl,
4-methoxybenzoyl, 4-nitrobenzoyl and aliphatic acyl substituted with an aromatic group which is a carboxylic acid derivative.
Compounds A, B, C and D of Formula II, organisms producing them, fermentation conditions, methods of isolation, and chemical modification of the products are fully described in U.S. Pat. No. 4,894,366, 1990; U.S. Pat. 4
929 611, 1990; U.S. Pat. No. 5,110,811, 1992.
Novel processes for the preparation of new compounds according to the present invention
12356789 illustrated below when R, R, R, R, R, R, RR,
II 11 .1 II 1 II.
R<sup>10</sup>, R<sup>11</sup>, E, W, and n have the meanings defined above unless otherwise stated. It will be apparent to those skilled in the art analyzing the synthesis route below that other compounds of formula I may be synthesized by substitution of the appropriate reagents and agents in the synthesis scheme provided.
I m m :ι ι i u··.
REACTION SCHEME a
<img file="LT3533B_D0029.tif" />
I.·
III III
II III I. II
REACTION SCHEME B
<img file="LT3533B_D0030.tif" />
4c 4b
AND THE H
REACTION SCHEME B (CONTINUED)
<img file="LT3533B_D0031.tif" />
( R<sup>2</sup>)<sub>3</sub>Bi (OAc)<sub>2 </sub>Cu (OAc)<sub>2 </sub>CH<sub>2</sub>C1<sub>2</sub>
<img file="LT3533B_D0032.tif" />
4a
5a
<img file="LT3533B_D0033.tif" />
4b
<img file="LT3533B_D0034.tif" />
5b
IIBIl · IJJLlill
I NIKIU ,10 J
REACTION SCHEME C
<img file="LT3533B_D0035.tif" />
<img file="LT3533B_D0036.tif" />
HUNU.
REACTION SCHEME D
<img file="LT3533B_D0037.tif" />
2b
IIIIJIH !J
100 reaction scheme e
<img file="LT3533B_D0038.tif" />
4c
4b
1I0UI 1111
I I ί AL I, I
101
REACTION SCHEME E (CONTINUED)
<img file="LT3533B_D0039.tif" />
<img file="LT3533B_D0040.tif" />
a'
4a '
<img file="LT3533B_D0041.tif" />
4b‘ b*
REACTION SCHEME F
III · m I:: I! I JU !,
102
<img file="LT3533B_D0042.tif" />
Th
REACTION SCHEME G
ulll UUI
EI! IU ί i, Kl
103
<img file="LT3533B_D0043.tif" />
<img file="LT3533B_D0044.tif" />
<img file="LT3533B_D0045.tif" />
ch<sub>3</sub>o and.
, i O o, pyndina
EtjO
<img file="LT3533B_D0046.tif" />
ch<sub>3</sub>o and<sub>3</sub>
1111 3111111 III E 11
I 11. »11 i U I
104
REACTIONS
SCHEME G (CONTINUED)
<img file="LT3533B_D0047.tif" />
<img file="LT3533B_D0048.tif" />
REACTION SCHEME H iubiili mm ι
E I L1IJ I , Kl
105
<img file="LT3533B_D0049.tif" />
CH<sub>3</sub>O and<sub>3</sub>
K (Ph)<sub>3</sub>BH
THF
<img file="LT3533B_D0050.tif" />
5
<img file="LT3533B_D0051.tif" />
illllll 11.1 LI; . 1 LlJlI BH
106
REACTION SCHEME I
<img file="LT3533B_D0052.tif" />
ch<sub>3</sub>o and,, 10
<img file="LT3533B_D0053.tif" />
,10
Illll I1U1II1IH
II! i, ft i.
107
REACTION SCHEME J
<img file="LT3533B_D0054.tif" />
8'
8
· I · ΙΙΙΙ iJIEIIIJ.L, I n ;; i
108
REACTION SCHEME J (CONTINUED)
<img file="LT3533B_D0055.tif" />
9
UI 11.11 n.
REACTION SCHEME J
109 (CONTINUATION)
<img file="LT3533B_D0056.tif" />
CH<sub>3</sub>O
HI IHIUllIilE; , I LUII
110
REACTION SCHEME J (CONTINUED)
<img file="LT3533B_D0057.tif" />
HF- pyridinas
THF
<img file="LT3533B_D0058.tif" />
IKI MII lllll: ll 1 II, HII.I ,; KJ
111
Reaction Scheme A:
As shown in Reaction Scheme A, a solution of 4 '' - hydroxy-3''methoxymacrolide in an inert organic solvent such as methylene chloride, benzene, toluene, chloroform or the like or a mixture thereof is treated with trietheroaryl bismuth diacetate (where R<sup>1 </sup>is heteroaryl) (synthesized immediately before use by adding acetic acid to triheteroaryl bismuthimide carbonate in an inert organic solvent such as methylene chloride, chloroform or the like or a mixture thereof) at a catalytic amount of copper (II) acetate at 20-50 ° C, more suitable room temperature , from one hour to seven days, a more suitable time is one day, and 4 '' - O-heteroaryl-3 '' - methoxymacrolide 2 is obtained. Alternatively, the triheteroarylbismuth (V) reagent may be synthesized by treating triheteroarylbismutin with a suitable oxidizing agent such as peracetic acid, benzoyl peroxide, iodobenzene diacetate, bis (trifluoroacetoxy) iodobenzene and the like. in an inert solvent such as methylene chloride, chloroform, benzene, toluene or the like or a mixture thereof. Trietheroaribismut (V) reagent may be used without purification or may be purified by chromatography on silica gel. The triheteroarylbismutins may be prepared by reacting the corresponding heteroaryl Grignard reagent or a lithium aryl lithium derivative with bismuth trichloride in or in an inert organic solvent such as tetrahydrofuran, diethyl ether, toluene or 1,4-dioxane for 1 hour to 48 hours at room temperature. close to room temperature. General procedures for the synthesis and use of triarylbismuth reagents are given in Barton, DHE, et al., J. Chem. Soc. Chem. Commun., 1986, 65, and in the works cited in this article.
112
I : 1.01! · a
Reaction Scheme B:
As shown in Reaction Scheme B, 3 '', 4 '' - Dihydroxy Macrolide 3 is treated with trietheroarylbismuth diacetate as described in Reaction Scheme A. This gives a mixture of 3 '' - hydroxy-4 '' - O-heteroarylacrolide 4a, 3 '. '-O-heteroaryl-4' '- hydroxymacrolide 4b and 3' ', 4' '-di-O-heteroarylacrolide 4c. At this stage, a solution of 3 '' - hydroxy-4 '' - O-heteroarylacaclide 4a or 3 '' - O-heteroaryl-4 '' - hydroxymacrolide 4b may be treated with triarylbismuth diacetate (prepared immediately before the methods described above), and yielding 3 '' - O-aryl-4 '' - O-heteroarylacrolide 5a, or 3 '' - O-heteroaryl-4 '' - O-arylacrolide 5a, respectively.
Reaction Scheme C:
As shown in Reaction Scheme C, the 14-hydroxy group in macrolide 5a or 5b (when R<sup>1</sup>, R<sup>2</sup>, R<sup>5</sup>, R<sup>10</sup>, W, and n have the meanings defined above) can be eliminated by treatment with p-toluenesulfonic acid, benzenesulfonic acid or methanesulfonic acid in an inert organic solvent such as benzene or toluene at a temperature of 40 ° C to 60 ° C for about 0.5 to 6 hours. or for a sufficient period of time to eliminate the 14-hydroxy group. After neutralization with an aqueous solution of a weak base such as an aqueous saturated solution of sodium bicarbonate, 14,15-dehydromacrolide 6a or 6b is obtained. Alternatively, the 14-hydroxy group may be eliminated by activation and subsequent elimination by treatment with a base as described in U.S. Pat. No. 4,894,366.
By changing the sequence of fusion steps, all the substituent variations can be obtained.
l· Iii ,. s
113
Reaction Scheme D:
As depicted in Reaction Scheme D, 4 '' -hydroxy-3 '' methoxymacrolide in solution in an inert organic solvent such as methylene chloride, chloroform, pentane, hexane, cyclohexane, heptane, or a mixture thereof, is reacted with heteroarylalkyl, heteroarylalkenyl or heteroaryl prepared by reacting the corresponding sodium alkoxide with trichloroacetonitrile as described by Wessel, HP, Iversen, T., Bundle, DR, J. Chem. Soc., Perkin Trans. I, 1985, 2247), in the presence of a mild acidic catalyst such as trifluoromethanesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, or mixtures thereof, at a temperature of 20 ° -50 ° C for a period of from 1 hour to seven days gives 4 ''. -O-heteroarylalkyl, 4 '' - 0 heteroarylalkenyl or 4 '' - O-heteroarylalkynyl-3 '' - methoxymacrolide 2a.
Reaction Scheme E:
In a manner analogous to Reaction Scheme E, 34 '' - dihydroxymacrolide in an inert organic solvent such as methylene chloride, chloroform, pentane, hexane, cyclohexane, heptane, or a mixture thereof, under the action of heteroarylalkyl, heteroarylalkenyl or heteroarylalkynyl D) at 20 ° C to 50 ° C, 40 ° C for 1 hour to 7 days is more appropriate, more preferably a time of 6 hours to obtain a mixture of 4 '' - O-heteroarylalkyl, 4 '' - O-heteroarylalkenyl or 4 '' - O-heteroarylalkynyl 3 '' - hydroxymacrolide 4a <sup>1</sup> , 3 '' - O-heteroarylalkyl-, 3''O-heteroarylalkenyl-arba 3 '' - O-heteroarylquinyl-4hydroxyacrolido 4b 'ir 3' ', 4' '- di-O-heteroarylalkyl-,
IMU IIUI JI II! SI .1 II
114
3 '', 4 '' - di-O-heteroarylalkenyl and 3 '', 4 '' - di-O-heteroarylalkynylacrolide 4c '. Thereafter, a solution of 4 '' - O-heteroaryl, 4 '' - O-heteroarylalkyl, 4 '' - O-heteroarylalkenyl or 4 '' - O-heteroarylalkynyl-3 '' - hydroxymacrolide 4a from Reaction Scheme B or 4a 'or 3' '- Oheteroaryl-, 3<sup>1</sup>A solution of '-O-heteroarylalkyl, 3' '- O-heteroarylalkenyl or 3' '- O-heteroarylalkyl-4' '- hydroxymacrolide 4a from Reaction Scheme B or 4b' may be treated with arylalkyl, alkenyl, or alkynyl trichloroacetimidate according to the procedures described above) and the macrolide 5a is obtained<sup>1</sup> or 5b<sup>1</sup> .
The procedures described in Reaction Schemes C and D may be carried out, if necessary, according to the procedures described in Reaction Scheme E or F. Alternatively, the procedures described in Reaction Scheme F may be performed.
The macrolide in each of the above reaction schemes (where R and / or R contains alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and wherein R<sup>3</sup> is hydroxy or C 1-8 alkoxy, R<sup>4</sup> is hydrogen, or R<sup>3</sup> and .R<sup>4</sup> together form a double bond) can be reduced to the reduced macrolide by treatment with tri-n-butyl tin hydride in the presence of tetrakis (triphenylphosphine) palladium (O) catalyst and acetic acid in an organic solvent such as toluene or tetrahydrofuran at close to room temperature for 2 to 10 minutes. hours.
The procedures described in Reaction Scheme F may be performed with mono-substituted products of Reaction Scheme B (and vice versa) to synthesize mixed disubstituted products. In fact, in Reaction Schemes B and F, mixed mono-substituted products can yield mixed disubstituted products by treating the monosubstituted products with different reagents.
115
Reaction Scheme F:
The hydroxyl groups in the C-3 '', C-4 '' and / or C-14 radicals may be protected by known methods adapted to compounds of formula II, for example, by treatment with 2,6-lutidine and triisopropylsilyl trifluoromethanesulfonate in methylene chloride solution; 2,6-lutidine and t-butyldimethylsilyl trifluoromethanesulfonate in methylene chloride solution; pyridine and acetic anhydride in methylene chloride solution; pyridine and p-nitrobenzoyl chloride in dichloromethane solution; imidazole and t-butyldiphenylsilyl chloride in methylene chloride solution; and etc. For example, as shown in Reaction Scheme F, C-4 '', 14-Dihydro'-C-3 '' -methoxymacrolide β can be protected at C-14 as t-butyldimethylsilyl ether by treatment with t-butyldimethylsilyl trifluoromethanesulfonate in methylene chloride solution. -4 ′ ′, 14-diO-TBDMS macrolide. Treatment with toluene sulfuric acid in methanol selectively removes the C-4 '' filament ether and yields the C-14-O-TBDMS macrolide 8.
Reaction Scheme G:
As shown in Reaction Scheme G, 4 '' - hydroxy-3''R<sup>2</sup>0-macrolide J3 or 3 '' -hydroxy-4 '' -R<sup>2</sup>0 - macrolide (not shown in the diagram) (where R<sup>3</sup> is protected hydroxyl or hydrogen) can react with alkenyl trichloroacetimidate (when alkenyl is C<sub>3</sub>_<sub>10</sub> alkenyl) under reaction conditions in Scheme E to give O-alkenylacrolide 10. By acting on a stoichiometric amount of osmium tetroxide in an inert organic solvent such as diethyl ether or tetrahydrofuran, an amine base such as pyridine at room temperature or near room temperature yields the corresponding glycol 11 (when A is C).<sub>x</sub>_<sub>8</sub> alkyl). The action of glycol 11 on the sodium metaperate in the tetrahydrofuran / 'water mixture yields the aldehyde 12. As an alternative to the alkenylιαηιι
116 macrolide 10 can be reacted with sodium metaperiodate in the presence of catalytic amounts of osmium tetroxide in an organic solvent to produce the aldehyde directly. The aldehyde 12 may be further oxidized to the carboxylic acid 13 by any known method.
Reaction Scheme H:
As shown in Reaction Scheme H, many compounds can be synthesized from aldehyde 12. Reaction of the aldehyde 12 6 7 with primary or secondary amines, HNR R (when R<sup>6</sup> and / or R<sup>7</sup> has the meanings as defined above and has a heteroaryl group) in an organic solvent such as tetrahydrofuran, which is obtained by imine reduction in situ with a hydrogen reducing agent such as sodium cyanoborohydride to give the macrolide 14 having an aminoalkoxy group at the C-4 '' position. The aldehyde 12 may be reduced to the corresponding alcohol 15 by treatment with a hydride reducing agent such as potassium triphenylborohydride or sodium cyanoborohydride in an organic solvent such as tetrahydrofuran. The alcohol 15 can then be modified using the methods in Reaction Scheme B (where R<sup>1</sup> has the meanings defined above) or in Reaction Scheme E to afford the macrolide 116 .. The procedures described in Reaction Scheme H can be readily adapted for the synthesis of compounds having analogous groups at the C-3 '' position.
Reaction Scheme I:
The amide derivatives can be synthesized from carboxylic acid 13 according to Reaction Scheme I. The carboxylic acid 13 can be attached to the primary 6 7 6 7 or secondary amine, HNR R (wherein R and / or R have the meanings given above and have a heteroaryl group) commonly used peptide coupling method such as BOP reagent or DCC / HOBT.
I I II II I HUi 1.
J Ji UI! . i B;
Reaction Scheme J:
117
The hydroxyl or fluorine may be introduced at position C-20 using the procedures in Reaction Scheme I. As shown in Reaction Scheme R, the 4'-14-dihydroxymacrolide (or 14-deoxymacrolide) is protected as di (t-butyldimethylsilyl ether) by t-butyldimethylsilyl triflate in an inert organic solvent such as methylene chloride, chloroform or the like in the presence of a non-nucleophilic base such as 2,6-lutidine. The disubstituted macrolide is oxidized at the C-20 position to selenium dioxide in an alcoholic solvent such as ethanol in the presence of pyridine at the boiling point of the solvent to give 20-hydroxymacrolide (18). The 20-hydroxymacrolide is then derivatized at C-20 by alkylation, acylation or phosphorylation to give ether, ester or phosphate derivatives using methods known to those skilled in the art. It is further shown that the reaction of 20-hydroxy-4 '', 14-di-OTBS-macrolide with diethylaminosulfotrifluoride in an inert organic solvent such as methylene chloride, chloroform or the like at a temperature from about 0 ° C to -90 ° C is more suitable 78 ° C to give 20-fluoro-4,14-di-OTBS macrolide (19). Removal of the silyl ether protecting groups by treatment with the fluorine-hydrogen-pyridine complex in tetrahydrofuran affords 20-fluoro-414-dihydroxymacrolide, which can then be derivatized by any of the methods described above. The procedures outlined in Reaction Scheme J can also be performed with 3 '', 4 '', 14-trihydroxymacrolide to give 20-fluoro-3 '', 4 '', 14-trihydroxymacrolide. The procedures outlined in Reaction Scheme J may be performed before, concurrently, or after the procedures outlined in Reaction Schemes AI.
The target compounds of formula I obtained by the reactions explained above can also be isolated
I · RELIGIOUS IIJ, 101 · ί
118 purified by known techniques such as extraction, precipitation, fractional crystallization, recrystallization, chromatography, and the like.
In compounds of formula I, OR<sup>1</sup> may be substituted at C-4 '' or C-3 '' or C-4 '' and C-3 '' positions (where R<sup>2</sup> is independently selected from R<sup>1</sup> values.), but better when -OR<sup>1</sup> substituted at C-4 '' position.
It should be noted that the stereoisomers of starting materials and end products in the above reactions and in the post-reaction reaction mixture may, due to the presence of asymmetric carbon atoms or double bonds in the final products of formula I, sometimes be transformed into other stereoisomers and such also included within the scope of the present invention.
Compounds having asymmetric centers in the present invention may exist in the form of racemates, diastereomeric mixtures and individual isomers, and all isomeric forms are included in the present invention. They may be synthesized using methods such as those disclosed in the publications describing the synthesis pathways of the macrolide FR-900506 moieties and the entire synthesis of the macrolide FR-900506 itself (J. Am. Chem. Soc., 1989, 111, 1157; J. Am. Soc., 1990, 112, 2998; J. Org. Chem. 1990, 55, 2786; J. Am. Chem. Soc. 1990, 112, 5583; Tetrahedron
Lett. 1988, 29, 277; Tetrahedron Lett. 1988, 29, 3895; J. Org. Chem. 1988, 53, 4643; Tetrahedron Lett. 1988,
29, 4245; Tetrahedron Lett. 1988, 29, 4481; J. Org.
Chem. 1989, 54, 9; J. Org. Chem. 1989, 54, 12; J. Org. Chem. 1989, 54, 15; J. Org. Chem. 1989, 54, 17; Tetrahedron Lett. 1989, 30, 919; Tetrahedron Lett. 1988,
30, 1037; J. Org. Chem. 1989, 54, 2785; J. Org. Chem. 1989, 54, 4267; Tetrahedron Lett. 1989, 30, 5235; Tetrahedron Lett. 1989, 30, 6611; Tetrahedron Lett.
ii; iii Linui, i
<td></td><td></td><td> 119</td><td></td><td></td>
<td> 1989, 30,</td><td> 6963;</td><td>Synlett 1990,</td><td>38; J. Org. Chem.</td><td> 1990,</td>
<td> 55, 2284;</td><td>J. Org</td><td>. Chem. 1990,</td><td>55, 2771; J. Org.</td><td>Chem.</td>
<td> 1990, 55,</td><td> 2776;</td><td>Tetrahedron</td><td>Became. 1990, 31,</td><td> 1439;</td>
<td colspan="2">Tetrahedron Lett</td><td> . 1990, 31,</td><td>3007; Tetrahedron</td><td>Became.</td>
<td> 1990, 31,</td><td colspan="2"> 3283, 3287) .</td><td></td><td></td>
<td colspan="4">The compounds of the present invention may form salts with</td><td>owls</td>
inorganic and organic acids and bases, and such salts are also included in the present invention. Examples of such acid salts (which are negatively ionic and denoted herein as M ') include acetate, adipate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, ethanesulfonate, fumarate, hemisulfate, heptanoate, hexanoate, hydrochloride , hydroiodide, methanesulfonate, lactate, maleate, 2-naphthalenesulfonate, oxalate, pamoate, persulfate, picrate, pivalate, propionate, succinate, tartrate, tosylate and undecanoate. The base salts (which are positive kaunter-ions and are referred to herein as M<sup>+</sup>) may be ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, etc. The basic nitrogen-containing groups may be quaternized with the following agents: lower alkyl halides such as methyl, ethyl, propyl and butyl chloride, bromides, and iodides; dialkyl sulfates including dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides including decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides such as benzyl bromide and the like. Non-toxic physiologically acceptable salts are preferred, although other salts are also useful, for example, in isolation or purification of the product.
I · UUUilHI 'i I II JII JII;
120
Salts may be prepared by standard methods, for example, by reacting the product as the free base with one or more equivalents of the appropriate acid in a solvent or medium insoluble in the salt, or in a solvent such as water that is removed under vacuum or lyophilization, or anion on a suitable ion exchange resin.
C. Use of compounds according to the present invention.
The compounds of formula I may be used as immunosuppressants or antimicrobial compounds according to such methods and at such doses as are known and indicated for compounds of formula I. These compounds exhibit pharmacological activity such as antimicrobial activity and the like and are therefore useful in transplant resistance or rejection of transplanted organs or tissues (e.g., heart, kidney, liver, lung, bone marrow, cornea, pancreas, small intestine, muscles, treatment and prophylaxis of nerves, bone marrow, skin, pancreatic islet cells, etc., including xenografts, treatment of graft-versus-host disease, in the treatment of autoimmune diseases such as rheumatoid arthritis, systemic lupus nephrotic lupus syndrome, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, type II adult diabetes, uveitis, nephrotic syndrome, and steroid dependent, purulent palmar rash, allergic encephalomyelitis, glomerulonephritis, and 1.1, and infectious diseases caused by pathogenic microorganisms.
The compounds of formula I are also useful in the treatment of inflammatory, proliferative and hyperproliferative skin diseases and immune disorders iiiii dilium i.
j ji ui 111
121 on the skin such as psoriasis, psoriatic arthritis, atopic dermatitis, contact dermatitis and other eczema dermatitis, seborrheic dermatitis, lupus erythematosus, bullous, bullous bullous, bullous epidermolysis, urticaria, erysipelas, aleus, angioedema, eusinophilic fasciitis and atherosclerosis. The compounds of formula I are particularly useful for hair regeneration, for example in the treatment of male or female alopecia or senile alopecia, for the prevention of epilation, for hair maturation and / or for hair formation and growth.
The compounds of formula I are also useful in the treatment of respiratory diseases such as sarcoidosis, pneumoclerosis, idiopathic interstitial pneumonia and reversible obstructive airways diseases including asthma, including bronchial asthma, allergic asthma, hereditary asthma, acquired asthma, asthma, particularly chronic asthma that is difficult to treat (for example, late asthma and airway hyperresponsiveness), bronchitis and the like. Compounds of formula I may also be useful in treating liver injury associated with ischemic disease.
The compounds of the present invention are also suitable for use in certain ocular disorders such as keratoconjunctivitis, spring conjunctivitis, uveitis, conjunctivitis with Behcet's disease, keratitis, conic cornea, corneal epithelial dystrophy, corneal leukoma, blistering of the eye, Greneal ulcer, scleritis severe intraocular inflammation and so on.
The compounds of formula I are also useful in the treatment of multiple drug resistance in cancer cells (i.e., enhancing the activity and / or sensitivity of chemotherapeutic agents), inflammation of the mucous membranes or blood vessels, or its proI · Ι1ΙΙ iBLIlII; i! II. .11B J EI «ί
122 phylactics (for example, leukotriene B<sub>4</sub> diseases caused by stomach ulcers, vascular injury due to ischemic disease and thrombosis, ischemic bowel disease (such as Crohn's disease and ulcerative colitis, necrotic enterocolitis, or intestinal lesions associated with thermal burns, cytomegalovirus infection, particularly HCMV infection.
In addition, compounds of formula I are useful in the treatment and prophylaxis of renal disease, including interstitial nephritis, Goodpasture syndrome, haemolytic uremic syndrome, and diabetic nephropathy; nerve diseases including multiple myositis, Guillain-Barre syndrome, Meniere's disease and radiculopathy; endocrine disorders including hyperthyroidism and Bazedov's disease; blood diseases including true erythrocytic aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic pink rash, autoimmune hemolytic anemia, agranulocytosis and anerythroplasia; bone diseases, including osteoporosis; respiratory diseases, including sarcoidosis, pneumofibrosis, and idiopathic interstitial pneumonia; skin diseases including dermatomyositis, leukoderma, ichthyosis, photosensitivity and skin T-cell lymphoma; circulatory diseases including arteriosclerosis, aortitis, multiple nodular inflammation and myocardosis; collagenous scleroderma, Wegener's granuloma, and Sjogren's syndrome; adiposis; eusinophilic fasciitis; periodontal disease; nephrotic syndrome; hemolytic uremic syndrome and muscular dystrophy.
In addition, the compounds of the present invention are useful in the treatment of diseases such as gastrointestinal inflammation and allergies such as Coelia disease, proctitis, eusinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis; food allergies,
IBIUI uui «jįjį i.
1.1: Hll):: a
123 with symptomatic manifestations outside the gastrointestinal tract such as migraine, rhinitis and eczema.
The compounds of the present invention also exhibit liver regenerative activity and / or activity in stimulating hepatocyte hypertrophy and hyperplasia. Therefore, they are useful for the treatment and prevention of liver diseases such as immunogenic diseases (including chronic autoimmune liver diseases such as autoimmune hepatitis, primary biliary cirrhosis and sclerotic cholangitis), partial liver resection, acute liver necrosis (e.g., toxin-induced necrosis, viral hepatitis, shock or anoxia), hepatitis B, non-A and non-B hepatitis, and cirrhosis.
The compounds of the present invention are useful as antimicrobial agents and may therefore be used in the treatment of diseases caused by pathogenic microorganisms and the like.
Compounds of Formula I may act as antagonists of macrocyclic immunosuppressants, including 12 (2'-cyclohexyl-1)<sup>1</sup>-methyl vinyl) -13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -oktakoz18-eno derivatives, and thus be useful in the treatment of immunodepression (e.g. AIDS, cancer, senile dementia, trauma (including wound healing, surgery and shock), chronic bacterial infection and some central nervous system disorders), overdosage or toxicity of immunosuppressants and use them as adjunct vaccines.
The pharmaceutical compositions of the present invention may be used in the form of pharmaceutical preparations such as solid, semi-solid or liquid formulations containing one or more compounds of the present invention as active ingredients in admixture with organic or inorganic carriers or
I fllll: llfil.111 .11 to .11 i. I lli the ·
124 fillers suitable for topical, enteral or parenteral administration. The active ingredient may be formulated with, for example, conventional non-toxic, pharmaceutically acceptable carriers for tablets, pills, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers used are water, glucose, gelatin, mannitol, starch paste, magnesium trisilicate, talc, keratin, colloidal silicon, potato starch, urea and other carriers suitable for use in the preparation of solid, semi-solid or liquid preparations; in addition, auxiliary, stabilizing, thickening and coloring agents and flavoring agents may be used. For example, compounds of formula I may be used with hydroxypropylmethylcellulose as described in U.S. Pat. No. 4,916,138, 1990, or with a surfactant as described in EPO no. 0 428 169. Oral dosage forms may be prepared as described by T. Hondo, et al., Transplantation Proceedings, 1987, XIX, Supp. 6, 17-22. Dosage forms for topical use may be prepared as described in EPO No. 4,198. 0 423 714. The pharmaceutical composition comprises an amount of the active target compound sufficient to achieve the desired effect depending on the process or condition.
Compounds of formula I for use in the treatment of ailments and diseases caused by immune system disorders may be administered by the oral, topical, parenteral, spray or rectal routes. Their dosage unit contains conventional non-toxic, pharmaceutically acceptable carriers, adjuvants and excipients. The term parenteral as used herein refers to subcutaneous, intravenous, intramuscular, intrasternal or infusion procedures.
lllll flIUIILIE i su. > i a i
125
For the treatment of reversible obstructive airway disease, the use of a compound of formula I for pulmonary inhalation is preferred.
In order to modify the activity and / or toxicity of FK-506 type immunosuppressants, a compound of formula I may be administered prior to, concurrently, or following administration of an FK-506 type compound.
The compounds of Formula I may be used in combination with an antiproliferative agent selected from the group consisting of: azathioprine, brequinar sodium, deoxyspergauine, mizaribine, morpholine ester of mycophenolic acid, cyclosporine, and rapamycin.
Dosages of the compounds of the present invention range from about 0.005 mg to about 50 mg per kilogram of body weight per day, more preferably from about 0.1 mg to about 10 mg per kilogram of body weight per day. Such doses are useful for the indications indicated above (from about 0.7 to about 3.5 mg per patient per day, assuming a patient weight of 70 kg). In addition, the compounds of the present invention may be administered in the intermittent mode; ie daily, semi-weekly, weekly, semi-monthly or monthly.
The amount of active ingredient that can be combined with the carrier to produce a single dosage form will vary depending upon the subject being treated and the route of administration. For example, a formulation for oral administration to humans may contain from 0.5 mg to 5 g of the active compound in admixture with an appropriate and conventional carrier range ranging from about 5 to 95% of the total composition. A dosage unit will generally contain from about 0.01 mg to about 500 mg, more preferably from about 0.5 mg to about 100 mg of active meι · ιιιι amu uuiu .1 uu ·
126 yogis. In a formulation for topical use, the amount of a compound of formula I in the formulation may be present
<td></td><td>from</td><td> 0.0001 %</td><td>to</td><td>60% by weight, more</td><td>fit</td><td>quantity</td>
<td></td><td>from</td><td>0.001 to</td><td> 10</td><td>% by weight, most</td><td>fit</td><td>quantity</td>
<td> 5</td><td>from</td><td>0.005 to</td><td> 0.8</td><td>% by weight.</td><td></td><td></td>
It will be appreciated that the specific dosage for each patient will depend on a variety of factors including the activity of the compounds used, the age of the individual, body weight, general health, sex, diet, time and route of administration, rate of release, drug combination and severity of treatment.
The following examples are merely illustrative of the present invention and are not to be construed as limiting the scope or scope of the present invention.
127
SYNTHESIS OF INITIALS AND INTERMEDIATES
17-Ethyl-1-hydroxy-12- [2'- (4 '' - hydroxy-3 '' -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27, 27-tetramethyl -ll, 28-dioxa-4-azartricyclo [22.3.1. ON<sup>4</sup>'<sup>9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
A solution of 500 mg of 17-ethyl-1,14-dihydroxy-12 - [2 '- (4' '-hydroxy-3' '- methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1.0<sup>4</sup>'<sup>9</sup>] octacos-18-en-2, 3, 10, 16-tetraone and 7 mL of benzene, treated with 10 mg of ptoluenesulfonic acid and heated at 60 ° C for two hours. The reaction mixture was poured into a saturated sodium bicarbonate solution and extracted with ethyl acetate. The combined organic layers were washed with water and saturated sodium chloride solution, dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel (66% ethyl acetate: 33% hexane: 1% methanol) to give 350 mg of product. This material is dissolved in 10 ml of ethyl acetate and reduced with 15 mg of 5% Rh / C. Hydrogen was bubbled through the reaction mixture and stirred until the reaction was complete. The mixture is filtered through diatomaceous earth, concentrated and the residue is chromatographed (75% CH 2 Cl 2)<sub>2</sub>C1<sub>2</sub>: 5% MeOH: 20% hexane) to give 294 mg of product.
17-Ethyl-1-hydroxy-12- [2 '- (4' ', 3' '-dihydroxy-oxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21,
27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1. SHE<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
A solution of 210 mg 17-ethyl-1,14-dihydroxy-12 [2'- (4 '' -hydroxy-3 '' -hydroxycyclohex) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21 , 27-tetramethyl-11,
28- dioxa-4-azatricyclo- [2.2.3 .1. ABOUT<sup>4,9</sup>] Oct-18-in-2,.
3, 10, 16-tetraone, 40 ml benzene, and catalytic content is low
128 p-toluenesulphuric acid, boiled under nitrogen for 4 hours. The solvent is removed under reduced pressure, the dark residue is chromatographed (silica gel), 7% i-propanol / CH<sub>2</sub>Cl<sub>2</sub>) to give 180 mg of a white solid, 17-ethyl-1-hydroxy-12- [2 '- (4' '-hydroxy 3' '- isopropyloxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19 , 21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4</sup>'<sup>9</sup>] octacos-14, 18-diene-2,3,10,16tetraone. This material was dissolved in ethanol (20 mL) and treated with 5% Rh / C (40 mg). The hydrogen is purged from the cylinder for 30 minutes, after which the mixture is filtered through celite. Chromatography (silica gel) gives 172 mg of the title compound. Mass spectra,
H, C NMR spectra are consistent with the structure of the title compound.
17-Ethyl-1-hydroxy-12- [2 '- (4' '-triisopropylsilyloxy3' '- methoxycyclohexyl) -1'-methylvinyl] -14-triisopropylsilyloxy-23, 25-dimethoxy-13, 19, 21, 27- tetramethyl, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] oktakoz-18-en2, 3, 10, 16-tetraonas
To a cooled (0 ° C) solution of 17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' -hydroxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy -13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [2.3.1.0]<sup>4</sup>'<sup>9</sup>] octacos-18-en-2, 3, 10, 16-tetraone (120 mg and dry methylene chloride (15 mL), 2,6-lutidine (64.3 mg) and triisopropylsilyl trifluoromethanesulfonate (184 mg) were added. The reaction mixture is brought to room temperature and stirred overnight under nitrogen atmosphere, 10 ml of water are added to quench the reaction and the mixture is extracted with ethyl acetate.<sub>3</sub>saturated NaCl) and dried (anhydrous MgSO4). The solvent was removed by silica gel chromatography (70% hexane / ethyl acetate) to give 150 mg of product.<sup>+</sup> + Li).
name mm ι:
129
17-Ethyl-1-hydroxy-12- [2 '- (4' '-hydroxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -14-triisopropylsilyloxy 23, 25-dimethoxy-13, 19, 21, 27- tetramethyl-1,11-28-dioxa-4-azatricyclo- [22.3.1. ON<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas
The title compound from the above procedure (680 mg) was dissolved in methylene chloride (45 mL) and a 10% solution of p-toluene sulfuric acid in methanol (45 mL) was added with stirring. The mixture was stirred at room temperature and followed by thin layer chromatography (TLC). After 4 hours, the reaction was quenched with saturated sodium bicarbonate solution and extracted three times with ethyl acetate. After work-up and removal of the solvent, the residue is chromatographed on a silica gel column (80% ethyl acetate / hexane) to give 560 mg of product (2a) as a white solid. Mass Spectrum: (FAB) 954 {M<sup>+</sup> + Li).
17- Ethyl-1-hydroxy-12- [2 '- (4' '- t-butyldimethylsilyloxy3' '- methoxycyclohexyl) -1'-methylvinyl] -14- t-butyldimethylsilyloxy-23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxsa-4-azatriciclo- [22.3.1.O<sup>4</sup>’<sup>9</sup>] octacos18-en-2, 3, 10, 16-tetraone in a cooled (0 ° C) solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] 2,6-lutidine (160 mg) and t-butyldimethylsilyl trifluoromethanesulfonate (250 mg) were added to octacos-18-en-2, 3, 10, 16-tetraone (395 mg) and dry methylene chloride (15 mL). The reaction temperature was raised to room temperature and stirred overnight under a nitrogen atmosphere. To quench the reaction, add 10 mL of water and extract with ethyl acetate. The organic layer is washed (water saturated with NaHCO3)<sub>3</sub>, saturated with NaCl) and dried (noI MII! IVUI.IIIII JI II -JI 19 III ·
130 water MgSO<sub>4</sub>). Removal of the solvent gives 500 mg of crude product. Mass Spectrum: (FAB) 1023 {M<sup>+</sup> + Li).
17-Ethyl-1-hydroxy-12- [2 '- (4' '-hydroxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -14- t-butyldimethyl-silyloxy-23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-II, 28dioxsa-4-azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octave-18-in-2, 3, 10,
16- tetraonas
The product from the above sample (500 mg) was dissolved in acetonitrile (20 mL) and 100 mL of hydrogen fluoride (48%) was added. The reaction mixture was stirred for 20 min at room temperature, quenched with saturated sodium bicarbonate solution, then extracted with ethyl acetate. After removal of the solvent in vacuo, the residue is chromatographed on silica gel (80% ethyl acetate / hexane) to give 300 mg of product. Mass spectra,<sup>4</sup>H <sup>13</sup>C NMR spectra are consistent with the structure of the title compound.
17- Ethyl-1-hydroxy-12- [2 '- (4' '- t-butyldimethylsilyloxy3' '- hydroxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl- 11, 28-dioxa-4-azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2'- (3 '', 4 '' - dihydroxycyclohexyl) -1'-methylvinyl] -2,3,5-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1. O<sup>4</sup>'<sup>9</sup>] An excess of imidazole (809 mg) and t-butyldimethylsilyl chloride (716 mg) were added to octacos-18-en-2, 3, 10, 16-tetraone (3.01 mg) and dry methylene chloride (70 mL). After stirring for 3 days at room temperature, the mixture was diluted with ethyl acetate, then the ethyl acetate layer was washed with IN HCl, saturated NaHCO<sub>3</sub> saturated NaCl solution and purified by flash chromatography (ethyl acetate: hexane (1: 3)). 941 mg is obtained under the name nuroι · ιιιι northern ι ι
11, n .: i
LT 3533 Β
131 of a given compound. <sup>X.</sup>Η NMR spectra are consistent with the structure of the desired compound.
17-Ethyl-1-hydroxy-12- [2 '- (4' '-t-butyldimethylsilyloxy3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl- 11, 28-dioxa-4-azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2 '- (4''-hydroxy-3' '-methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-azatricyclo [2.3.1. O<sup>4,9</sup>] An excess of 2,6-lutidine (45 μΐ) was added to octacos-18-en-2, 3, 10, 16-tetraone (200 mg) and dry methylene chloride (3 mL) and stirred at room temperature. After 10 minutes, trifluoromethanesulfonate (64 μΐ) was injected with a syringe. After 15 minutes, the reaction mixture was diluted with ethyl acetate extracted from saturated bicarbonate, washed with brine, dried over magnesium sulfate. After removal of the solvent in vacuo, the product is purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 2) + 1% methanol). 235 mg of the title compound are obtained. .<sup>X</sup>H NMR spectra are consistent with the structure of the desired compound.
17-Ethyl-1,20-dihydroxy-12- [2 '- (4' '- t-butyldimethylsilyloxy-3' '-methoxycyclohexyl-1'-methyl-vinyl) -23,25-dimethoxy-13,19,21,27-tetramethyl -11,28-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2 '- (4'-butyldimethylsilyloxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13, 19, 21, 27-tetramethyl, 28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] octacos-18-en2, 3, 10, 16-tetraone (235 mg) and 95% ethanol (2.2 ml) with stirring added 53 μΐ of pyridine followed by
132 selenium dioxide (58 mg). Connect the flask to the water refrigerator and heat to 70 ° C. After 20 hours, the mixture was cooled to room temperature, filtered through diatomaceous earth and the filtrate was poured into a saturated sodium bicarbonate solution, extracted with ethyl acetate, washed with saturated NaCl solution and dried over magnesium sulfate. The solution is concentrated and the product is purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 2) + 1% methanol). 89 mg of the title compound are obtained.
U NMR spectra are consistent with the structure of the desired compound.
17-Ethyl-20-fluoro-1-hydroxy-12- [2 '- (4' '- t-butyldimethylsilyloxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19. 2-1, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
A solution of 17-ethyl-20-dihydroxy-12- [2 '(4' '- t-butyldimethylsilyloxy-3' '- methoxycyclohexyl) 1'-methyl-vinyl] -23,25-dimethoxy-13,19,21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone (30.5 mg) and methylene chloride (0.5 mL) were cooled to -78 ° C in a dry ice / isopropanol bath. Sulfuric diethylaminotrifluoride (4.5 μΐ) was added to the stirred solution. After 3 minutes saturated sodium bicarbonate (500 μΐ) was added followed by ethyl acetate (2 mL) and the mixture was warmed to room temperature. Extract with ethyl acetate, dry over magnesium sulfate. The product was purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 2) + 1% methanol). 22 mg of the title compound are obtained.
I Ii 11 ... i B
133
17-Ethyl-1,2-dihydroxy-12- [2 '- (4' '-hydroxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,
19, 21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1,20-dihydroxy-12- [2 '(4' '- t-butyldimethylsilyloxy-3' '- methoxycyclohexyl) 1'-methyl vinyl] -23,25-dimethoxy-13 , 19, 21, 27 tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4</sup>'<sup>9</sup>] octacos-18 8-en-2, 3, 10, 16-tetraone (7 mg) and acetonitrile (0.3 mL), a 2% solution of hydrogen fluoride in aqueous acetonitrile (100 μΐ) was added and the mixture was stirred at room temperature. After 28 hours, the solution was diluted with ethyl acetate, extracted with saturated sodium bicarbonate, and the organic phase dried over a column filled with magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate: hexane (2: 1) + 1% methanol) to give the title compound.
17-Ethyl-20-fluor-1-hydroxy-12- [2 '- (4' '- hydroxy-3''methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27 -tetramethyl-11, 28-dioxsa-4-azatriciclo [22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-20 fluoro-1-hydroxy-12 [2 '- (4' '- t-butyldimethylsilyloxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy -13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone (7 mg) and acetonitrile (0.3 mL), a 2% solution of hydrogen fluoride in aqueous acetonitrile (100 μΐ) was added and the mixture was stirred at room temperature. After 2 hours, the solution was diluted with ethyl acetate, extracted with saturated sodium bicarbonate and the organic phase was dried through a column filled with magnesium sulfate. The concentrate was purified by flash chromatography on. J. liti! III L uaiui ΒΐΜΐιΐί ri .1
134 silica gel (ethyl acetate: hexane (1: 1) + 1% methanol) to give the title compound.
Mass Spectrum: (FAB) 816 {M<sup>+</sup> + Na).
Partial <sup>13</sup>C NMR spectrum, chemical shifts: 211.5 (C-16); 196.1 (2) 169.3 (10); 165.0 (3); 138.1 (C-19);
135.8 (C-1 '); 121.0 (C-18 'main); 84.1 (C-3 '');
43.1 (C-15); 26.0 (C-21).
17-Ethyl-1, 14,20-trihydroxy-12- [2 '- (4' '- hydroxy-3' methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27- tetramethyl-1,11-dioxa-4-azatricyclo [22.3.1. ON<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
THE ALTERNATIVE ROUTE OF SYNTHESIS
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '-hydroxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] 23, 25-dimethoxy-13, 19, 21 , 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] octave-18-in-2, 3, 10,
16-Tetraone (5.15 g, 0.065 mol) and glacial acetic acid (500 ml), a solution of selenium dioxide (9.27 g, 0.083 mol) in water (90 ml) was added at room temperature. The reaction mixture was stirred at room temperature for 41 hours, then poured into a stirred mixture of water (3 L) and celite. After stirring for 15 minutes, the mixture is filtered through a pad of celite and extracted with diethyl ether (1 x 2L, 2 x 1L). The organic fractions are washed with a saturated solution of sodium bicarbonate and sodium chloride, dried over magnesium sulfate, filtered and evaporated in vacuo. The product was purified by chromatography on silica gel (acetone: hexane 2: 5) to give the title compound having mass and NMR spectra consistent with structure.
ιιβιιιι oniui.ii U
AND HE'S IN. 11J
135
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (2-furanyl)<sub>m</sub>ethoxy3'-methoxy-cyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyl 1 o - [22.3.1. ON<sup>4,9</sup>] oktakoz-18en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '-hydroxy-3' '-methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19, 21, 27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1. O<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16tetraone (63 mg, dissolved in 1.0 mL of methylene chloride), furfuryl trichloroacetimidate (39 μΐ, undiluted) was added and the reagents were stirred for 5 minutes. Add camphor sulfonic acid (3.7 mg) and stir at room temperature.
After 4.5 hours, quench the reaction with saturated sodium bicarbonate solution and extract with ethyl acetate (3x5 mL). The combined organic layers were washed with brine and dried over magnesium sulfate. The concentrate was purified by flash chromatography on. silica gel (ethyl acetate: hexane (1: 2) + 1% methanol) to give the title compound (20 mg). Mass Spectrum: (FAB) 878 (M + Li). Partial<sup>1</sup>H NMR, chemical shifts: 7.38 pis, 1H); 6.30 (m, 3H); 5.32 M, 5.19 ppm J = 3Hz); 4.83m, 4.21M pis, 1H); 4.62 (dd J = 15 Hz, 2H); 4.41 pld J = 14Hz, 1H).
AND EXAMPLE 3
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- furanyl) methoxy3' '-hydroxycyclohexyl) -1' -methylvinyl] -23,2,5-dimethoxy-13,19,21 , 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. ON<sup>4,9</sup>] okuakoz-18-en-2, 3, 10, 16-tetraonas ir 17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- (2-furanyl) methoxycyclohexyl ) -1'-methylvinyl] -23, 25-dimimeII.ll 11911. IIII! .1 I .11 ..IH l.ll
136 toxic-13, 19, 21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3. 1.0<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, _3, _10, _16tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(3' ', 4' '- dihydroxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1. O<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16tetraone (52 mg, dissolved in 0.9 mL methylene chloride), furfuryl trichloroacetamide (20 μΐ, undiluted) was added and the reagents were stirred for 5 minutes. Camphor sulfonic acid (2 mg) was added and the mixture was stirred at room temperature. After 3.5 hours, quench the reaction with saturated sodium bicarbonate solution and extract with ethyl acetate (3x5 mL). The combined layers are washed with brine and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 1) + 1% methanol) to give the title compounds (16 mg of 4 '' ether; 13 mg of 3 '' ether).
4 '' Ether: Mass spectrum: (FAB) 864 (M + Li). Partial<sup>4</sup>H NMR, chemical shifts: 7.38 pis, 1H); 6.30 (m,
3H); 5.32 M, 5.19m pld J = 3Hz, 1H); 4.83m, 4.21M pis,
1H) ; 4.62 (dd J= 15Hz, 2H); 4.41 pld J = 14Hz, 1H) .
3 '' Ether: Mass spectrum: (FAB) 864 (M + Li). Partial
NMR, chemical shifts: 7.44 pis, 1H); 6.37 (m,
2H); 5.32M, 5.19m (pld J = 3Hz, 1H); 4.88m, 4.27M pis,
1H) ; 4.41 pld J = 14Hz, 1H) .
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (2-thiophene) -methoxy3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19. 21, 27-Tetramethyl-1,11, 28-dioxa-4-azaLT 3533 B
137 tricyclo [2.3.1. ON<sup>4,9</sup>] octave-18-in-2, 3, 10, 16-tetraonas imi unm.
I Ui III: J ia:
The title compound was synthesized as described in Figure 1 using 2-thiophenylmethyltrichloroacetimidate as the alkylating agent.
Partial <sup>X</sup>H NMR, chemical shifts: 7.27 (m, 1H):
6.96 (m, 2H) ; 5.31M, 5.18m pld J = 3Hz, 1H) ; 4.81m, 4.22M (pis, 1H); 4.41 (pld J = 14 Hz, 1H); 3.07 (d J = 4Hz, 1H).
AND EXAMPLE 6
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (2-thiophene) -methoxy3' '-hydroxycyclohexyl) -1-methyl-vinyl] -23, 25-dimethoxy-13,19 , 21, 27-Tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] octacos-18-en-2, 3, 10, 16-tetraonasyl 17-ethyl-1, 14-dihydroxy-12- [2 '- (4' '- methoxy-3' '- (2-thiophene) - methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. ON<sup>4</sup>'<sup>9</sup>] octacose-18-en-2,3,10, 16-tetraonas
The title compounds were synthesized as described in Figures 2 and 3 using 2-thiophenylmethyltrichloroacetamidate as the alkylating agent.
<td> 4 ' '</td><td>ether: Mass</td><td>spectrum:</td><td>(FAB)</td><td>896 (M + Na).</td><td>Partial</td>
<td>U</td><td>NMR, chemical</td><td>shifts</td><td> : 7.29</td><td>(m, 1H);</td><td>6.97 (m,</td>
<td>2H)</td><td>; 5.31M, 5.19m</td><td>(pld J =</td><td>3Hz,</td><td>1H); 4.41</td><td>(pld J =</td>
<td colspan="2">14Hz, 1H); 3.04 (d</td><td colspan="3">J = 4Hz, 1H); 2.63M, 2.61 m</td><td>(s, 1H).</td>
<td> 3 ' '</td><td>ether; The masses</td><td>spectrum:</td><td>(FAB)</td><td>880 (M + Na).</td><td>Partial</td>
<td>1 ’H</td><td>NMR, chemical</td><td>shifts</td><td> : 7.28</td><td>(m, 1H);</td><td>6.97 (m,</td>
<td>2H)</td><td colspan="2">; 5.19m, 5.19m (pld J = 3Hz</td><td>, 1H) ;</td><td>4.41 (pld J</td><td>= 14 Hz,</td>
<td>1H)</td><td colspan="2">; 3.08 (d J = 3Hz, 1H); 2.</td><td>69 (s,</td><td>1H) .</td><td></td>
I MIDI II13I11H I. I! I .11 . Lili Ii·
138
AND EXAMPLE 8
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (3-thiophene) -methoxy) -1'-hydroxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19. 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16tetraonasyl 17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- (3-thiophene) -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,20 dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octacose-18-en-2,3,10, 16-tetraonas
The title compounds were synthesized as described in Figures 2 and 3 using 3-thiophenylmethyl trichloroacetimidate as the alkylating agent.
<td> 4 ' '</td><td>ether: Mass</td><td>spectrum: (FAB)</td><td>880 (M + Li)</td><td>. Partial</td>
<td>Y</td><td>NMR, chemical</td><td>shifts: 7.30</td><td>(m, 1H) ;</td><td>7.04 (m,</td>
<td>2H)</td><td>; 5.31 M, 5.19m</td><td>(pld, J = 3Hz,</td><td>1H); 4.89</td><td>m, 4.19 M</td>
<td>(s,</td><td>1H); 4.41 (pld</td><td>J = 14Hz, 1H); 3.</td><td>04 (d J =</td><td>4Hz, 1H).</td>
<td> 3' '</td><td>ether: Mass</td><td>spectrum: (FAB)</td><td>880 (M + Li)</td><td>. Partial</td>
<td>Y</td><td>NMR, chemical</td><td>displacements: 7.28</td><td>(m, 2H) ;</td><td>7.05 (dd,</td>
<td>J =</td><td>= 5,2 Hz, 1H); 5</td><td>.31M, 5.19m (pld,</td><td>J = 3Hz,</td><td>1H); 4.83</td>
<td>m,</td><td>4.25 M (udder, H)</td><td>; 4.41 9pld, J =</td><td>14Hz, H);</td><td>3.06 (d,</td>
<td>J =</td><td>3Hz, 2.69 (s,</td><td>H) .</td><td></td><td></td>
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (2-benzothienyl) oxy-3 '' -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19 , 21, 27-Tetramethyl-11,12-dioxa-4-azatricyclo- [22.3.1.0<sup>4</sup>'<sup>9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of tri (benzothien-2-yl) bismutin (100 mg, 0.164 mmol) in methylene chloride (2 mL) was added peracto imi αωι, ιιιπ ι;
11: huh?:! u;
139 acid (0.05 mL, 0.224 mmol, 32% in acetic acid) and then 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '-hydroxy-3' '- methoxycyclohexyl) was added over 10 minutes. -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. 0<sup>4,9</sup>] octakoz-18-en-2, 3, 10, 16-tetraonas (100 mg, 0.126 mmol) bei Cu (OAc)<sub>2</sub> (15 mg, 0.083 mmol).
The reaction mixture was stirred for 16 hours at room temperature. The reaction was quenched by the addition of a saturated sodium bicarbonate solution and then extracted 3 times with methylene chloride. The extracts were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The product is isolated and purified by preparative TLC 3X on silica gel (3: 1, hexane / acetone) to give 23 mg of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (2-benzothienyl) oxy). 3''-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] octave-18-in-2.3,
10,16-tetraono.
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (thien-2-yl) oxy3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21 , 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4</sup>'<sup>9</sup>] o kt a ko z-18-en-2,3,10,16-tetraonas
Peracetic acid (0.06 mL, 0.253 mmol, 32% in acetic acid) was added to a stirred solution of tri (thien-2-yl) bismuthine (80 mg, 0.175 mmol) in methylene chloride (2 mL) and then added over 15 minutes. 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '-hydroxy-3' '-methoxycyclohexyl)' 1'-methyl-vinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl11, 2 8-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] octakoz-18-en2, 3,10,16-tetraonas (100 mg, 0.126 mmol) bei Cu (OAc)<sub>2 </sub>(10 mg, 0.055 mmol).
i. i. imu iii ... ι i some «
140
The reaction mixture was stirred for 3 days at room temperature. The reaction was quenched by the addition of a saturated sodium bicarbonate solution and then extracted with methylene chloride. The extracts were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The product was isolated and purified by preparative TLC 2 times on silica gel (2: 1, hexane / acetone) to give 36 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4 (thien-2-yl) oxy). 3 '' - methoxycyclohexyl) -1'-methyl vinyl] 23.25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1.0].<sup>4,9</sup>] octacose-18-en-2,3, 10,16-tetraono.
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- 5-indolylaminocarbonylmethoxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23.25-domethoxy-13,19,21,27-tetramethyl -ll, 28-dioxa-4azatricycle- [22.3.1.0<sup>4</sup>'<sup>9</sup>] octacose-18-en-2,3, 10,16-tetraonas
11A STAGE
17-Etil-l-hisdrokil-14-t-butildimetil-silicon-12- [2 '(4' '- t-butildimetilsil-3' '- metoksicikloheksil) 1'-metilvinil] --23,25-dimet-13 , 19,21,27-tetrametilll, 28-dioksa-4-azriciklo- [22.3.1.O<sup>4,9</sup>] -oktakoz-18-en2,3,10,16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '-hydroxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-13,19,21 , 27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1.0].<sup>4,9</sup>] An excess of 2,6-lutidine (1.2 mL) was added to octacos-18-ene-2,3,10,16-tetraone (2g) and dry methylene chloride (25 mL) and the mixture was stirred at room temperature. After 10 minutes, t-butyldimethylsil trifluoromethanesulfonate is administered by syringe
141 (1.8 mL). After 1 hour, the reaction mixture was diluted with ethyl acetate, washed with 1N HCl, water, saturated sodium bicarbonate, and brine. The organic phase is dried over magnesium sulfate. The solvent is removed in vacuo and flash chromatography on silica gel (ethyl acetate: hexane (1:60 + 1% methanol) gives the title compound (2.37 g).<sup>1</sup>The H NMR spectrum is consistent with the desired structure.
11B STAGE
17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) —12— [2 '(4' '-hydroxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 2 3,2 5-dimethoxy-1,3,19 , 21,27-tetramethyl-11, 28-dioxa-4azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] octacose-18-en-2,3, 10, 6-tetraonas
To a solution of 17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy-12- [2 '- (4' '- t-butyldimethylsilyloxy] 3'-methoxycyclohexyl) -1'-methyl vinyl] -23,25- dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-trichloro 22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (2.37 g) (STEP 11A) and dry methylene chloride (25 ml), add 10% p-toluene sulfuric acid in methanol (ml) and After stirring at room temperature for 10 minutes, the mixture was cooled to 0 ° C and quenched by the addition of a saturated sodium bicarbonate solution. The mixture was diluted with ethyl acetate and the layers separated. The organic layer is washed with a saturated solution of sodium bicarbonate and salt and dried over magnesium sulfate, acetate-hexane (1: 2) + 1% by flash chromatography
The concentrate was purified on silica gel (ethyl methanol) to give the title compound (2.1 g).
The H NMR spectrum is consistent with the desired structure.
I · IIIII J1BMI.III.III »1 I 11 ll'UP B
142
11C STAGE
17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '(4' '- allyloxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-l3,19,21 , 27-tetramethyl-ll, 28-dioxa-4-azatricycle- [22.3.1,0 ounces
4,9.
octacos-18-ene-2,3,10,16-tetrail solution containing 17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '- (4' '- hydroxy-3' ') -methoxycyclohexyl) -1'-methylvinyl] -23,2 5-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] octacos18-en-2,3,10,16-tetraone (2.1 g) (STEP 11B) and 24 ml of a 33% solution of methylene chloride in cyclohexane were added allyl trichloroacetimidate (938 mg, undiluted) and the reaction mixture was stirred for 5 minutes. Slowly inject trifluoromethanesulfonic acid (41 μΐ, undiluted) using a syringe and stir at room temperature. After 24 hours, the reaction mixture was diluted with ethyl acetate, saturated sodium bicarbonate, and brine. The organic layer was dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate: hexane) (1: 5) + 1% methanol) to give the title compound (1.03 g) according to the desired structure.
H NMR Spectrum
11D STADIJA
17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '(4' '- 2,3-dioxy-1-propoxy) -3' '- methoxycyclohexyl) -1'methylvinyl] -2 3 , 25-dimethoxy-1,3,19,21,27-tetramethyl, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] oktakoz-18-en2,3,10,16-tetraonas
To a solution of 17-ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '- (4' '- allyloxy-3' '- methoxycyclic)
143 hexyl) -1<sup>1</sup>-methylvinyl] -2 3,25-dimethoxy-13,19,21,27 tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] octacos-18-ene-2,3,10,16-tetraone (1.03 g) (STEP 11C) and 22 ml of tetrahydrofuran, N-methylmorpholine N-oxide (883 mg) was added followed by 0.25 M osmium tetraoxide solution THF (871 μΐ), the mixture was stirred at room temperature. After 3 h, the reaction was quenched by the addition of 20% sodium bisulfite (20 mL), the precipitate was filtered through celite and washed with ethyl acetate. The combined filtrates were washed with 20% sodium bisulfite (2 times), saturated sodium bicarbonate and brine, and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate: hexane (2: 1) + 1% methanol) to give the title compound (705 mg).<sup>X</sup>The H NMR spectrum is consistent with the desired structure.
HE STADIJA
17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '(4' '-ethanoxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-13,19,21 , 27-tetramethyl-11,12-dioxa-4azatricyclo- [22.3.1.0<sup>4,9</sup>] octacose-18-en-2,3,10,16-tetraonas
To a solution of 17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '- (4' '- (2,3-dioxy-1-propoxy) 3' '- methoxycyclohexyl) -1 '-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] octacos-18-en-2,3,10,16-tetraone (1.56 g) (STEP 11D) and 20% tetrahydrofuran solution (20 ml) were added sodium metaperiodate (510 mg) and the mixture was stirred vigorously for 30 minutes. An additional 170 mg of sodium metaperiodate is added. After 30 minutes, the mixture was diluted with ethyl acetate, filtered through celite, washed with ethyl acetate. The organic layer is washed with a saturated solution of sodium bicarbonate and salt,
IMU UlIilUIII. IU .1 i II! ·.: I fl I
4 Dry over magnesium sulfate and purify by flash chromatography on silica gel (ethyl acetate: hexane (1: 2) + 1% methanol) to give the title compound (1.45 g). <sup>1</sup>The H NMR spectrum is consistent with the desired structure.
11F STAGE
17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '(4' '- carboxymethoxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19. 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1. ABOUT<sup>4,9</sup>] octave-18-in-2, 3,
10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '- (4' '-ethanaloxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25- dimethoxy-13, 19, 21,
27-tetramethyl-11, tacos-18-en-2,3,
28-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] ok16-tetraone (311 mg) (STEP 11E) and t-butanol (6.6 mL) and 2-methyl-2-butene (1.65 mL), sodium chloride (273 mg) and sodium dihydrophosphate (272 mg) were slowly added in water ( 2.7 ml). After 2 hours, the solvent is removed in vacuo, the residue is dissolved in water and acidified to pH 3 by addition of IN HCl. The aqueous layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layers were washed with brine. They are then dried over magnesium sulfate and purified by flash chromatography on silica gel (2% methanol in methylene chloride followed by 2% methanol in methylene chloride + 0.5% acetic acid) to give the title compound (1.45 g). <sup>X</sup>The H NMR spectrum is consistent with the desired structure.
11G STADIUM
17-Ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) —12 — t 2 '(4' '- 5-indolylamino-carbonylmethoxy-3' '- methoxy-cyclol HILU IttVIfllUII. III 11 I ll 1. 11
145 hexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21,
27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '- (4' '-carboxymethoxy-3' '- methoxycyclohexyl) -1<sup>1</sup>-methylvinyl] -23, 25-dimethoxy-13, 19,
21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone (311 mg) (STEP 11F) and dry methylene chloride (1.6 mL), benzotriazol-1-yloxy-tris (dimethylamino) -phosphonium hexafluorophosphate added (103 mg) followed by triethylamine (43 μΐ). After 10 minutes, 5-aminoindole (43 mg) was added to the reaction mixture and stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with IN HCl, water, saturated sodium bicarbonate and brine. The organic layer was dried over magnesium sulfate and purified by flash chromatography on silica gel (ethyl acetate: hexane) (1: 2) + 1% methanol) to give the title compound (138 mg). <sup>X</sup>The H NMR spectrum is consistent with the desired structure.
11H STAGE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- 5-indolylaminocarbonylmethoxy-3' '- methoxy-cyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19. 21, 27-tetramethyl-11,12-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -to-18-in-2, _3,
10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-14-t-butyldimethylsilyloxy) -12- [2 '- (4' '-5-indolylamino-carbonylmethoxy-3' '-methoxy-cyclohexyl) -1'-methylvinyl] ] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. O<sup>4</sup>'<sup>9</sup>] -octacos-18-en-2, 3, 10, 16tetraone (138 mg per ml tetrahydrofuran polyΙ · ΙΙΙΙ! HWJII.UI UI I i! »
146 in a propylene tube), add 200 μΐ of fluorine-hydrogen-pyridine complex (40% solution in tetrahydrofuran-pyridine (2: 1)) and stir the mixture at room temperature. After 2 days, cautiously quench the sodium bicarbonate solution and extract with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated in vacuo and purified by flash chromatography on silica gel (ethyl acetate / methanol) to give a slurry. Mass Spectrum (FAB) 971 (M + Li); partial<sup>X</sup>H NMR Spectrum, chemical shifts: 9.52 (pis, 1H); 8.15 (pis, 1H); 7.91 (s, 1H); 7.30 (s,
2H) ; 7.16 (dd, J = 3,3Hz, 1H) ; 6.49 (dd, J = 3Hz, 1H) ; 4.41 (pld, J = 14 Hz, 1H).
that: hexane (1: 1) + 1% in the name i
EXAMPLE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (methyl-N-tryptophanylcarbonylmethoxy-3' '- methoxy-cyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19 , 21, 27-Tetramethyl-11,12-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] -to-18-in-2, _3,
10, 16-tetraonas
12A STAGE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (allyloxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -2,35-dimethoxy-13,19.
21, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2'- (4''-hydroxy-3 '' -methoxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19, 21, 27-Tetamethyl-11,28-dioxa-4-azatricyclo- [22.3.1. O<sup>4,9</sup>] -octacos-18-en-2, 3, 10, 16tetraone (510 mg) and 6.6 mL of 33% methylene chloride in cyclohexane, added with ale trichloroacetimidate ae ι · ιιιι oniiii ai .ii nm;
147 (266 mg, undiluted) and the reaction was stirred for 5 minutes. Trifluoromethanesulfonic acid (12 μΐ, undiluted) was slowly injected and the mixture was stirred at room temperature. After 24 hours, the reaction mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution, water, and brine. The organic layer was dried over magnesium sulfate, purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 9) + 1% methanol) to give the title compound (434 mg). <sup>X</sup>The H NMR spectrum is consistent with the desired structure.
12B STAGE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (2,3-dioxy-1-propoxy) -3' '-methoxy-cyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13, 19, -21, 27-tetramethyl-1,11, 28-dioxa-4azatricyclo- (22.3.1, O<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2'- (4 '' allyloxy-3 '' - methoxycyclohexyl) -i'-methyl vinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. O<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16tetraone (434 mg) (STEP 12A) and 15 ml of tetrahydrofuran, N-methylmorpholine N-oxide (431 mg) was added followed by 0.25 M osmium tetroxide solution in THF (425 mg). μΐ), the mixture is stirred at room temperature. After
The reaction was quenched by the addition of 20% sodium bisulfite (20 mL) for 4.5 hours, the precipitate was filtered through celite and washed with ethyl acetate. The combined filtrates were washed with 20% sodium bisulfite (2 times), saturated sodium bicarbonate and brine, and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate: hexane (3: 1) + 1% methanol) to give a residue.
148 the title compound (177 mg). The NMR spectrum corresponds to the desired structure.
12C STAGE
17-Ethyl-1-hydroxy-12- [2 '- (4' '-ethanoxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21,
27-Tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2 '- (4' '(2,3-dioxy-1-propoxy) -3' '- methoxycyclohexyl) -1'-methyl vinyl] -23, 25-Dimethoxy-13,19,21,27-tetramethyl], 28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -octacos-18-en2,3,10,16-tetraone (177 mg) (STEP 12B) in tetrahydrofuran 20% aqueous solution (2 ml), sodium metaperiodate (67 mg) was added and the mixture was stirred vigorously for 30 minutes. A further 20 mg of sodium metaperiodate is then added. After 30 minutes, the mixture was diluted with ethyl acetate, filtered through celite, washed with ethyl acetate. The organic layer was washed with a saturated solution of sodium bicarbonate and brine, dried over magnesium sulfate and purified by silica gel flash chromatography (ethyl acetate: hexane (2: 3) + 1% methanol) to give the title compound (157 mg). <sup>1</sup>The H NMR spectrum corresponds to the desired structure.
12D STADIJA
17-Ethyl-1-hydroxy-12- [2 '- (4' '- carboxymethoxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, -21, 27-tetramethyl -ll, 28-dioxa-4-azatricyclo [22.3.1. ON<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2 '- (4''-ethanaloxy-3' '-methoxy-cyclohexyl) -1'-methyl-vinyl] -23,
I · ΙΙΙΙ 1IUII11.111,1 II. 11.1 .1 II. IIIH.I1.WI
149
25-dimethoxy-13, 19, 21, 27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1. Oh<sup>4</sup>'<sup>9</sup>] -octacos-18-en-2, 3, 10, 16tetraone (157 mg) (STEP 12C), t-butanol (4 mL) and 2-methyl-2-butene (1 mL), sodium chloride (159 mg) was added ) and sodium dihydrophosphate (159 mg) in water (1.6 mL). After 1 hour, the solvent is removed in vacuo, the residue is dissolved in water and acidified to pH 3 by addition of IN HCl. The aqueous layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layers were washed with brine. They are then dried over magnesium sulfate and purified by flash chromatography on silica gel (2% methanol in methylene chloride followed by 2% methanol in methylene chloride ιΟ. 5% acetic acid) to give the title compound (114 mg). <sup>1</sup>The H NMR spectrum is consistent with the desired structure.
12E STAGE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- methoxy-N-tryptophanylcarbonylmethoxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy-13, 19, -21. 27-tetramethyl-1,11-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -October-18-in-2, 3,
10, 16-tetraonas
To a solution of 17-ethyl-1-hydroxy-2- [2 '(4' 'carboxymethoxy-3' '-methoxycyclohexyl) -1'-methyl vinyl] 23, 25-dimethoxy-13, 19, 21, 27 -tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -October-18-in-2, 3,
10, 16-Tetraone (39 mg.) (STEP 12D) in methylene chloride (0.5 mL), benzotriazol-1-yloxy-tris (dimethylamino) -phosphonium hexafluorophosphate (31 mg) was added followed by triethylamine (14 μΐ). After 10 minutes, tryptophan methyl ester hydrochloride (24 mg) was added to the reaction mixture and stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with IN HC1, water, saturated sodium bicarbonate and salt, respectively ι · ιιιιι ιπιι.ΐ; .ιιι, ι i, mji imi., I
150 solution. The organic layer was dried over magnesium sulfate and purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 1) + 1% methanol) to give the title compound (28 mg). Mass Spectrum (FAB) 1041 (M + Li); partial<sup>X</sup>H NMR Spectrum, chemical shifts: 8.21 (pis, 1H); 8.04 (dd, J = 8 Hz, 1H); 7.56 (d, J = 8 Hz, 1H); 7.33 (d,
J=8Hz, 1H) ; 7.11 (m, 3H); 4.41 (pld, J=14Hz, 1H); 3,64 (s, 3H) .
EXAMPLE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- 3-indolylethylaminocarbonylmethoxy-3' '-methoxycyclohexyl) -1'-methylvinyl] 23, 25-dimethoxy-1,3,19, -21,27- teramethyl-11,18-dioxa-4azatricyclo- [22.3.1. ON<sup>4</sup>'<sup>9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2'- (4<sup>1</sup> 'carboxymethoxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-1,3,19,21,27-tetramethyl-1,12-dioxa-4azatricyclo- [22.3.1. Oh<sup>4,9</sup>] -octacos-18-en-2,3,10,16-tetraone (13 mg) (STEP 12D) in methylene chloride (150 μΐ), benzotriazol-1-yloxy-tris (dimethylamino) -phosphonium hexafluorophosphate (10.3) was added. mg) followed by triethylamine (4.3μ1). After 10 minutes, tryptamine (5 'mg) was added to the reaction mixture and stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with IN HCl, water, saturated sodium bicarbonate and brine respectively. The organic layer was dried over magnesium sulfate and purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 1) + 1% methanol) to give the title compound (7.5 mg). Mass Spectrum (FAB) 983 (M + Li); partial<sup>X</sup>H NMR Spectrum, chemical shifts: 8.32 (pis, 1H); 7.89 (m, 1H); 7.58 (d, J = 8 Hz, 1H); 7.31 (m,
I · III III IH1IIIJII.I II. III. II; i
151
1H) ; 7.10 (m, 3H) ; 4.51 (pld, J=3Hz, 1H) ; 4.41 (pld,
J=14Hz, 1H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25 dimethoxy-13 , 19, -21,27-tetramethyl-11,18-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10, 16-tetraonas
14A STADIJA the Methyl-5-bromindolas
A mixture of sodium hydroxide (0.4 g, 10 mmol) and DMSO (20 mL) was heated to 80-85 ° C for 6 hours until most of the solids dissolved and then cooled to room temperature. To the stirred mixture was added 5-bromoindoias (2.0 g, 10 mmol), and after 1 hour methyl iodide (0.62 mL, 10 mmol) was added. Stir for a further 3 hours until the reaction is complete by TLC. The reaction mixture was diluted with water and extracted with ether. The extracts are washed twice with water, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo to give 2.08 g of a yellow oil of l-methyl-5-bromoindole which is considered to crystallize.
14B STAGE
Tri (l-methyl-indole-5-yl) bismutinas
To a solution of 1-methyl-5-bromoindole (5.0 g, 23.8 mmol) in ether (100 mL) was added 1.7 M t-butyl lithium pentane (28 mL, 47.6 mmol) at -78 ° C. The mixture was stirred at -78 ° C for 1 hour. A solution of bismuth trichloride (2.36 g, 7.5 mmol) in THF is then added to the reaction mixture via a syringe.
152 (25 mL). The reaction mixture is kept in a refrigerated bath for two hours and then allowed to warm to room temperature overnight. In the morning, ice water is added to the mixture and the product is extracted twice with toluene.
The extracts are combined, washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo to a volume of about 30 ml. After keeping the solution in the refrigerator for several hours, the solid product is filtered off, which is washed with cold toluene and dried in vacuo. This gives tri (1-methyl10 indol-5-yl) bismuthine (1.7 g) as a solid, mustard color.
14C STAGE
17-Ethyl-1,4-dihydroxy-12- [2 '-) 4' '- (1N-methyl-5-indolyl) oxy-3'. ' -methoxycyclohexyl) -1'-methylvinyl] -2 3,25 dimethoxy-13,19, -21,27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a stirred solution of tri (1-methylindol-5-yl) bismuthine (450 mg, 0.75 mmol) (STEP 14 B) and methylene chloride. (10 mL), Peracetic acid (0.158 mL, 0.75 mmol, 32% in acetic acid) was added, followed by addition of 17-ethyl-1,14-dihydroxy-12- [2'25 (4 '') -hydroxy in 15 minutes. -3 '' -methoxy-cyclohexyl) -1'-methylvinyl] 23,2 5-dimethoxy-13,19,21,27-tetramethyl-11,8,8-dioxa-4aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -Octakoz-18-en-2,3,10,16-tetraonas (350 mg, 0.442 mmol) with Cu (OAc)<sub>2</sub>· The mixture is stirred at room temperature for 2 days. The reaction was quenched by addition of saturated aqueous NaHCO<sub>3</sub> solution and the product is extracted 3 times with methylene chloride. The extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product is isolated and purified twice by preparative TLC 35 to give 203 mg of the title compound as a colorless solid. Mass Spectrum (FAB) 927 (M + Li); partial Z NMR spectrum, (CDCl1<sub>3</sub>, 200 MHz) m; mum, m, i
153 cheminiai poslinkiai: 7.19 (pis, 1H) ; 7.17 (d, J=10Hz, 1H) ; 6.98 (d, J=4Hz, 1H) ; 6.91 (dd, J= 3Hz ir 10Hz, 1H); 6.34 (d, J=4Hz, 1H); 3.72 (s, 3H); 3.51 (s, 3H) .
EXAMPLE
17-Ethyl-1, 14,20-trihydroxy-12- [2 '- (4' (1-N-methylindol-5-yl) oxy-3 '' -methoxycyclohexyl) -1'-methylvinyl] 23,25- dimethoxy-1,3,19,21,27-tetramethyl-1,12-dioxa-4azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a stirred solution of tri- (1-methylindol-5-yl) bismuthine (350 mg, 0.584 mmol) and methylene chloride (6 mL) was added peracetic acid (0.15 mL, 0.74 mmol, 32% acetic acid). ), 17-ethyl-1,14,20-trihydroxy-12- [2 '(4' '-hydroxy-3' '-methoxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy- is added after 15 minutes. 13,19,21,27-tetramethyl-11,28-dioxa-4aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octacos-18-ene-2,3, 10,16-tetraone (250 mg, 0.32 mmol) and Cu (OAc) 2 (35 mg, 0.138 mmol). The mixture was stirred at room temperature for 2 days. The reaction was quenched by addition of a saturated aqueous solution of NaHCO3 and the product was extracted twice with methylene chloride. The extracts were combined, dried over Na2SO4, filtered, and concentrated in vacuo. The product is isolated and purified by flash column chromatography on silica gel (3: 1 hexane / acetone) and preparative TLC (3% methanol in methylene chloride) to give 111 mg of the title compound. Mass Spectrum (FAB) 943 (M + Li); partial<sup>7</sup>1 H NMR Spectrum, (CDCl 3, 200 MHz) chemical shifts: 7.21 (pis, 1H); 7.18 (d, J = 7.5 Hz, 1H);
6.98 (d, J=3Hz, 1H) ; 6.94 (dd, J=2.5Hz ir 7.5Hz, 1H) ;
6.37 (d, J=3Hz, 1H); 3.75 (s, 3H); 3.59 (s, 3H).
154
EXAMPLE
17-Ethyl-1-hydroxy-12- [2'- (4 '' - (1'-methylindol-5yl) oxy-3 '' methoxycyclohexyl) -1'-methyl vinyl] -23,25dimethoxy-13,19 , 21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4</sup>'<sup>9</sup>] -octakozo-18-en-2,3, 10,16-tetraonas
To a stirred solution of tri (1-methylindol-5-yl) bismuthine (35 mg, 0.058 mmol) and methylene chloride (0.7 mL) was added peracetic acid (0.015 mL, 0.074 mmol, 32% acetic acid). , 17-ethyl-1-hydroxy-12- [2 '- (4' '- hydroxy-3' '-methoxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19 is added after 15 minutes. , 21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -oktakoz-18-en-2,3,10,16-tetraonas (25 mg, 0, 032 mmol) in Cu (OAc)<sub>2</sub> (5 mg, 0.03 mmol). The mixture was stirred at room temperature for 3 days. The reaction was quenched by the addition of saturated aqueous NaHCO<sub>3</sub> and the product was extracted twice with methylene chloride. The extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product is isolated and purified by preparative TLC on silica gel (2: 1 hexane / acetone followed by 5% methanol in methylene chloride) to give 10.2 mg of the title compound. Partial NMR spectrum, 0 CDC1<sub>3</sub>, 200 MHz) chemical shifts: 7.18 (pis, 1H); 7.16 (d, J = 7Hz,
1H) ; 6.98 (d, J=3Hz, 1H) ; 6.92 (dd, J=2.5Hz ir 7.5Hz,
1H); 6.33 (d, J=3Hz, 1H); 3.64 (s, 3H); 3.51 (s, 3H).
AND EXAMPLE 18
17-Ethyl-1,14-dihydroxy-12- [2 '- {3' '- hydroxy-4' - (1-ττε -ylindol-5-ii) oxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy -13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4</sup>'<sup>9</sup>]-octane-18-en-2,3,10,16-tetraonas ir 17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- (1-Nmethyl- indol-5-yl) oxycyclohexyl) -1'-methylvinyl] -23,25II. IM 11II
155 dimethoxy-13,19,21,27-tetramethyl-11,18-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a stirred solution of tri (1-methylindol-5-yl) bismuthine (150 mg, 0.25 mmol) and methylene chloride (2 mL) was added peracetic acid (0.05 mL, 0.23 mmol, 32% acetic acid). , 17-ethyl-1,14-dihydroxy-12- [2 '- (3' ', 4' '- dihydroxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27 is added after 15 minutes. -tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (100 mg, 0.129 mmol) and Cu (OAc) 2 (20 mg, 0.11 mmol). The mixture was stirred at room temperature for 2 days. The reaction is quenched by the addition of a saturated aqueous solution of NaHCO3 and the product is extracted twice with methylene chloride. The extracts were combined, dried over Na2SO4, filtered, and concentrated in vacuo. The product is isolated and purified by preparative TLC on silica gel (2: 1 hexane / acetone followed by 5% methanol in methylene chloride) to give 19 mg of 17-ethyl-1,14-dihydroxy-12 [2 '- (3' '- hydroxy). -4 '' - (1-N-methylindol-5-yl) oxycyclohexyl) -1'-methyl vinyl] -2,35-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4 azatricyclo- [22.3.1.0<sup>4</sup>'<sup>3</sup>] -octacos-18-ene-2,3,10,16-tetraone. Partial<sup>X</sup>1 H NMR Spectrum, (CDCl 3, 200 MHz) Chemical shifts: 7.19 (d, J = 10 Hz, 1H); 7.17 (d, J = 2.5 Hz, 1H); 7.00 (d, J-3Hz, 1H); 6.88 (dd, J = 2.5Hz and 10Hz, 1H); 6.35 (d, J = 3 Hz, 1H); 3.73 (s, 3H), and 33 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4''-hydroxy-3' '- (1-N-methyl-indol-5-yl) ) oxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-1,2,8-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octacos-18-en2,3,10,16-tetraone. Partial<sup>X</sup>H BMR spektras, (CDC1)<sub>3</sub>, 200 MHz) chemical shifts: 7.18 (d, J = 8 Hz 1H); 7.16 (d, J = 2.5 Hz, 1H); 6.98 (d, J = 3 Hz, 1H); 6.88 (dd,
J=2.5Hz,ir 8Hz, 1H); 6.33 (d, J=3Hz, 1H); 3.73 (s, 3H).
IMI! 1! UBU EI! .1 I l.ll IJ1
156
EXAMPLE
Tri (indol-5-yl) bismutinas
To a solution of 5-bromoindole (5.0 g, 25.5 mmol) in ether (50 mL) at 0 ° C was added a suspension of KH (2.8 g, 25 mmol, 35% in oil, washed three times with hexane) in ether (40 mL). The reaction mixture was stirred for 20 minutes, then cooled to -78 ° C. Subsequently, the pre-cooled t-butyl lithium solution (29.7 ml,
50.5 mmol, 1.7 M solution in pentane), after 40 min a solution of bismuth trichloride (1.89 g, 6.0 mmol) in THF (25 mL) was added. The reaction mixture is kept in a refrigerated bath for two hours and then allowed to warm to room temperature overnight. The reaction is quenched with ice water and the product is extracted 3 times with toluene. The extracts are combined, washed with water, dried over NA<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo. The residue is diluted with 75 ml of toluene and stored overnight at 4 ° C. The solid product is filtered off and dried in air. Tri (indol-5-yl) bismuthine (1.53 g) is obtained.
19B Stage
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (indol-5-yl) oxy3'-methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21, 27-Tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
Peracetic acid (0.5 mL, 2.31 mmol, 32 mL) was added to a stirred solution of tri (indol-5-yl) bismuthine (1.3 g, 2.33 mmol), synthesized according to STEP 14B and methylene chloride (30 mL). % solution in acetic acid), 17-ethyl-1,14-dihydroxy-12- [2'- (4 '' - hydroxy) is added after 10 minutes.
157
3 '' - methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy13.19.21.27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. ON<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (1.0 g, 1.26 mmol) and Cu (OAc) 2 (100 mg, 0.55 mmol). The mixture was stirred at room temperature for 3 days. The reaction is quenched by the addition of a saturated aqueous solution of NaHCO3 and the product is extracted twice with methylene chloride. The extracts were combined, dried over Na2SO4, filtered, and concentrated in vacuo. The product was isolated and purified by preparative TLC (2 times) on silica gel (2: 1 hexane / acetone and once hexane / ethyl acetate 2: 1) to give 208 mg of the title compound. Mass Spectrum (FAB) M + 906. Partial<sup>4</sup>1 H NMR Spectrum, (CDCl 3, 200 MHz) Chemical shifts: 8.12 (pis, 1H); 7.26 (d, J = 10 Hz, 1H); 7.22 (d, J = 2.5 Hz, 1H); 7.18 (m, 1H); 6.9 (dd, J = 2.5 Hz and 10 Hz, 1H); 6.44 (m, 3H); 3.53 (s, 3H).
EXAMPLE
17-Alyl-1,14-dihidroxy-12- [2 '- (4' '- (indol-5-yl) oxy3' '- methoxycyclohexilT-1'-methylvinyl] -23.25-dimethoxy 13.19.21. 27- tetramethyl-II, 28-dioxa-4-azatricyclo 2.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a stirred solution of tri (indol-5-yl) bismuthine p (150 mg, 0 · 2; 7 mmol) and methylene chloride (3 mL) was added peracetic acid (0.05 mL, 0.23 mmol, 32% solution). acetic acid), 17-allyl-1,14-dihydroxy-12- [2'- (4 '' -hydroxy-3''-methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13 is added after 15 minutes, 19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octakoz-18-en-2,3,10,16-tetraonas (100 mg, 0.124 mmol) with Cu (OAc)<sub>2</sub> (20 mg, 0.11 mmol). The mixture was stirred at room temperature for 2 days. The reaction was quenched by the addition of saturated aqueous NaHCO<sub>3</sub> solution and the product is extracted with methylene chloride. Extracts
158 combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC (2 x 2: 1 hexane / acetone followed by 5% methanol in methylene chloride) to give 11 mg of the title compound. Mass Spectrum (FAB) M + Li 925. Partial<sup>4</sup>H BMR spektras, (CDC1)<sub>3</sub> 200 MHz) cheminiai poslinkiai: 8.12 (pis, 1H) ; 7.24 (d, J=10Hz, 1H) ; 7.22 (d, J=2.5Hz, 1H) ; 7.17 (t, J=3Hz, 1H) ; 6.9 (dd, J=3Hz ir 10Hz, 1H) ; 6.44 (pis, 3H); 5.70 (m, 1H); 3.53 (s, 3H).
EXAMPLE
The 17 Ethyl, 14 dihidroksi-12- [2'(4 '- (5-to etilindol the) OKSI 3' -metoksicikloheksil) -1'-metilvinil] -23,25-dimetoksi -13,19,21,27 Tetramethyl ll, 28 dioksa 4-azatriciklo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] -octakozo-18-en-2,3, 10,16-tetraonas
Peracetic acid (0.063 mL, 0.03 mmol) was added to a stirred solution of tri (1-ethylindol-5-yl) bismuthine (150 mg, 0.23 mmol) synthesized according to the procedures in STEP 14A and B and methylene chloride (3 mL). , 32% solution in acetic acid), 17-ethyl-1,14-dihydroxy-12- [2 '- (4''-hydroxy-3' '-methoxycyclohexyl) -1'-methyl-vinyl] -23 is added after 15 minutes. , 25-dimethoxy-13,19-21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -Octakoz-18-en-2,3,10,16-tetraonas (100 mg, 0.126 mmol) with Cu (OAc)<sub>2</sub> (20 mg, 0.11 mmol). The mixture was stirred at room temperature for 3 days. The reaction was quenched by the addition of saturated aqueous NaHCO<sub>3</sub> and the product was extracted twice with methylene chloride. The extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo to give a brown oil. The product is isolated and purified by preparative TLC (2 times) on silica gel (first 2: 1 hexane / acetone followed by 3% methanol in methylene chloride) to give 60 mg of the title compound.
FAMILY | J, ».1111! I; .1 I h, UI 1.11
159
Mass Spectrum (FAB) M + Na 957. Partial <sup>X.</sup>Η NMR spectrum, (CDC1<sub>3</sub>, 200 MHz) cheminiai poslinkiai: 7.19 (d, J=10Hz, 1H); 7.18 (d, J=3Hz, 1H) ; 7.05 (d, J=4Hz, 1H) ; 6.90 (J=3Hz, 10H) ; 6.35 (d, J=4Hz, 1H) ; 4.09 (kv, J=6.7Hz,
2H); 3.5 (s, 3H); 1.4 (t, J=6.7 Hz, 3H) .
EXAMPLE
The 17 Ethyl, 14 dihidroksi-12 [2 - (4 '- (the etilindol-5il) OKSI 3' -hidroksicikloheksil) -1'-metilvinil] -23,25dimetoksi-13,19 , 21,27-tetramethyl-l, 2, 4, 8 dioksa azatriciklo- [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3,1.0,16-tetraonas
To a solution of tri (l-ethylindol-5-yl) bismuthine (0.2 g) synthesized according to the procedures described in
IN STEP 14A AND B, and methylene chloride (2 mL), add peracetic acid (37μ1, 0.2 mmol). After stirring for 15 minutes at room temperature, 17-ethyl-1,14-dihydroxy-12 [2'- (4 '', 3 '' -dihydroxy-cyclohexyl) 1'-methyl-vinyl] -23,25-dimethoxy-13,19,21 is added. , 27-tetramethyl, 28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -oktakoz-18-en2,3, 10, 16-tetraonas (0.2 g, 0.25 mmol) ir po to Cu (OAc)<sub>2</sub> (20 mg) and the reaction mixture was stirred for 2 days. Saturated aqueous NaHCO is then added<sub>3</sub> the solution and product are extracted twice with methylene chloride. The extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. Mixture of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-ethylindol-5-yl) oxy-3' '- hydroxycyclohexyl) -1'-methyl vinyl] -23 , 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>]-octane-18-en-2,3,10, 16-tetraono-17-ethyl-1,14-dihydroxy-12- [2'- (4 ''-hydroxy-3 '' - (1ethylindole-5- il) oxycyclichexyl) -1'-methylvinyl] -23,25dimethoxy-13,19,21,27-tetramethyl-ll, 28-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone was separated by chromatography (silica gel, 3: 1,
II 1.11
160 hexane: ethyl acetate to give the title compound (0.035 g).
TLC (silica gel, 3: 1, hexane: ethyl acetate) R<sub>f</sub>= 0.55. Partial<sup>1</sup>H BMR spektras, (CDC1)<sub>3</sub>, 200 MHz) chemical shifts: 7.21 (d, J = 10 Hz, 1H); 7.14 (d, J = 3 Hz, 1H); 7.08 (d, J = 4Hz, 1H); 6.85 (dd, J = 3 Hz and 10 Hz, 1H); 6.36 (d, J = 4Hz, 1H); 4.10 (kv, J = 6.7 Hz, 2H); 1.42 (t, J = 6.7 Hz, 3H).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' - (1-propylindol-5yl) oxy-3 '' -methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13, 19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -okfakoz-18-en-2,3,10,16-tetraonas
To a stirred solution of tri (l-propylindol-5-yl) bismuthine (200 mg,<sup>-</sup>0.29 mmol), synthesized according to the procedures in STEP 14A and B, and methylene chloride (3 mL), added peracetic acid (0.075 mL, 0.36 mmol, 32% acetic acid), followed by the addition of 17-ethyl- 1,14-dihydroxy-12- [2 '- (4''-hydroxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11, 28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octakoz-18-en-2,3,10,16-tetraonas (150 mg, 0.19 mmol) with Cu (OAc)<sub>2</sub> (30 mg, 0.17 mmol.) The mixture was stirred at room temperature for 20 hours. The reaction was quenched by addition of saturated aqueous NaHCO<sub>3 </sub>and the product is extracted with methylene chloride. The extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated) in vacuo. The product was isolated and purified by preparative TLC (3 times) on silica gel (2: 1 hexane / acetone; 3% methanol in methylene chloride; 2: 1 hexane / acetone) to give 70 mg of the title compound. Mass Spectrum (FAB) M + Na 971. Partial X NMR Spectrum, (CDC1<sub>3</sub>, 200 MHz) che161
<td>crowd shifts:</td><td> 7.17</td><td>(d, J=10 Hz, 1H) ; 7.02</td><td>(d,</td><td>J = 4 Hz,</td>
<td>1H) ; 6.88 (dd,. J=</td><td>= 3Hz</td><td>ir J=10Hz, 1H) ; 6.32</td><td>(d,</td><td>J=4Hz,</td>
<td>1H); 3.97 (t, J=7</td><td>Hz,</td><td>2H); 3.50 (s, 3H); 1.8</td><td>(m,</td><td>2H).</td>
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-propylindol-5yl) oxy-3' '-hydroxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19 -21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
Peracetic acid (0.075 mL, 0.36 mmol) was added to a stirred solution of tri (1-propylindol-5-yl) bismuthine (200 mg, 0.29 mmol), synthesized according to the procedures outlined in STEP 14D IR B and methylene chloride (3 mL). , 32% solution in acetic acid), 17-ethyl-1,14-dihydroxy-12- [2 '(3' ', 4' '- dihydroxy-3' '- cyclohexyl) -1'- methyl vinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4aza-tricyclo [22.3.1.0]<sup>4</sup>'<sup>9</sup>] -octakoz-18-en-2,3, 10, 16-tetraonas (150 mg, 0.19 mmol) with Cu (OAc)<sub>2</sub> (30 mg, 0.17 mmol). The mixture was stirred at room temperature for 20 hours. The reaction was quenched by the addition of saturated aqueous NaHCO<sub>3</sub> and the product is extracted with methylene chloride. The extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product is isolated and purified from C-3 '' ether by preparative TLC to give the title compound.
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-hydroxyethylindol-5-yl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy -13,19,21,27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
162
25A STAGE
1-(2-Hidroksietil)-5-bromindolas
A mixture of NaOH (4.4 g, 0.011 mol) and DMSO (175 mL) was stirred at room temperature. 100 ° C for 5 hours, then cool to 20 ° C. To this mixture was added 5-bromoindole (20 g, 0.102 mol) and the reaction mixture was stirred at room temperature for 8 hours. A solution of ethylene oxide (5.1 g, 0.125 mol). This solution was slowly added to the reaction mixture with bromindole and stirred for a further 2.5 hours. The reaction mixture was then poured into ice water and extracted twice with diethyl ether. The combined ethereal extracts are concentrated in vacuo to crystallization. beginning. The crude product is recrystallized from diethyl etherhexane (3: 2) to give the title compound (6.25 g).
STEP 25B
1- (2-t-;Butildimetilsiiiloksietil) -5-bromindolas
A solution of 1- (2-hydroxyethyl) -5-bromoindole (6 g, 0.025 mol), t-butyldimethylsilyl chloride (4.5 g, 0.03 mol) and triethylamine (4.2 ml, 0.03 mol) in methylene chloride (60 ml) was stirred for 12 hours. hours at room temperature. The reaction mixture was then washed twice with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The title compound is obtained (yellow oil). Z NMR spectrum follows desired structure.
To II X «Lili II
II X III IJ
163
25C STAGE
Tri [1- (2-t-butildiraetilsililoksietil) -indol-5-] bismutinas
To a solution of 1- (2-t-butyldimethylsilyloxyethyl) -5-bromoindole (1.4 g, 0.004 mol) in diethyl ether (14 ml) was added, at -78 ° C, t -butyllithium (4.7 ml of a 1.7 M solution in pentane, 0.008 mol). After stirring for 1.5 h, a solution of bismuth trichloride (0.4 g, 0.013 mol) in THF (4 mL) was added. The reaction mixture was stirred at -78 ° C for 2 hours, then allowed to slowly warm to room temperature and stirred for a further 8 hours. The reaction mixture is then poured into water and extracted with toluene. The organic extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the filtrate concentrated in vacuo. Purify by chromatography (silica gel, 4: 1, hexane: ethyl acetate) to give the title compound (semi-solid).<sup>1</sup>The H NMR spectrum is consistent with the desired structure.
STEP 25D
17-Ethyl-1,4-dihydroxy-12-L 2'-4 '' - (1-t-butyldimethylsilyloxyethylindol-5-yl) oxy-3 '' - methoxycyclohexyl) -1'methylvinyl] -23,25-dimethoxy -1,3,19,21,27-tetramethyl, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -oktakoz-18-en2,3,10,16-tetraonas
To a solution of tri [1- (2-t-butyldimethylsilyloxyethyl) -indol-5-yl] bismuthine (1.03 g, 0.001 mol) in methylene chloride (10 ml) was added peracetic acid (150 μΐ) at room temperature. Stir for 15 minutes, then add 17-ethyl-1,14-dihydroxy-12- [2'- (4 '' -hydroxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13 , 19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] Oct: akoz-18-en-2, 3, 10, 16-tetraonas (1 g) ir, Cu (OAc)<sub>2</sub>
III
164 (0.04 g). The mixture was stirred at room temperature for 20 hours. The reaction was quenched by the addition of saturated aqueous NaHCO<sub>3</sub> and the product is extracted with methylene chloride. The extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The crude product was purified by chromatography (silica gel, 3: 1, hexane: ethyl acetate) to give the title compound (0.38 g).<sup>1</sup>The H NMR spectrum is consistent with the desired structure.
25E STAGE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-hydroxyethylindol-5-yl) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy- 13,19,21,27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1.0<sup>4,9</sup>] -octacos-18-en-2,3,10,16-tetraone to a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (t-butyldimethylsilyloxyethylindol-5-yl) ) oxy-3''-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,
19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclone 22.3.1. SHE<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (0.38 g) in methylene chloride (10 mL), para-toluene sulfuric acid (0.05 g) in methanol (10 mL) was added at room temperature. The reaction mixture was stirred for 3 hours until TLC analysis indicated that the reaction was complete. The reaction mixture is poured into saturated NaHCO3<sub>3</sub> solution and extracted twice with methylene chloride. The combined extracts were dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by chromatography (silica gel, 2: 1, hexane: ethyl acetate) to give the title compound (0.245 g). Mass Spectrum (FAB) M + Li 957. Partial<sup>X</sup>H
NMR Spectrum, (CDCl<sub>3</sub>, 200 MHz) chemical shifts: 7.18 (d, J = 10 Hz, 1H); 7.16 (pis, 1H); 7.06 (d, J = 4Hz,
IH) ; 6.86 (dd, J=3Hz, ir 10Hz, 1H) ; 6.33 (d, J=4 Hz,
I · η <3 FIGURE II J II i II ui
165
1H) ; 4.13 (t, J=6.7 Hz, 2H); 3.83 (t, J=6.7Hz, 2H); 3.43 (s, 3H) .
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1'-allylindole-5'ii) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25dimethoxy- 13,19,21,27-tetramethyl-ll, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
26A STAGE
1-Ali1-5-bromindolas »
To a stirred mixture of NaOH (204 mg, 5.1 mmol, 1 equiv) in dimethylsulfoxide (10 mL) was added 5-bromoindole (1.0 g, 5.1 to mmol, 1 equiv). The mixture was stirred for 3 hours until NaOH was completely dissolved (about 1 hour). To this solution is injected allyl iodide (0.466 mL, 5.1 mmol, 1 eq) via syringe. After 2 hours, the mixture was diluted with water and extracted twice with diethyl ether. The organic extracts were combined, dried over magnesium sulfate, filtered and concentrated in vacuo. The product was purified by flash chromatography on silica gel (4: 1 hexane / acetone) to give 730 mg of the title compound (7.5 mg) of l-allyl-5-bromoindole.
26B STAGE
Tri- (1-allylindol-5-yl) bismutins
To a solution of 1-allyl-5-bromoindole (730 mg, 3.09 mmol, 1 equiv.) In diethyl ether (15 mL) at -78 ° C under nitrogen was added 1.7 M t-butyl lithium pentane (1.8 mL) with stirring. , 3.09 mmol, 1 eq). The mixture was stirred at -78 ° C under nitrogen. 1.1 l.ll I
166 in the sphere for 1 hour. A solution of bismuth trichloride (292 mg, 0.93 mmol, 0.3 equiv.) In dry THF (3 mL) was added dropwise to the reaction mixture. Fill the ice bath with dry ice and cover the flask. The reaction mixture was allowed to warm to room temperature overnight. The reaction mixture is then diluted with toluene and washed with brine. The layers are separated and the aqueous layer is extracted three times with toluene. The organic extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The residue was dissolved in ether and filtered through a 0.4 micron PTFE membrane. The product self-crystallizes. Cool the solution in the refrigerator. The crystals were collected to give 200 mg of tris (l-al-i-lindol-5-yl) bismuthine.
26C STAGE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- allylindole-5'ii) oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23.25dimethoxy-13.19, 21,27-tetramethyl-ll, 28-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a stirred solution of tri (l-allylindol-5ii) bismutin (186 mg, 0.275 mmol, 1.2 eq.) And methylene chloride (3 mL) was added peracetic acid (0.064 mL, 0.303 mmol, 32% in dilute acetic acid). in acid, 1.32 eq.). To this solution was added THF (1 mL) and, after 10 minutes, 17-ethyl-1,14-dihydroxy-12 [2'- (4 '' -hydroxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl-23] was added. , 25-Dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (181 mg, 0.229 mmol, 1 eq) and copper (II) acetate. (10 mg, 0.055 mmol, 0.24 eq.). The mixture was sealed and stirred overnight. The reaction mixture was diluted with saturated aqueous NaHCO3<sub>3</sub> and the product is extracted 4 times with methylene chloride. The organic extracts are combined, dried over beI BIIIJI .11111.1111. !. I II .11111 n
167 of water Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product is isolated and purified by flash chromatography on silica gel (2: 1 hexane / acetone) and preparative TLC (3.5% methanol / methylene chloride) to give 56 mg of the pure title compound. Mass Spectrum (FAB) M + Li 953. Partial<sup>FROM</sup>H BMR spektras, (CDC1)<sub>3</sub>, 200 MHz) cheminiai poslinkiai: 7.17 (bs, 1H) ; 7.15 (d, J=10 Hz, 1H) ; 7.02 (d, J=3Hz, 1H) ; 6.88 (dd, J=2Hz ir 10Hz, 1H); 6.36 (d, J=3Hz, 1H); 5.95 (m, 1H); 4.63 (pld, J=14Hz, 1H); 3.50 (s, 3H).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4 *' - (1'-allylindole-5'ii) oxy-3 '' -hydroxy-cyclohexyl) -1 '-methylvinyl] -23, 25dimethoxy-13,19,21,27-tetramethyl-ll, 28-dioxa-4-azatricyclo- [22.3.1. O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
Peracetic acid (0.315 mL, 1.62 mmol, 1.32) was added to a stirred solution of tri (1-allylindol-5-yl) bismuthine (1.0 g, 1.48 mmol, 1.2 equiv.), Methylene chloride (9 mL), and THF (3 mL). eq., 32% solution in dilute acetic acid). To this solution is added 17-ethyl-1,14-dihydroxy-12- [2'-4 (4 '', 3 '' - dihydroxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21 , 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -okta0.1 eq), Reaction mixture
1.23 mmol, 0.123 mmol), 4 days. aqueous cos-18-ene-2,3,10,16-tetraone (956 mg, eq) and copper (II) acetate (22 mg,
The mixture was sealed and diluted with saturated methylene chloride several times. The organic extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product is isolated and purified by flash chromatography on silica gel (3: 1 hexane / acetone) and preparative TLC (3.5% methanol / methylene chloride) to give 163 mg of pure 17-ethyl-1,14-diNaHCO3 solution and
111 in
168 hydroxy-12- [2 '- (4' '- (1'-allylindole-5'-ii) oxy-3' '- hydroxy-cyclohexyl) -1'-methylvinyl] -23,25-dimethoxy13,19,21,27 -tetramethyl-ll, 28-dioxa-4-azatricycle [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone. Mass spectrum (FAB) M + Li. 953. Partial<sup>X</sup>H BMR spektras, (CDC1)<sub>3</sub>, 200 MHz) chemical shifts: 7.17 (d, J = 10 Hz, 1H);
7.15 (pis, 1H) ; 7.05 (d, J=3Hz, 1H) ; 6.86 (dd, J=10Hz ir J=2.5Hz, 1H) ; 6.39 (d, J=3Hz, 1H) ; 6.05-5.85 (m,
1H); 4.66 (pld, J=5Hz, 2H); 4.57 (pld, J=5Hz, 1H); 4.38 (pld, J=13Hz, 1H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (9'-methylcarbazol3'-ii) oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy- 13,19,21,27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3,10, 16-tetraonas
28A STAGE
Tri (9-metilkabazol-3-yl) bismutinas
To a stirred solution of 3-bromo-9-methylcarbazole (646 mg, 2.48 mmol, 1 equiv.) In diethyl ether (12 mL) at -78 ° C (carbazole not completely dissolved) was added 1.7 M t-butyl lithium solution under nitrogen. pentane (3.0 mL, 4.96 mmol, 2 eq). The mixture was rapidly warmed to room temperature and then rapidly cooled to -78 ° C and stirred under nitrogen for 40 minutes. A solution of bismuth trichloride (235 mg, 0.744 mmol, 0.3 equiv.) In dry THF (2.5 mL) was then added dropwise to the reaction mixture. Fill the ice bath with dry ice and cover the flask. The reaction mixture was allowed to warm to room temperature overnight. The reaction mixture is then poured into a separatory funnel containing salts
IJHII1I „UILiliII UI IU .11 IH I.
169 solution and extracted four times with methylene chloride. The organic extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The residue is triturated with ether and a mixture of ether and methanol. The solid is collected and the resulting 200 mg is filtered through a 0.4 micron PTFE membrane. The product self-crystallizes. Cool the solution in the refrigerator. The crystals were collected to give 200 mg of tri (9-methylcarbazol-3-yl) bismutin. The supernatant is stored until further purification.
28B STAGE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (9'-methylcarbazol-3'-ii) oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] 23,25-dimethoxy- 13, 19,21,2 7-Tetramethyl-11,28-dioxa-4-azatricyclo-L 22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
Peracetic acid (0.062 mL, 0.295 mmol) was added to a stirred solution of tri- (9-methylcarbazol-3-yl) bismuthine (200 mg, 0.267 mmol, 1.2 equiv.), Methylene chloride (3 mL), and THF (1 mL). 1.32 eq., 32% in dilute acetic acid). To this solution is added 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '-hydroxy-3' '-methoxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19, 21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (175 mg, 0.222 mmol, 1 equiv) and copper (II) acetate (10 mg, 0.055 mmol, 0.24 equiv). The mixture was sealed and stirred for 48 hours. The reaction mixture was diluted with saturated aqueous NaHCO3<sub>3</sub> solution and extracted 4 times with methylene chloride. The organic extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product is isolated and purified by flash chromatography on silica gel (3: 1 hexane / acetone) and preparative TLC (3.5% meLT 3533 B).
170 tannol / methylene chloride) to give 100 mg of the pure title compound. Mass Spectrum (FAB) M + Li 977. Partial<sup>X</sup>H BMR spektras, (CDC1)<sub>3</sub>, 200 MHz) chemical shifts: 7.68 (d, J = 2 Hz, 1H); 7.48-7.10 (m, 6H);
4.58 (pld, J=4.8Hz, 1H) ; 4.39 (pld, J=14Hz, 1H) ; 3.80 (s, 3H); 3.53 (s, 2H).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1'-benzylindol-5-yl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13, 19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1.0]<sup>4</sup>'<sup>9</sup>] -octakozo-18-en-2,3, 10,16-tetraonas
29A STADIJA the benzyl 5-bromindolas
To a mixture of NaOH (204 mg, 5.1 mmol, 1 eq) and DMSO (10 mL) was added 5-bromoindole (1.0 g,
5.1 mmol, 1 eq). The reaction mixture was stirred at room temperature for 20 hours after the NaOH had completely dissolved (about 1 hour). To this solution was added benzyl bromide (0.606 mL, 5.1 mmol, 1 eq.) Via syringe. After 7 or. the reaction mixture was diluted with water and extracted four times with diethyl ether. The combined ethereal extracts were dried over anhydrous MgSO 4<sub>4</sub>, filtered and concentrated in vacuo. The product is recrystallized from a mixture of diethyl ether and hexane to give 888 mg of 1-benzyl-5-bromoindole.
ι · υι have mi; i .ι ι: i. iii ui
171
29B STAGE
Tri (l-benzilindol-5-yl) bismutinas
To a stirred solution of 1-benzyl-5-bromoindole (888 mg, 3.105 mmol, 1 equiv.) In diethyl ether (15 mL) at -78 ° C (indole not completely dissolved) was added 1.7 M t-butyl lithium solution under nitrogen. pentane (3.65 mL, 6<sub>t</sub>21 mmol, 2 equiv). The mixture was stirred at -78 ° C under nitrogen for 1 hour. A solution of bismuth trichloride (294 mg, 0.932 mmol, 0.3 equiv.) In dry THF (3.0 mL) was then added dropwise to the reaction mixture. Fill the ice bath with dry ice and cover the flask. The reaction mixture was allowed to warm to room temperature overnight. The reaction mixture is then poured into a separatory funnel containing brine and extracted four times with methylene chloride. The organic extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The residue is deleted in ether. The solid is collected and the resulting 200 mg is filtered through a 0.4 micron PTFE membrane. The product self-crystallizes. Cool the solution in the refrigerator. The crystals were collected to give 200 mg of tri (l-benzylindol-5-yl) bismutin. The supernatant is stored until further purification.
29C STAGE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1'-benzylindol-5-yl) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13 , 19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
Peracetic acid (0.060 mL, 0.285 mmol, 1.4) was added to a stirred solution of tri (1-benzylindol-5-yl) bismuthine (200 mg, 0.242 mmol, 1.2 equiv.), Methylene chloride (3 mL), and THF (1 mL). eq; 32% thiII, III; IIJIIHI Ii, 1! .1 II I 1,11 III
172 palas in dilute vinegar. in acid). To this solution was added 17-ethyl-1,14-dihydroxy-12- [2'- (4 '' -hydroxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octacos-18-ene-2,3, 10,16-tetraone (159 mg, (10 mg, eq.) and copper (II) acetate 0.24 eq.). The mixture is sealed and stirred. The reaction mixture is diluted with saturated extraction
0.202 mmo1,
0.055 mmol, overnight.
aqueous NaHCO<sub>3</sub> solution and 4 methylene chloride. The organic extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The product is isolated and purified by flash chromatography on silica gel (3: 1 hexane / acetone) and preparative TLC (3.5% methanol / methylene chloride) to give 100 mg of the pure title compound. Mass spectrum (FAB) M + Li
1003
Partial H NMR spectrum,: cdci
3'
200 MHz) chemical shifts: 7.3-7.0 (m, 8H); 6.84 (dd, J = 9 Hz, 1H); 6.40 (d, J = 3 Hz, 1H); 5.23 (pis, 2H); 4.6 (pd, J = 6Hz, 1H); 4.38 (pld, J = 14 Hz, 2H); 3.50 (s, 3H).
EXAMPLE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) oxy-3' '-allyloxycyclohexyl) -1'-methylvinyl] -23,25 dimethoxy-13,19 , 21,27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
31A STAGE
17-Ethyl-hydroxy-12- [2 '- (4' '- (t-butyldimethylsyloxy) 3' '-alyloxycyclohexyl) -1' .- methylvinyl] -23,25-dimethoxy-13, 19,21, 27-tetramethyl-ll, 2 8-dioxy-4-azatricycle [22.3.1.0<sup>4</sup>'<sup>9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2 '- (4'-butyldimethylsilyloxy) -3' '- hydroxycyclohexyl) -1'-methyl]
173 tilvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-1,12 dioxa-4-aza-tricyclo- [22.3.1. ON<sup>4</sup>'<sup>9</sup>] -octacos-18-ene-2,3,3,10,16-tetraone (300 mg) and 9 ml of 33% methylene chloride in cyclohexane were added trichloroacetamidate (138 mg, undiluted) and the reaction stirred for 5 minutes. Trifluoromethanesulfonic acid (18 μΐ, undiluted) was slowly injected and the mixture was stirred at room temperature. After 3 days, the reaction mixture was diluted with ethyl acetate and quenched with saturated sodium bicarbonate solution. The layers were separated and the organic layer was washed with brine by flash chromatography on silica gel (ethyl acetate: hexane (1: 4) + 1% methanol) to give the title compound (230 mg, trichloroacetamide present). <sup>X</sup>H NMR spectrum corresponds to desired structure.
31B STAGE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- hydroxy-3' '- allyloxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl- 11,2-dioxa-4-azatricyclo- [22.3.1. ON<sup>4,9</sup>] octacose-18-en-2,3, 10,16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2'- (4'-butyldimethyloxy) -3''-allyloxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19 , 21,27-tetramethyl] -11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octacos-18-en2,3,10,16-tetraone (115 mg) (STEP 31A) and acetonitrile (2.5 mL), 2% HF in aqueous acetonitrile (40 μΐ) was added and the reaction stirred at room temperature. After 5 hours, the reaction mixture was diluted with ethyl acetate and quenched with saturated sodium bicarbonate solution. The layers are separated, the organic layer is washed with brine and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silicaIMI III, IIHIIMII 'II I II, 1,11 UI
174 gel (ethyl acetate: hexane (1: 2)) to give the title compound (42 mg). <sup>1</sup>The H NMR spectrum is consistent with the desired structure.
31C STAGE
17-Ethyl-1-hydroxy-12- [2 '(4' '- (1N-methyl-5-indolyl) oxy-3' '-alyloxycyclohexyl) -1'-methylvinyl] -23,25 dimethoxy-1,3,3, 19 , 21,27-tetramethyl-11, 28-dioxa-4-azatriciclo- [22.3.1. SHE IS<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of tri (methylindol-5-yl) bismutin (53 mg) and methylene chloride (700 μΐ). peracetic acid (17 μΐ) was added and the mixture was stirred at room temperature for 15 minutes. 17-Ethyl-1-hydroxy-12- [2 '(4' '-hydroxy-3' 'allyloxycyclohexyl) -1'-methyl vinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11, 28-Dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>-<sup>9</sup>] -octacos-18-ene-2,3,10,16-tetraone (42 mg) was dissolved in methylene chloride (270 μΐ) and added to the reaction mixture. After 18 hours, the reaction mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution, brine and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel (ethyl acetate: hexane (1: 3) + 1% methanol) to give the title compound (25 mg). Mass Spectrum (FAB) 938 (M + Li); Partial<sup>1</sup>NMR Spectrum, chemical shifts: 7.19 (s, 1H); 7.18 (d, J = 9 Hz, 1H); 6.98 (d, J = 3 Hz, 1H); 6.92 (dd, J = 9.3Hz, 1H); 6.34 (d, J = 3Hz,
1H); 5.89 (m, 1H); 4.56 (brd, J=4Hz, 1H); 3.72 (s, 3H).
EXAMPLE
17-Ethyl-1-hydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) oxy-3' '-n-propyloxycyclohexyl) -1'-methylvinyl] -23,25 dimethoxy-13 , 19,21,27-tetramethyl-1,11, 29-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] -oktakoz-18-en-2, 3, 10, 16-tetraonas ll XKII.IIII N Ί II II lU III
175
To a solution of 17-ethyl-1-hydroxy-12- [2 '- (4' '(1N-methyl-5-indolyl) -oxy-3' '- allyloxycyclohexyl) -1'-methylvinyl] -23.25 -dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (20 mg) (Example 31) In ethyl acetate (500 μΐ) was added rhodium on carbon (5 mg). The flask is filled with hydrogen and the mixture is stirred at room temperature. After 1.5 hours, the mixture was filtered through celite, then the solvent was evaporated in vacuo to give the title compound (20 mg). Mass Spectrum (FAB) (M + Li); Partial<sup>!</sup>NMR Spectrum, chemical shifts: 7.18 (s, 1H); 7.16 (d, J = 9 Hz, 1H); 6.96 (d, J = 3 Hz, 1H); 6.92 (dd, J = 9.3Hz, 1H); 6.34 (D, J = 3Hz, 1H); 4.55 (dd, J = 4Hz, 1H); 3.72 (s, 3H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '- 1-propyloxycyclohexyl) -1'-methylvinyl] 23 , 2 5-Dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3, 10,16-tetraonas
33A STAGE
17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' -hydroxy-3 '' - i -propyloxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(3' ', 4' '- dihydroxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27 -tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (300 mg) and 4.5 ml of 33% methylene chloride in cyclohexane were added isopropyl trichloroacetamidate (142 mg, undiluted) and the reaction stirred for 5 minutes.
176
Introduce trifluoromethanesulfonic acid (13.4 μΐ, undiluted) by slow injection and stir at room temperature. After 5 days, the reaction mixture was diluted with ethyl acetate and quenched with saturated sodium bicarbonate solution. The layers are separated, the organic layer is washed with brine and dried over magnesium sulfate. The concentrate was purified by preparative TLC on silica gel (ethyl acetate: hexane (1: 1), 1% methanol) to give the title compound (42 mg). <sup>1</sup>The H NMR spectrum is consistent with the desired structure.
33B STAGE
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (1N-methyl-5-indolyl) -oxy-3 '' -i-propyloxycyclohexyl) -1'-methylvinyl] 23,25 -Dimethoxy-13,19,21,27-tetramethyl-11,18-dioxa-4azatricyclo- [22.3.10<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of tri (l-methylindol-5-yl) bismutin (52 mg) in methylene chloride (700 μΐ) was added peracetic acid (17 μΐ) and the mixture was stirred at room temperature for 15 minutes. 17-Ethyl-1,14-dihydroxy-12 [2 '- (4' '-hydroxy-3' '- i -propyloxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl -11,28-dioxa-4-aza-tricyclo [2.3.1. O<sup>4,9</sup>] -octacos-18-en-2, 3,10,16-tetraone (42 mg) was dissolved in methylene chloride (450 μΐ) and added to the reaction mixture. After 18 hours, the reaction mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate. The concentrate was purified by preparative TLC on silica gel (ethyl acetate: hexane (1: 1) + 1% methanol) to give the title compound (9 mg). Mass Spectrum (FAB) 956 (M + Li); Partial<sup>X</sup>NMR Spectrum, chemical shifts: 7.19 (s, 1H); 7.16 (d ,,
J=9 Hz, 1H) ; 6.97 (d, J=3Hz, 1H) ; 6.92 (dd, J=9,3 Hz,
177
1H) ; 6.34 (d, J=3Hz, 1H) ; 4.41 (pld, J=14Hz, 1H); 2.72 (s, 3H).
EXAMPLE
17-Ethyl-1, 14-dihydroxy-12- [2 '- (4' '- (1N-methyl-5-indolyl) -oxy-3' '-anyloxycyclohexy) -1'-methylvinyl] -23, 25- dimethoxy-13,19,21,27-tetramethyl-11,18-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
STAGE 34A
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- t-butyldimethylsiloxy) -3'<sup>1</sup>-hydroxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-1,2,8-dioxa-4-aza-tricyclo - [22.3.1. SHE<sup>4,9</sup>] -okjtakoz-18-en-2, 3,10,16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(3' ', 4' '-dihydroxycyclohexyl) -1'-methylvinyl] -23,2 5-di-methoxy-13,19,21 , 27 t.etramethyl- 1,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4</sup>’<sup>9</sup>] -octacos-18-en-2, 3,10, 16-tetraone (1.0 g) in dry methylene chloride (14 mL) was added 2,6-lutidine (240 μΐ) and the mixture was stirred at room temperature. After 10 minutes, t-butyldimethylsilyl trifluoromethanesulfonate (295 μΐ) was added via syringe. After 15 minutes, the reaction mixture was diluted with ethyl acetate, washed with IN HCl, water, saturated sodium bicarbonate solution, and brine. The organic phase is dried over magnesium sulfate. The solvent was evaporated in vacuo and purified by flash chromatography on silica gel (ethyl acetate / hexane (1: 3) + 15 methanol) to give the title compound (293 mg). <sup>:</sup>Η The NMR spectrum follows the desired structure.
178
34B STAGE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- t-butyldimethylsiloxy) -3' '- allyloxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27 -tetramethyl-11,28-dioxa-4-aza-tricyclo - [22.3.1. SHE<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- t-butyldimethylsiloxy) -3' '- hydroxycyclohexyl) 1'-methyl vinyl] -23,25-dimethoxy-13, 19,21,27-tetramethyl], 28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -octacos-18-ene-2,3,3,10,16-tetraone (290 mg) and 3.9 ml of 33% methylene chloride in cyclohexane were added allyl trichloroacetimidate (131 mg, undiluted) and the reaction mixture was stirred for 5 minutes. Inject the trifluoromethanesulfonic acid using a slow syringe<sup>1</sup> (6μ1, undiluted) and the mixture was stirred at room temperature. After 5 days, the reaction mixture was diluted with ethyl acetate and quenched with saturated sodium bicarbonate solution. The layers are separated, the organic layer is washed with brine and dried over magnesium sulfate. The concentrate was purified by preparative TLC on silica gel (ethyl acetate: hexane (1: 5) + 1% methanol) to give the title compound (150 mg).<sup>X</sup>The H NMR spectrum is consistent with the desired structure.
34C STAGE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '-hydroxy-3' 'allyloxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl- 11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of 17-ethyl-1-hydroxy-12- [2 '- (4'-butyldimethylsilyloxy) -3''-allyloxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19 , 21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -oktakoz-18-en-2,3, ι: III BLIUII li .1 ll (I .I, III III. ·
179
10,16-Tetraone (150 mg) and acetonitrile (3 mL), 2% HF in aqueous acetonitrile (80 μΐ) was added and the reactions were stirred at room temperature. After 2 hours, the reaction mixture was diluted with ethyl acetate and quenched with saturated sodium bicarbonate solution. The layers are separated, the organic layer is washed with brine and dried over magnesium sulfate. The concentrate was purified by flash chromatography on silica gel. (ethyl acetate-hexane (1: 1) + 1% methanol) to give the title compound (63 mg). <sup>X</sup>The H NMR spectrum is consistent with the desired structure.
34D STAGE
17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' - (1-N-methyl-5-indo) -oxy-3 '' - allyloxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19,21,27-tetramethyl-1,28-dioxa-4-azatricyclo- [22.3.1. O<sup>4,9</sup>] -octakozo-18-en-2,2,10, 16-tetraonas
To a solution of tri (l-methylindol-5-yl) bismutin (60 mg) and methylene chloride (1 mL) was added peracetic acid (23 μΐ) and the mixture was stirred at room temperature for 15 minutes.
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '-hydroxy-3' '- allyloxy-cyclohexyl-1'-methylvinyl] -23,25-dimethoxy-13,19,
21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (60 mg) was dissolved in methylene chloride (500 μΐ) and added to the reaction mixture. After 20 hours, the reaction mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution, brine and dried
The concentrate was purified on silica gel (ethyl acetate: hexane (1: 2) + 1% methanol) to give the title compound (26 mg). Partial<sup>X</sup>NMR spectrum, chemical shifts; 7.18 (s, 1H); 7.16 (d, over magnesium sulphate, RMS TLC)
180
J=9 Hz, 1H) ; 6.97 (d, J=3Hz, 1H) ; 6.91 (dd, J=9,3Hz,
1H) ; 6.34 (d, J=3Hz, 1H) ; 5.89 (m, 1H) ; 4,57 (pld, J=4Hz, 1H) ; 4.41 (pld, J=4Hz, 1H) ; 3.70 (s, 3H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (1N-methyl-5-indolyl) -oxy-3 '' -n-propyloxycyclohexyl) -1'-methylvinyl] 23,25 -Dimethoxy-1,3,19,21,27-tetramethyl-11,28-dioxa-4azatricyclo- [2.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (1-N-methyl-5-indolyl) oxy-3' '- allyloxycyclohexyl) -1'-methyl vinyl] - 23,25-Dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -octacos18-en-2,3,10,16-tetraone (14 mg) in ethyl acetate (400µΐ) was added rhodium on carbon (4 mg). The flask is filled with hydrogen and the mixture is stirred at room temperature. After 1.5 hours, the mixture was filtered through celite, then the solvent was evaporated in vacuo. Purification by flash chromatography gave the title compound (10 mg). Partial<sup>1</sup>NMR Spectrum, chemical shifts: 7.17 (s, 1H); 7.15 (d, J = 9 Hz, 1H); 6.97 (d,
J=3Hz, 1H) ; 6.92 (dd, J=9,3Hz, 1H) ; 6.34 (d, J=3Hz,
1H) ; 4.56 (pld, J=4Hz, 1H) ; 4.40 (pid, J=14Hz, 1H) ;
3.71 (s, 3H).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2'- (4 '' - (1'-3-t-butyldimethylsilyloxypropylindol-5-yl) -oxy-3 '' - allyloxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. O<sup>4,9</sup>] -octakozo-18-en-2,3,10,15-tetraonas
181
To a solution of tri- (3-t-butyldimethylsilyloxypropyl) indol-5-yl) bismuthine (? 43 g, 0.4 mmol) and methylene chloride (4 'mL) was added peracetic acid (0.075 mL, 32%) at room temperature. solution of acetic acid and after 15 minutes add 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- methoxycyclohexyl-1'-methylvinyl) -23,15-dimethoxy-13,19,21 , 27-tetramethyl
11.28-dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] -oktakoz-2,3,10,
16- tetraonas (350 mg, 0.44 mmol) ir Cu(OAc)<sub>2</sub> (30 mg). The reaction mixture was stirred for 2 days. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC on silica gel (3: 1, hexane / acetone) to give the title compound (144 mg).
EXAMPLE
17- Ethyl-1,14-dihydroxy-12- [2'- (4 '' - (1- (3-hydroxypropyl) indol-5-yl) -oxy-3 '' - methoxyciclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19-21,27-tetramethyl-11, 28-dioxsa-4-azatriciclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10, 16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (1- (3-t-butyldimethylsilyloxypropylindol-5-yl) -oxy-3' '-methoxycyclohexyl) -1 '-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0-o]<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (144 mg) in methylene chloride (4 mL) was added at room temperature in p-toluene hydrochloric acid (20 mg) in methanol (4 mL). The reaction mixture was stirred for 3 hours. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts are combined, dried over sodium sulfate, and dried
182 filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC on silica gel (2: 1, hexane / acetone) to give the title compound (81 mg). Partial<sup>X</sup>NMR Spectrum, (CDCl<sub>3</sub>, 200MHz) d:7.22 (d, J=9Hz, 1H); 7.18 (d, J=3 Hz, 1H) ; 7.07 (d, J=3Hz, 1H) ; 6.89 (dd, J=3Hz,ir
J=9Hz, 1H) ; 6.34 (d, 3Hz, 1H); 4.20 (t, J=6. 5Hz, 2H) ; 2.00 (m, 2H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (3' '- hydroxy-4' '- (1-t-butyldimethylsilyloxyethyl-5-yl) -oxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy -13,19,21,27-tetramethyl, 28-dioxa-4-azatricyclo - [- 22.3.1.O<sup>4,9</sup>] -oktakoz-18-en2,3,10,16-tetraonas
To a solution of tri [1- (2-t-butyldimethylsilyloxyethyl) indol-5-yl] bismuthine (250 mg, 0.24 mmol) and methylene chloride (2 mL) was added peracetic acid (0.05 mL, 32% solution) at room temperature. acetic acid) and, after 1.5 minutes, 17-ethyl-1,14-dihydroxy-12- [2 '- (3' ', 4' '- dihydroxycyclohexyl) -1'-methyl vinyl] -2,2,2-dimethoxy-13-is added. , 19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octakoz-18-en-2, 3, 10, 16-tetraonas (200 mg, 0.25 mmol) with Cu (OAc)<sub>2</sub> (20 mg). The reaction mixture was stirred for 2 days. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC on silica gel (3: 1, hexane / acetone) to give the title compound (74 mg).
183
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (3' '- hydroxy-4' '- (l-butyldimethylsilyloxyethyl-5-yl) -oxycyclohexyl) -1'-methylvinyl] -23.2 5 -dimethoxy-13, 19,21,27-tetramethyl-ll, 2 8-dioxy-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -to-18-in-2,3,10,
16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(3' '- hydroxy-4' '- (1-t-butyldimethylsilyloxyethylindol-5-yl) oxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (74 mg) in methylene chloride (2 mL) was added at room temperature in p-toluene sulfuric acid (10 mg) in methanol (2 mL). The reaction mixture was washed for 2 hours. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The extracts were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The product was purified by preparative TLC on silica gel (2: 1, hexane / acetone) to give the title compound
<td> (44 .</td><td>8 mg)</td><td>Partial</td><td><sup>X</sup>NMR spectrum,</td><td>(CDC1</td><td><sub>3</sub>, 200</td><td>MHz)</td><td>d:</td>
<td> 7.24</td><td>(d,</td><td>J = 9Hz, IH)</td><td>; 7.15 (d, J =</td><td>= 3 Hz,</td><td>1H);</td><td> 7.12</td><td>(d,</td>
<td>J=3,</td><td>5Hz,</td><td>THEM); 6.86</td><td>(dd, J=3Hz ir</td><td>J=9Hz,</td><td>1H);</td><td> 6.39</td><td>(d,</td>
<td>J=3,</td><td>5Hz,</td><td>THEM); 4.20 (</td><td>t, J=5Hz, 2H).</td><td></td><td></td><td></td><td></td>
EXAMPLE
Tri- [1-2 (t-butyldimethylsilyloxyethyl) -indol-6-yl] -bismutinas
Stage A: 6-Bromindolas
To a solution of 4-bromo-2-nitrotoluene (4.3 g, 20 mmol) in DMF (40 mL) was added DMF dimethylacetal (7.15 g, 60 mmol) and pyrrolidine (1.4 g, 20 mmol). The solution is heated to
184
110 ° C for four hours, then cooled to room temperature and diluted with ethyl ether. The mixture is washed three times with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent evaporated. The residue was dissolved in 80% acetic acid (125 mL) and heated to 75 ° C. Zinc dust (9.75 g, 150 mmol) was added portionwise over 20 minutes. The reaction mixture was heated at 85 ° C for 2 hours, cooled to about 35 ° C, and filtered to remove unreacted zinc. The filtrate was diluted with ethyl ether, washed 3 times with water and saturated NaHCO3<sub>3</sub> solution. The solution was dried over sodium sulfate, filtered and concentrated in vacuo to about 30 mL, then diluted with hexane and filtered. The filtrate was concentrated to a solid, which was dissolved in hexane, filtered, concentrated to give 1.65 g of the title compound as a light green solid.
Stage B:
1-2-(t-Butildimetilsililoksietil)-6-bromindolas
To a suspension of NaH (192 mg, 4.8 mmol, 60% oil dispersion) in DMF (4 mL) was added a solution of 6-bromoindole (0.85 g, 4.34 mol) in DMF (4 mL). After stirring for 10 minutes at room temperature, 2-t-butyldimethylsilyloxyethyl bromide (1.15 g, 4.8 mmol, undiluted) is added and the mixture is stirred for 1.5 hours and then poured into a mixture of ice water and hexane. The organics are washed twice with water, dried over sodium sulfate, filtered and concentrated in vacuo to give a dark oil. The product is isolated by flash column chromatography (silica gel, 4: 1, hexane / acetone) to give 1.04 g of the title compound (oil).
Hillll! U ii I.!. 1.11 Ii ·
185
Stage C:
Tri [1-2 (t-butyldimethylsilyloxyethyl) -indol-6-yl] -bismutinas
To a solution of 1-2 (t-butyldimethylsilyloxyethyl) -6-bromoindole (1.0 g, 2.81 mmol) in ethyl ether (10 mL) at -78 ° C was added t-butyllithium (3.4 mL, 5.8 mmol, 1.7 M in pentane). . After stirring for 10 min, a solution of bismuth trichloride (285 mg, 0.9 mmol) in THF (3 mL) was added. The reaction mixture was stirred at -78 ° C for a further 10 minutes, then allowed to slowly warm to room temperature overnight. The reaction mixture is then poured into a mixture of ice water and methylene chloride. The organic layer was washed with water, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo until a dark oil is obtained. Purification by flash chromatography (silica gel, 4: 1, hexane: acetone) affords the title compound (630 mg, dark oil) which is used without further purification (Example 41, step a).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-t-butyldimethylsilyloxyethylindol-6-yl) -oxy-3' '- methoxycyclohexyl) 1'-methylvinyl] -23,25 -Dimethoxy-13,19,21,27-tetramethyl, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] -octacos-18-en2,3,10,16-tetraone to a solution of tri [1-2 (t-butyldimethylsilyloxyethyl) -indol-6-yl] -bismutin (0.6 g, 0.58 mmol) and methylene chloride ( 5 ml), peracetic acid (0.080 ml, 32% acetic acid solution) was added at room temperature and 17-ethyl-1,14-dihydroxy-12- [2'- (4 '' - hydroxy-3 '' -methoxy) was added after 15 minutes. -cyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -oktakozLT 3533 B
186
18-in-2, 3,10,16-tetraones (350 mg, 0.44 mmol) go Cu (OAc)<sub>2</sub> (30 mg). The reaction mixture was stirred for 20 hours. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts are combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC on silica gel (3: 1, hexane / acetone) to give the title compound (150 mg).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1- (3-hydroxyethyl) indol-6-yl) -oxy-3' '' -methoxycyclohexyl) -1 '-methylvinyl ] -23,25-dimethoxy-13,19,21,27-tetramethyl-11, 28-dioxsa-4-azatriciclo- [22.3.1.O<sup>4,9</sup>] -oktakoz-18-en-2,3,10,16tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (tert-butyldimethylsilyloxyethylindol-6-yl) -oxy3' '- methoxycyclohexyl) -1'-methyl vinyl] -23, 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (150 mg) in methylene chloride (4 mL) was added at room temperature in p-toluenesulfonic acid (20 mg) in methanol (4 mL). The reaction mixture was stirred for 2 hours. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product was purified by preparative TLC on silica gel (2: 1, hexane / acetone) to give the title compound (55 mg). Partial<sup>4</sup>NMR Spectrum, (CDCl<sub>3</sub>, 200 MHz) d: 7.47 (d, J=6Hz, 1H);'..7.O3 (d, J=3 Hz, 1H) ; 6.94 (pis, 1H) ; 6.82 (dd, J=1.5 HZ ir J=6Hz, 1H) ; 6.41 (d,
I · 1.1. "I.1III! on I JUIII 1! ·
187
J=3Hz, 1H) ; 6.41 (t, J=3Hz, 1H) ; 4.20 (t, J=5Hz, 2H) ;
3.93 (t, J=5Hz, 2H); 3.50 (s, 3H).
EXAMPLE
Tri (the metilindol-6-) bismutinas
To a solution of 1-methyl-6-bromoindole (760 mg, 3.6 mmol) in ethyl ether (15 mL) at -78 ° C was added t-butyllithium (4.4 mL, 7.5 mmol, 1.7 M in pentane). Stir for 10 minutes, then add bismuth trichloride (375 mg,
1.2 mmol) in THF (4 mL) and quenched. The reaction mixture was stirred for 4 hours, then poured into ice water and extracted with methylene chloride. The extracts are combined, washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo until a dark oil is obtained. The product is crystallized from methanol to give the title compound (290 mg, brownish solid).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-methylindol-6yl) oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] -23,25dimethoxy- 13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2,3, 10, 16-tetraonas
To a solution of tri [l-methylindol-6-yl) bismuthine (200 mg, 0.33 mmol) and methylene chloride (2 mL) was added peracetic acid (0.070 mL), 32% solution in acetic acid at room temperature, and 17-ethyl-1,14-dihydroxy-12- [2'- (4 '' -hydroxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21 is added over a minute, 27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4</sup>'<sup>9</sup>] octacose-18-en-2,3,10,16-tetraonas (150 mg, 0.19 mmol) with Cu (OAc)<sub>2</sub> (30 mg). The reaction mixture was stirred at 4 dieLT 3533 B
188 nas. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product was isolated and purified by preparative TLC on silica gel (2: 1, hexane / acetone) to give the title compound (76 mg).
Partial <sup>X</sup>BMR spektras, (CDC1, 400 MHz) d: 7.44 (d, J=7Hz, 1H) ; 6,91 (d, J=3 Hz, 1H) ; .6.88 (d, J=2Hz, 1H) ; 6.81 (m, 1H); 6.37 (d, J=3Hz, 1H) ; 3.68 (s,,3H), 3.51 (s, 3H).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-dibenzylphosphonooxyethylindol-5-yl) oxy-3' 'methoxycyclohexyl) 1'-methyl vinyl] -23,25 -dimethoxy-13,19,21,27-tetramethyl-1, 28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -oktakoz-18-en2,3,10,16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (1-hydroxyethylindol-5-yl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] - 23,25-Dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] octacos-18-ene-2,3,10,16-tetraone (202 mg, azeotropic with toluene) in dry THF, dibenzyl phosphate (88.6 mg) was added followed by triphenylphosphine (83.5 mg). The reaction mixture was cooled to 0 ° C and diethyl azodicarboxylate (50 mL) was added. The reaction mixture was stirred for 5 minutes, the ice bath removed and stirred at room temperature for 2 hours. The reaction mixture was directly applied onto a silica gel column and purified (ethyl acetate: hexane (2: 3) + 1% methanol) to give the title compound (197 mg).
Partial <sup>4</sup>NMR Spectrum, (CDCl<sub>3</sub>) d: 7.29 (m, 6H); 7.18 (m,
5H) ; 7.12 (d, J=9Hz, 1H) ; 7.0 (d, J=4Hz, 1H) ; 6.89 (dd,
IB UBUI. . I II I III III
189
J=9,2Hz, 1H) ; 6.36 (t, J=4Hz, 1H) ; 4.82 (m, 4H) ; 4.40 (pld, J=14Hz, 1H) ; 4.20 (m, 4H).
EXAMPLE
17-Ethyl-1,14-ahydroxy-12- [2'- (4 '' - (1-phosphonoxyethylindol-5-yl) -oxy-3 '' - methoxycyclo-hexyl) -1'-methylvinyl] -23, 25-dimethoxy-13,19,21,27-tetramethyl-11, 28-dioxsa-4-azatriciclo- [22.3.1.O<sup>4</sup>'<sup>9</sup>] -to-18-in-2,3,10,
16- Monocalium salt of tetraon
To a solution of 17-ethyl-1,14-dihydroxy-2- [2 '(4' '- (1-dibenzylphosphatethylindol-5-yl) -oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] ] -2,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] octacos-18-ene-2,3,10,16-tetraone (197 mg) in methanol (3.2 mL), potassium bicarbonate (16.3 mg) dissolved in water (200 mL) was added. Palladium hydroxide is added to the carbon and hydrogen from the balloon is passed through the reaction mixture. When the reaction is complete (10 min by TLC), it is filtered through celite, washed with methanol and a little water. The solvent is removed in vacuo and the crude is purified on an HP-20 column. The title compound is obtained (69 mg). Partial<sup>X</sup>NMR spectrum, (CD<sub>3</sub>OD) d: 7.34 (d, J=9Hz, 1H) ;
7.27 (d, J=4Hz, 1H) ; 7.12 (d, J=2Hz, 1H) ; 6.85 (dd, J=9,2 Hz, 1H) ; 6.31 (d, J=4Hz, 1H) ; 5.23 (m, 2H) ; 4.35 (m, 2H); 4.13 (m, 2H); 4.13 (m, 2H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-N, N-dimethyl) glyyloxy) ethylindol-5-yl) -oxy-3' '- methoxycyclohexyl) - 1'-methylvinyl] -2 3,2 5-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. ON<sup>4</sup>'<sup>9</sup>] -oktakoz18- en-2,3,10,16-tetraonas
190
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (1-hydroxyethylindol-5-yl) -oxy-3' '- methoxycyclohexyl ·) -1'-methyl vinyl] -2,2,2-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (26.6 mg) in dry methylene chloride (0.3 ml) added at room temperature with N, N-dimethylglycine hydrochloride (5.8 mg), DMAP (3.4 mg) respectively. and EDC (8 mg). The reaction mixture was stirred for 4 hours, diluted with ethyl acetate and washed with a saturated solution of sodium bicarbonate and brine. The organic layer was dried over magnesium sulfate and the solvent removed in vacuo. The crude material was purified by flash chromatography (1: 2, acetone / hexane) to give 23 mg of the title compound.
Partial <sup>X</sup>NMR Spectrum, (CDCl<sub>3</sub>) d: 7.21 (m, 2H); 7.04 (d, J=4Hz,lH); 6.91 (dd, J=9, 2Hz, 1H) ; 6.49 (d, J=4 Hz, 1H) ; 4.41 (m, 2H) ; 4.32 (m, 2H); 3.07 (s, 3H); 2.26 (s, 3H) .
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-succinyloxyethylindol-5-yl) -oxy-3' '- methoxycyclo-hexyl) -1'-methylvinyl] -23. 25-dimethoxy-13,19,21,27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. ON<sup>4,9</sup>] -octakozo-18-en-2,3,10, 16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (1-hydroxyethylindol-5-yl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl-23 , 25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (109 mg) in dry methylene chloride, succinic anhydride (11.5 mg) and triethylamine (19 ml) were added. DMAP (7 mg) was then added and the reaction followed by TLC. After 1.5 hours, the reaction mixture was diluted with ethyl acetate and the pH adjusted
IBIUI II .1 1 .11.111 III
191 to 4 with IN HC1. Pour the reaction mixture into a separatory funnel and separate the layers. The aqueous layer was extracted with ethyl acetate and the combined organic layers washed with brine. The organic layer was dried over magnesium sulfate. The crude material was purified by flash chromatography (3% methanol / CH<sub>2</sub>Cl<sub>2</sub>) and 66 mg of the title compound are obtained.
Partial <sup>1</sup>NMR Spectrum, (CDCl<sub>3</sub>) d: 7.19 (m, 2H); 7.04 (d, J=4Hz, 1H) ; 6.91 (dd, J=9, 2Hz, 1H) ; 6.39 (d, J=4 Hz, 1H); 4.32 (m, 4H); 2.49 (pis, 4H) .
EXAMPLE
17-Ethyl, 14-dihydroxy-12- [2'- (4 '' - (1-methyl-3-phenylindol-5-yl) -oxy-3 '' - methoxycyclo-hexyl) -1'-methylvinyl] -23,25 -Dimethoxy-13,19,21,27-tetramethyl, 28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -oktakoz-18-en2,3,10,16-tetraonas
Step A: 5-bromo-3-phenylizatinas
To a stirred solution of 5-bromisatin (5 g,
22.1 mmol, 1 eq. In dry THF (150 mL), phenylmagnesium bromide (14.7 mL, 44.2 mmol, 2 eq., 3M in diethyl ether) was added. (Grignard reagent is started to be added at -78 ° C. The reaction mixture becomes too viscous to stir after addition of about 5 ml Grignard reagent. The cooling bath is removed and the remaining Grignard reagent is rapidly added dropwise). The reaction mixture was stirred overnight. TLC analysis indicates that small amounts of starting materials remain unreacted. another 1.5 ml of Grignard reagent is added and the reaction mixture is stirred for a further 6 hours. The reaction mixture is poured into a separatory funnel containing a saturated aqueous solution of ammonium chloride and extracted 4 times with diethyl ether. OrI U 11
192 the organic extracts are combined, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The product is used without further purification.
Step B: 5-Brom-3-phenylindole
To a stirred solution of 5-bromo-3-phenylisatin (6.39 g, 21 mmol, 1 eq.) In dry THF (50 mL) at 0 ° C was added lithium aluminum hydride (2.0 g, 52.5 mmol, 2.5 eq.) Over 1.5 h. The cooling bath is removed and stirred overnight. The mixture was cooled to 0 ° C and carefully quenched with IN aqueous HCl. The mixture was filtered through celite and the celite washed with THF. The filtrate was concentrated in vacuo, dissolved in ethyl acetate and washed with water. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo.
Step C: 5-Brom-l-methyl-3-phenylindole
To a stirred solution of 5-bromo-3-phenylindole (2.4 g, 8.78 mmol, 1 equiv) in dimethylformamide (20 mL) was added NaH (422 mg, 60% oil dispersion, 10.54 mmol,
1.2 eq.). The mixture is stirred for 15 minutes. Methyl iodide (0.6 mL, 9.66 mmol, 1.1 eq) was added via syringe and the reaction mixture was stirred for 3 h. The reaction was quenched with water and extracted 4 times with ethyl acetate. The organic layers were combined, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The product was purified by flash chromatography (2: 1 hexane / acetone) to give 1.63 g of 5-bromo-1-methyl-3-phenylindole.
Step D: Tri (methyl-3-phenylindol-5-yl) bismutinases
To a stirred solution of 5-bromo-1-methyl-3-phenylindole (1.63 g, 5.7 mmol) in ethyl ether (35 mL) under a nitrogen atmosphere was added
I · B UBUI II .1 .1 11.IK 11
193
At -78 ° C, t-butylitis (6.7 mL, 11.4 mmol, 1.7 M solution in hexane, 2 equiv.) Was added via syringe. Stir for 10 minutes at -78 ° C. A solution of bismuth trichloride (540 mg, 1.71 mmol, 0.3 equiv.) In THF (7 mL) was then added dropwise. The reaction mixture was stirred at -78 ° C for a further 10 minutes, then the cooling bath was removed and the mixture was allowed to slowly warm to room temperature. After 3 hours, the reaction mixture is poured into a separatory funnel with water and extracted 4 times with methylene chloride. The organic extracts are combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The residue is triturated with ether, and the solid is collected, washed with ether to give 710 mg of tri (1-methyl-3-phenylindol-5-yl) bismutin.
Stage E:
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-methyl-3-phenylindol-5-yl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] - 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone to a stirred solution of tri (1-methyl-3-phenylindol-5-yl) bismuthine (645 mg, 0.78 mmol, 1.2 eq.) in methylene chloride (10 ml) and THF (3 ml) were added peracetic acid (0.514 ml, 32% solution in dilute acetic acid, 0.858 mmol, 1.3 eq). The mixture is stirred for 15 minutes and then 17-ethyl-1,14-dihydroxy-12- [2 '- (4''-hydroxy-3' '-methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethyl is added. -13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4</sup>'<sup>9</sup>] -oktakoz-18-en-2,3, 10,16-tetraonas (514 mg, 0.65 mmol, 1 equiv) with Cu (OAc)<sub>2</sub> (12 mg, 0.065 mmol, 0.1 eq). Stopper the flask and stir for 48 hours. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted 4 times with methylene chloride. The organic extracts are combined, nu, ii imu. .u .ι ii .aaui
194 dried over sodium sulfate, filtered and concentrated in vacuo. The product was purified by flash chromatography on silica gel (2: 1, hexane / acetone and 3.5% methanol / methylene chloride) to give 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-methyl-). 3-phenylindol-5-yl) -oxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21,27-tatramethyl-11,2,8-dioxa-4- azatricyclo- [22.3.1.O<sup>4,9</sup>] -Octacos-18-en-2,3,10,16-tetraonas (7 4 mg).
Mass Spectrum (FAB) 1003 {M<sup>+</sup> + Li); 996 (M<sup>+</sup>). Partial<sup>1</sup>NMR Spectrum, (CDCl<sub>3</sub>, 400 MHz) d: 7.59 (s, J=7Hz, 2H) ; 7.50 (m, 1H) ; 7.41 (t, J=7Hz, 2H) ; 7.25-7.15 (m, 3H) ; 6.99 (dd, J=9Hz, J=2Hz, 1H) ; 4.57 (d, J=6Hz, 1H); 4.39 (pld, J=13Hz, 1H); 3.78 (s, 3H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-methyl-3- (2-hydroxyethyl) indol-5-yl) oxy-3' '- methoxyciclohexyl) -1' methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl, 28-dioxsa-4-azatriciclo- [22.3.1.O<sup>4,9</sup>] -oktakoz-18-en2,3,10,16-tetraonas
Stage A: 5-Bromo-3-hydroxyethylindolas
To a stirred solution of 5-bromoindole-3-acetic acid (1.9 g, 7.48 mmol, 1 equiv.) In dry THF (17 mL) at 0 ° C was added portionwise lithium aluminum hydride (570 mg, 14.96 mmol) over 30 min. , 2 eq.). The reaction mixture coagulates. THF (20 mL) was added and the cooling bath removed. The mixture is vigorously stirred. Stir overnight. The reaction is carefully quenched by addition of 1N aqueous HCl and then acidified with 2N HCl. The mixture was filtered through celite and the celite washed with THF. The filtrate was concentrated in vacuo, dissolved in ethyl acetate and washed with water. Organic
195 the layer was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. Analysis of the residue by TLC results in unreacted starting material. The residue was dissolved in diethyl ether and extracted with 0.25N aqueous NaOH. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo, 1.16 5-bromo-3-hydroxyethylindole.
Stadija B: 5-brom-3- (2-t-butildimetilsililoksi) etilindolas
To a stirred solution of 5-bromo-3-hydroxyethylindole (1.16 g, 4.83 mmol, 1 equiv.) In methylene chloride (12 mL) was added triethylamine (1.0 mL, 7.25 mmol,
1.5 ekv), o po to-t-butildimetilchlorsilanas (875 mg,
1.2 mmol, 1.2 eq.) And dimethylaminopyridine (catalytic amount). The mixture was stirred overnight, poured into a separatory funnel with water and extracted 4 times with methylene chloride. The organic extracts are combined, dried over anhydrous sodium sulfate, filtered and concentrated. 1.66 g of 5-bromo-3- (2-t-butyldimethylsilyloxy) ethylindole are obtained.
Stage C:
Brom-5-methyl-t-butildimetilsililoksi 3-2) etilindolas
To a stirred solution of 5-bromo-3- (2-t-butyldimethylsilyloxy) ethylindole (1.66 g, 4.66 mmol, 1 eq.) And DMF (15 mL) was added NaH (225 mg, 60% oil dispersion), 5.6 mmol, 1.2 equiv). After 15 minutes, iodomethane (0.320 mL, 5.13 mmol, 1.1 eq.) Was added. The mixture was stirred for 4 hours, poured into a separatory funnel with water and extracted twice with ethyl acetate. The organic extracts were combined, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Gaunama 1.49 g bromine-5-methyl-3- (2-tbutildimetilsililoksi) etilindolo.
I am going. ji .ι
H J 3.1,1
196
Stage D:
Tri- (methyl-3- (2-t-butildimetilsililoksi) etilindol-5il) bismutinas
To a stirred solution of 5-bromo-1-methyl-3- (2-t-butyldimethylsilyloxy) ethylindole (1.49 mg, 4.03 mmol, 1 equiv.) In diethyl ether (15 mL) at -78 ° C was added a syringe under nitrogen atmosphere. butylitis (4.8 mL, 8.06 mmol, 2 eq., 1.7 M in pentane). After stirring for 10 minutes at -78 ° C, a solution of bismuth trichloride (381 mg, 1.21 mmol, 0.3 equiv.) In THF (5 mL) was added rapidly via syringe. Stir for 7 minutes at -78 ° C under nitrogen. The cooling bath is removed and the mixture cools to room temperature. After 1 hour, the mixture was poured into a separatory funnel with water and extracted 4 times with methylene chloride. The organic extracts are combined, washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. 554 mg of crude product are obtained. According to<sup>1</sup>The 1 H NMR spectrum of the residue contains a 2: 1 mixture of the desired bismuthine and reduced indole. Such crude mixture is used in the subsequent reaction.
Stage E:
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1-methyl-3- (2-butyldimethylsilyloxyethyl) indol-5-yl) oxy-3' '- methoxycyclohexyl) -1' -methyl-vinyl] -2 3,2 5-dimethoxy-1,3,19,21,27-tetramethyl-1,11-28-dioxa-4-azatricyclo- [22.3.1.Q<sup>4,9</sup>] octacose-18-en-2,3,10,16-tetraonas
Peracetic acid was added to a stirred solution of tri- (1-methyl-3- (2-t-butyldimethylsilyloxyethyl) indol-5-yl) bismuthine (554 mg, crude) in methylene chloride (10 ml) and THF (3 ml). (0.120 mL, 32% solution in dilute acetic acid, 0.571 mmol). The mixture is stirred iw mm i: ι ii n, n iii
197 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '-hydroxy-3' '-methoxycyclohexyl) -i'-methyl-vinyl] -23,25-dimethoxy-13,19 , 21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4</sup>'<sup>9</sup>] -to-18-in-2,3,10,
16- tetraonas (347 mg, 0.439 mmol) ir Cu(OAc)<sub>2</sub> (24 mg, 0.13 mmol). The mixture was stirred overnight. It is then poured into a separatory funnel with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated in vacuo. The product was purified by flash chromatography on silica gel (2: 1, hexane / acetone) to give 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-methyl-3- (2-t-butyldimethylsilyloxy) ethyl) ) indol-5-yl) -oxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl] -2,25-dimethoxy-13,19,21,27-tetramethyl-1,2,8-dioxa-4-aza-tricyclo [ 22.3.1.O<sup>4,9</sup>] -octacos-18-en2,3,10,16-tetraone (200 mg, brown oil).
Stadija F:
17- Ethyl-1,4-dihydroxy-12- [2 '- (4' '- 1-methyl-3- (2-hydroxyethyl) -indol-5-yl) -oxy-3' '- methoxyciclohexyl) 1' -methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl, 28-dioxsa-4-azatriciclo- [22.3.1.O<sup>4,9</sup>] -oktakoz-18-en2,3,10,16-tetraonas
A stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-methyl-3- (2-t-butyldimethylsilyloxyethyl) indol-5-yl) -oxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl] -23,2 5-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -octacos-18-ene-2,3,10,16-tetraone (200 mg) and methylene chloride (6 mL) and methanol (6 mL), p-toluenesulfonic acid monohydrate (30 mg) was added. The reaction mixture was stirred for 3 hours. The reaction is quenched by the addition of a saturated aqueous sodium bicarbonate solution and the mixture is extracted 4 times with methylene chloride. The organic extracts are combined, dried over anhydrous sodium sulfate,
Illll .Iii uaill II, 1 I III U I .. L
198 filtered and concentrated in vacuo. The product was purified by preparative TLC on silica gel (1: 1, hexane / acetone and '7% methanol / methylene chloride) and. 17-ethyl-1,14-dihydroxy-12- [2 (4 '' - (1-methyl-3- (2-hydroxyethyl) indol-5-yl) -oxy-3 '' - methoxycyclohexyl) -1 'is obtained. -methyl-vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -Octacos-18-en-2,3,10,16-tetraonas (75 mg).
Mass Spectrum (FAB) 972 {M<sup>+</sup> + Li). Partial<sup>1</sup>NMR Spectrum, (CDCl<sub>3</sub>, 400 MHz) d: 7.17-7.13 (m, 2H) ; 6.94 (dd,
J=9Hz, J=2Hz, 1H) ; 6.88 (s, 1H) ; 4.58 (d, J=6Hz, 1H) ; 4.39 (pld, J=13Hz, 1H) ; 3.84 (t, J=6Hz, 2H) ; 3.70 (s, 3H); 2.94 (t, J=7Hz, 2H).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1,3-dimethylindol5-yl) -oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25- dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] -octakozo-18-en-2, 3,10,16-tetraonas
Stage A: 5-Bromo-3-methylindolas
To a stirred solution of 5-bromisatin (5 g,
22.1 mmol, 1 equiv. In dry THF (150 mL), inject methylmagnesium bromide (32 mL, 1.4 M in toluene, 44.2 mmol, 2 equiv.) Via syringe. After 45 minutes, TLC analysis indicates that a small amount of starting material remains unreacted. Add 3.2 ml of methylmagnesium bromide and stir for a further 1 hour. The reaction mixture was cooled to 0 ° C. Lithium aluminum hydride (1.26 g, 33.15 mmol, 1.5 eq) was added in portions. Stir for 30 minutes. The cooling bath is removed and stirred overnight. The mixture was cooled to 0 ° C and quenched by careful addition of IN HCl.
Acidified with 2N flax and stirred with aqueous HCl. Refrigerate bath for 3 hours. Filtration through celite.
liLUIII Ii ii II .1.1.111 lill
199
Celite is washed with THF. The filtrate is concentrated in vacuo. The residue was diluted with water and extracted 4 times with methylene chloride. The organic extracts were combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was applied to a silica gel glass filter pad and eluted with hexane / acetone (4: 1). The fractions containing the desired product were collected and concentrated in vacuo to give 2.85 g of 5-bromo-3-methylindole.
Stage B:
5-Brom-l, 3-dimethylindole
To a stirred solution of 5-bromo-3-methylindole (2.85 g, 13.6 mmol, 1 eq.) And DMF (35 mL) was added NaH (651 mg, 60% oil dispersion, 16.28 mmol,
1.2 eq.). After stirring for 15 minutes, iodomethane (0.930 mL, 14.93 mmol, 1.1 eq.) Was added. The mixture was stirred for 2 hours. DMF is evaporated in vacuo. The residue was diluted with water and extracted 4 times with diethyl ether. The organic extracts were combined, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. 3.04 g of 5-bromo-1,3-dimethylindole are obtained in the form of a brown oil.
Stage C: Three (1,3-dimethylindol-5-yl) bismutinas
To a stirred solution of 5-bromo-1,3-dimethylindole (3.04 g, 13.57 mmol, 1 eq.) In ethyl ether (50 mL) under nitrogen atmosphere at -78 ° C was added dropwise t-butylitis (16 mL,
27.2 mmol, 1.7 M solution in hexane, 2 equiv). Stir for 10 minutes at -78 ° C. A solution of bismuth trichloride (1.28 g, 4.07 mmol, 0.3 equiv.) In THF (17 mL) was added rapidly via syringe. The reaction mixture was stirred at -78 ° C for a further 5 minutes, then the cooling bath was removed and the mixture was allowed to slowly warm to room temperature.
200 ratifications. The reaction mixture is poured into a separatory funnel with ice water and extracted 4 times with methylene chloride. The organic extracts are combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The residue is triturated with ether and the solid is filtered off. The filtrate is concentrated in vacuo to give 1.28 g of a brown oil. According to<sup>X</sup>The 1 H NMR spectrum of the residue contains a 1: 2 mixture of the desired tri (1,3-dimethylindol-5-yl) bismutin and dimethylindole. Such crude mixture is used further in Stage D.
Stage D:
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' - (1,3-dimethylindol-5-yl) oxy-3 '' - methoxycyclohexyl) -1'-methynyl vinyl] -23,25-dimethoxy-13 , 19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4</sup>'<sup>9</sup>] -oktakaz-18-en-2,3,10,16-tetraonas
To a stirred solution of tri (1,3-dimethylindol-5-yl) -indol-5-yl) bismutin (approximately 420 mg [1.28 g of a third of bismuthine, 0.7 mmol) was taken,
1.2 eq] and methylene chloride (12 mL) and THF (4 mL) were added peracetic acid - (0.193 mL, 32% acetic acid, 0.916 mmol, 1.3 eq). To this mixture is added 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- hydroxy-3' '- methoxy-cyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13, 19,
21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] octakoz-18-en-2,3,10,16-tetraonas (464 mg, 0.59 mmol, 1 equiv) ir Cu (OAc)<sub>2</sub> (3.0 mg, 0.176 mmol, 0.3 eq). The reaction mixture was stirred for 4 days. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product is isolated and purified by flash chromatography on silica gel (2: 1, hexane / acetone and again 3.5% methanol / methylene chloride) and preparative TLC.
L min i! , ι ji .0..11 ui.
201 method (eliuojama 6 cartridge 4: 1 hexanes / acetones), gaunama 117 mg 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1,3-dimethylindol-5-yl) -oxy-3 '' -methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-ll, 28dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -to-18-in-2,3,10,
16- tetraono.
Mass Spectrum (FAB) 934 {M<sup>+</sup>). Partial<sup>X</sup>BMR spektras, (CDCI3, 400 MHz) d: 7.14-7.10 (m, 2H) ; 6.91 (dd, J=9Hz, J=2Hz, 1H) ; 6.76 (s, 1H).; 4.57 (s, J=9Hz, 1H) ; 4.39 (pld, J=13Hz, 1H) ; 3.66 (s, 3H); 2.24 (s, 3H) .
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1-benzylinaol-5-yl) -oxy-3' '-hydroxycyclohexyl) -1'-methyl-vinyl] -23,2,5-dimethoxy-13 , 19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octa-koz-18-en-2,3,10,16-tetraone r · into a stirred solution containing tri (1-benzylindol-5-yl) indol-5-yl) bismutin ^ (about 1.28 g, 1.54 mmol,
1.2 eq) and methylene chloride (9 mL) and THF (3 mL) were added peracetic acid (0.357 mL, 32% solution in dilute acetic acid, 1.60 mmol, 1.3 eq). To this mixture is added 17-ethyl-1,14-dihydroxy-12- [2 '(3' ', 4' '-dihydroxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl -11,28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4</sup>'] -octakoz-18-en-2, 3,10,16-tetraonas (1 g, 1.28 mmol, 1 eq) ir Cu (OAc)<sub>2</sub> (23 mg). The reaction mixture was stirred for 2 days. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted 4 times with methylene chloride. The organic extracts were combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The product was purified by flash chromatography on silica gel (2: 1, hexane / acetone, 3.5% methanol / 'methylene chloride) and again (2: 1 hexane / 11.0 g).
202 nas / acetonas), gaunama 25-3 mg 17-ethyl-1, 14-dihydroxy12- [2 '- (4' '- (1-benzylindol-5-yl) -oxy-3' '-hydroxycyclohexyl) -1' -methylvinyl] -23,25-dimethoxy-13,19,21,27 tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraono.
Mass Spectrum (FAB) 934 {M<sup>+</sup> + Li). Partial<sup>1</sup>NMR Spectrum, (CDCl<sub>3</sub>, 400 MHz) d: :7.30-7.05 (m, 8H) ; 6.82 (dd, J=8Hz, J=2Hz, 1H) ; 6.43 (d, J=3Hz, 1H) ; 5.27 (s, 2H) ; 4.58 (d, J=6Hz, 1H); 4.40 (pld, J=13Hz, 1H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1- (3-hydroxypropyl) indol-5-yl) -oxy-3' '- methoxyciclohexyl) -1'-methylvinyl] -2 3,25-dimethoxy-13/19, 21,2 7-tetramethyl-11, 28dioxsa-4-azatriciclo- [22.3.1.0<sup>4,9</sup>] -to-18-in-2.3,
10,16-tetraonas
Step A: 2-t-Butyldimethylsilyloxy) ethyl bromide
To a solution of 2-bromoethanol (50 g, 0.40 mol) in methylene chloride (50 mL) was added t-butyldimethylchlorosilane (63.4 g, 0.42 m), triethylamine (45.4 g, 0.45 mol) and dimethylaminopyridine (0.5 g). The mixture was stirred overnight, washed 3 times with water. The organic fraction was dried over sodium sulfate, filtered and concentrated in vacuo. 85 g of the title compound are obtained (light yellow oil).
<sup>4</sup>NMR Spectrum, (CDCl<sub>3</sub>), chemical shifts: 3.85 (t,
2H); 3.36 (t, 2H); 0.86 (s, 9H); 0.05 (s, 6H).
Step B: 1-2 (t-Butyldimethylsilyloxyethyl) -5-bromoindole
Į NaH (12 g, 0.3 mol, 60% alginate suspension) DMF suspension (200 ml) with 5-bromindolo sulphate (50 g, nu mini chirp).
203
0.255 mol) solution in DMF (300 ml). After stirring for 15 minutes at room temperature, 2-t-butyldimethylsilyl-xoxyethyl bromide (60 g, 0.255 mol, undiluted) was added and the mixture was stirred for 1 hour, then poured into a mixture of ice water and hexane. The organics were washed with water, dried over sodium sulfate, filtered, and concentrated in vacuo. The product was purified by column chromatography (silica gel, 3: 1, hexane / acetone) to give 68.6 g of the title compound (light yellow oil).
<sup>X</sup>NMR Spectrum, (CDCl<sub>3</sub>), chemical shifts: 7.72 (s,
1H) ; 7.1-7.3 (m, 3H) ; 6.4 (d, 1H) ; 4.18 (t, 2H) ; 3.86 (t, 2H); 0.8 (s, 9H); -0.18 (s, 6H).
STAGE C:
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (1- (3-t-butyldimethylsilyloxypropyl) indol-6-yl) -oxy-3 '' - methoxycyclohexyl) -1 '- methylvinyl] -23,2 5-dimethoxy-13,19,21,27 tetramethyl-11,28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] octacos-18-en-2,3,10,16-tetraone tri [1- (3-t-butyldimethylsilyloxypropyl) indol-6-yl]) bismuthine (0.917 g, crude) in methylene chloride (7 mol) at room temperature peracetic acid (0.10 mL, 32% acetic acid) and 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '-hydroxy-3' '-methoxycyclohexyl) -1'-methyl-vinyl] -2,3 were added, 25-Dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -oktakoz18- en-2-, 3, 10, 16-tetraonas (500 mg. 0.63 mmol) with Cu (OAc)<sub>2</sub> (50 mg). The mixture is stirred for 2 days. The reaction is then quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product is isolated and purified by preparative TLC .1111 HIL
204 silica gel (3: 1, hexane / acetone) to give the title compound (318 mg).
STEP D:
17-Ethyl-1,4-dihydroxy-12- [2 '(4' '- (1- (3-hydroxypropyl) -indol-6-yl) -oxy-3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,
28-dioxa-4-azatricyclo- [22.3.1.0<sup>4,9</sup>] -October-18-in-2,
3, 10, 16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (1- (3-t-butyldimethylsilyloxypropyl) indol-6-yl) oxy-3' '-methoxycyclohexyl) ) -1'-methylvinyl] -23,25-di15 methoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-en-2, 3, 10, 16tetraone (318 mg) in methylene chloride (5 mL) was added at room temperature in p-toluenesulfonic acid (25 mg) in methanol (5 mL). The reaction mixture was stirred for 3 hours. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product was purified by preparative TLC on silica gel (2: 1, hexane / acetone) to give the title compound (190 mg).
Partial <sup>4</sup>NMR Spectrum, (CDCl<sub>3</sub>, 200 MHz), chemical shifts: 7.43 (d, J = 9 Hz, 1H); 7.02 (d, J = 2 Hz, 1H);
6.98 (d, J=3Hz, 1H) ; 6.78 (dd, J=2Hz ir J=9Hz, 1H) ;
6.38 (d, J=3Hz, 1H) ; 4.20 (t, J=6.5Hz, 2H) ; 2.00 (m,
2H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- ((2' '' - (3 '' '' diethylaminopropionyloxy) ethyl) indole-5 '' '- ii) - oxy-3''LT 3533 B
205 methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-2- [2'- (4 '' - (1 '' '- (2' '' '-hydroxyethyl) indole-5' '') ) -oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo-L 22.3.1. O<sup>4,9</sup>3-N, N-Diethylaminopropionic acid hydrochloride (57 mg, 0.315 mmol) was added under nitrogen to methylene chloride (2 mL) under methylene chloride.
1.5 eq.), Dimethylaminopyridine (26 mg, 0.210 mmol, 1 eq.) And EDC (60 mg, 0.315 mmol, 1.5 eq.). The reaction mixture was stirred for 1 hour. It is then diluted with ethyl acetate, washed with 1N aqueous HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Produces gryninamas flash chromatografijos method (3: 2 hexanes / acetones) ir gaunama 194 mg 17-ethyl-l, 14-dihydroxy-12- [2 '- (4'. '- ((2' '' '- - 3' '' '' -ethylaminopropionyloxy) ethyl) indole-5 '' '- ii) -oxy-3' '- methoxycyclohexyl) 1'-methylvinyl] -23,25-dimethoxy-13, 19, 21, 27-tetramethyl-ll , coz-lS-en-2, 1079 (M<sup>+</sup> +1)
28-dioxa-4-azatricyclo- [22.3.1.O<sup>4</sup>’<sup>9</sup>] -okta3, 10, 16-tetraone. Mass spectrum (BAB)
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4 ”- ((2' '- (3'dimethylaminopropionyloxy) ethyl) indole-5' '' - ii) -oxy-3 '' methoxyciclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11, 28-dioxsa-4-azatriciclo [22.3 .1. SHE IS<sup>4,9</sup>] -oktakoz-18-en-2, 3, 10, 16-tetraonas in iii
ΙΙΒΙΙΙ. b I .1 JUinB.l
206
The title compound is obtained as in Example 54 using 3-N, N-dimethylaminopropionic acid.
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- ((2<sup>,</sup>''<sup>,</sup>-(3'<sup>,,,</sup>'aminopropionyloxy) ethyl) indole-5' '' - (ii) -oxy-3 '' - methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28- dioxa-4-azatricyclo [22.3.1. O<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
The title compound is obtained as in Example 54 using appropriately protected 3-aminopropionic acid followed by removal of the amino protecting group.
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- ((2' '' - (3 '' 'benzyloxycarbonyl-2' '' '' - benzyloxycarbonylamino-propionyloxy) ethyl) indole-5 '' - (ii) -oxy-3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27 tetramethyl-1,1, 28-dioxa-4-azatricyclo- [ 22.3.1.O<sup>4,9</sup>] octacose-18-en-2, 3,, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - hydroxyethyl) indol5 '' '- yl) - oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -October-18-in-2, 3,
10,16-Tetraone (500 mg, 0.526 mmol, 1 equiv) in methylene chloride (5 mL) under N 2 was added N-Cbz-
<td colspan="2">of aspartic acid</td><td>beta-benzyl</td><td>ester</td><td> (225</td><td>mg,</td>
<td> 0.631</td><td>mmol, 1.2 ekv),</td><td colspan="2">dimetilaminopiridinas</td><td> (64</td><td>mg,</td>
<td> 0.526</td><td>mmol, 1 equiv) ir</td><td>EDC (120 mg,</td><td> 0.631</td><td>mmol,</td><td> 1.2</td>
<td>eq).</td><td colspan="2">The reaction mixture was stirred</td><td colspan="2">2 hours.</td><td>TLC</td>
now ι.
UBU t 1 .1 I .1 I ii Π ·
207 analysis indicates that the reaction is over. The mixture was diluted with ethyl acetate, washed with IN aqueous HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The product was purified by flash chromatography (70:30 hexane / acetone) to give 687 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- ((2' '' '- (3' ''))). '' - benzyloxycarbonyl-2 '' '' '- benzyloxycarbonylamino-propionyloxy) ethyl) indol-5'-yl) oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13, 19, 21, 27tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -octakozo-18-en-2,3, 10,16-tetraonas.
EXAMPLE
17-Ethyl-1, 14-dihydroxy-12- [2'- (4 '' - ((2 '<sup>11</sup>'- (aspartyloxy) ethyl) indole-5' '' - (ii) -oxy-3 '' - methoxycyclohexyl) 1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11 , 28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] octacose-i8-en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2'- (4 '' - ((2 '' '' - (3 '' '' ') - benzyloxycarbonyl-2' '' ') 'benzyloxycarbonylamino-propionyloxy) ethyl) indole-5' '' -ii) oxy-3 '' -methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11 ,
28-dioxa-4-azatricyclo- [22.3.1.O<sup>4,9</sup>] -October-18-in-2,
3,10,16-Tetraone (125 mg, 0.093 mmol, 1 eq) in methanol (2 mL) was added palladium hydroxide on carbon (25 mg). Fill the flask with hydrogen and stir for 30 minutes. The reaction mixture was filtered through a 0.45 micron PTFE membrane and concentrated in vacuo. The product was purified by flash chromatography (100: 10: 5: 0.5 / CHCl3: MeOH: formic acid: water) to give 95 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4 ((2')). '' '- (aspartyloxy) ethyl) indole-5' '' - ii) oxy-3 '' - meI III 11 suction, ii ii ιιιι u *
208 Toxicicyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo [22.3.1. Oh<sup>4,9</sup>] -octacos-18-en-2, 3, 10, 16-tetraone. Mass Spectrum (FAB) 1067 {M<sup>T</sup>) .
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- ((2' '' '- (1' '' '' imidazolylcarbonyloxy) ethyl) indole-5 '' '- ii) - oxy-3''-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4</sup>'<sup>9</sup>] -octakozo-18-en-2, 3, 10,, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' -hydroxyethyl) indole-5 '' '-ii) - oxy-3 '' - methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -October-18-in-2, 3, 10,
16-Tetraone (1.5 g, 1.58 mmol, 1 eq) in methylene chloride (15 mL) under nitrogen was added carbonyldiimidazole (256 mg, 1.58 mmol, 1 eq). After 45 minutes, the reaction mixture was diluted with ethyl acetate, washed with IN HCl and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The residue is used without further purification.
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- ((2' '' '- (1' '' '' piperazinocarbonyloxy) ethyl) indole-5 '' '- ii) - oxy-3''-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- ((2' '' '- (1' '' '' - imidazolylcarboxylate))
209 Nyloxy) ethyl) indole-5 '' - ii) -oxy-3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27 tetramethyl-1,11, 28-dioxa-4 -azatricyclo- [22.3.1.O<sup>4,9</sup>] octacos-18-ene-2, 3, 10, 16-tetraone (100 mg, 0.096 mmol, 1 eq.) and THF (Ί mL) at room temperature under nitrogen was added piperazine (82 mg, 0-.956 mmol, 10 eq. ). The mixture is stirred for 2 hours at room temperature, stored overnight in the refrigerator and stirred for another 6 hours at room temperature. The mixture was diluted with ethyl acetate, washed with 1 N HCl, saturated sodium bicarbonate solution and brine. The product was purified by flash chromatography on silica gel (5% methanol / methylene chloride + 1% ammonium hydroxide) to give 74 mg. Mass Spectrum (FAB) 1064 {M<sup>+</sup>+l).
EXAMPLE 61
17- Ethyl-1,14-dihydroxy-12- [2 '- (4'<sup>,</sup>- (1 '' - (2 '' '' (2 '' '' '- (2' '' '-hydroxy) ethylaminocarbonyloxy) ethyl) indole-5' '' -ii) -oxy-3-methoxycyclohexyl ) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,20 dioxa-4-azatriocyclo- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (! -' '' - (2 '' '' - (1 '' '' '-imidazolecarbonyloxy)) ) ethyl) indole-5 '' '- ii) oxy-3' '- methoxycyclohexyl) 1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4 -azatricyclo- [22.3.1.O<sup>4,9</sup>] -octacos18-ene-2, 3, 10, 16-tetraone (100 mg, 0.096 mmol, eq) and THF (i mL) were added ethanolamine (29 μΐ, 0.478 mmol, 5 eq) under nitrogen at room temperature. The reaction mixture was stirred overnight. The mixture was diluted with ethyl acetate, washed with IN HCl, saturated sodium bicarbonate solution and brine. The product is purified by flash chromatography on
Illlll ii IBIU. 11 I II .1111111JK.I.
210 silica gel (45/65 acetonas hexanes) ir gaunama 50 mg 17-ethyl-l, 14-dihydroxy - 12- [2 '- (4' '- ((2' '' '- (2' '' '' hydroxy ) ethylene amine carbonyl) ethyl) indol-5 '' '- ii) oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23, 25-di5 methoxy-13, 19, 21, 27-tetramethyl-ll, 28- dioxa-4-azatricycle- [22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2,3,10,16-tetraono.
Mass Spectrum (FAB) 1061 {M<sup>+</sup>+ In); 1038 [M<sup>+</sup>+l).
62 EXAMPLE,
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - (2 '' '' - (isopropylaminocarbonyloxy) ethyl)) indole-5 '' '-ii) oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] -23,25-di15 methoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1 . SHE<sup>4,9</sup>] -octakozo-18-en-2,3, 10,16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (l' '' - (2 '' '' - (l '' '' '- imidazolyl)) carbonyl (oxyloxy) ethyl) indole-5 '' '- (ii) oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa- 4-aza-tricyclo- [22.3.1. O<sup>4,9</sup>] -octacos-18-ene-2, 3, 10, 16-tetraone (116 mg, 0.111 mmol, 1 eq.) and THF (1 mL), isopropylamine (48 μΐ, 0.555 mmol, 5) was added at room temperature under nitrogen. eq.) The reaction mixture was stirred overnight. The mixture was diluted with ethyl acetate, washed with IN HCl and brine. The product was purified by flash chromatography on silica gel (2: 3 acetone / hexane) to give 50 mg of 17-ethyl-1,14-dihydroxy-12 [2 '- (4' '- (1' '' - (2 '' '))). '- (2' '' '- (isopropylaminocarbonyloxy) ethyl) indole-5' '' - (ii) oxy-3 '' - methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13, 19, 21, 27-Tetramethyl-1, 28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] -octacos-1835 en-2,3,5,16-tetraone. Mass Spectrum (FAB) 1043 {M<sup>+</sup>+ Li).
211
17-Ethyl-1,14-dihydroxy-12-f (1 '' '' '- piperidinecarbonyl) ethyl) indol-5' '- ii) -oxy3' '- methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-ll, 28-dioxa-4-aza-tricyclo-Į 22.3.1.O<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
EXAMPLE
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2<sup>,</sup>-(4<sup>,</sup>'-(l'<sup>,,</sup>-(2'<sup>,</sup>''-(l'<sup>,,</sup>'<sup>,</sup> -imidazolylcarbonyloxy) ethyl) indole-5 '' '- (ii) oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,2S-dioxa- 4-Aza-tricyclo- [22.3.1.0 tacos-18-ene-2, 3, 10, 16-tetraone (150 mg, 0.143 mmol, 1 eq) and THF (1 mL) were added piperidine (42 mL) at room temperature under nitrogen. μΐ, 0.717 mmol, 5 eq The reaction mixture was stirred for 1 h, diluted with ethyl acetate, washed with IN HCl and brine. The product was purified by flash chromatography on silica gel (4: 1 hexane / acetone) to give 115 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '(1' '' - (2 '' ')). '- (1' '' '' - piperidine-carbonyloxy) ethyl) indole-5 '' '- ii) oxy-3' '-methoxycyclohexyl) -1'-methyl vinyl] 23,25-dimethoxy-13,19,21, 27-Tetramethyl-11,28-dioxa-4-aza-tricyclo- [22.3.10]<sup>4</sup>'<sup>9</sup>] -October-18-in-2, 3,
10, 16-tetraono.
-okMass Spectrum (FAB) 1062 (M)
An example
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (2' '' '(1' '' '' - morpholinecarbonyloxy) ethyl) indole-5 '' '- ii) oxy '' -methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] -oktakoz-18-en-2, 3, 10, 16tetraonas
111911 I.LUU. JI .1 11 J1BI1B.L
212
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - (1 '' '' '- imidazolylcarbonyloxy)) -ethyl) indole-5 '' '- ii) oxy-3' '- methoxycyclohexyl) -1' -methyl vinyl] -23,25-dimethoxy-13,19,21,
27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. SHE<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone (100 mg, 0.096 mmol, equiv.) and THF (1 mL), morpholine (42 μΐ, 0.478 mmol, equiv.) was added at room temperature under nitrogen. After 4 hours, the mixture was diluted with ethyl acetate, washed with IN HCl, saturated sodium bicarbonate solution and brine, and purified by preparative TLC on silica gel (4% methanol / methylene chloride) to give 85 mg of product. The compound was further purified by preparative TLC on silica gel (4% methanol / methylene chloride) to give 67 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 ''))). '' - (1 '' '' '- Morpholinecarbonyloxy) ethyl) indole-5' '' - ii) oxy-3 '' - methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13, 19, 21 , 27tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0].<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraono.
Mass Spectrum (FAB) 1064 {M<sup>+</sup>) .
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - (diphenylaminocarbonyloxy) ethyl) indole-5 '' '- ii) oxy -3''-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-di-. hydroxy-12- [2'- (4 '' - (1 '' '- (2' '' '-hydroxyethyl) indole-5' '' - (ii) -oxy-3 '' - methoxycyclohexyl) -1'-methyl vinyl] 23,25-Dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -October-18-in-2, 3,
UIII JI .1 11 1LII III.!.
213
10,16-Tetraone (100 mg, 0.105 mmol, 1 equiv) in methylene chloride (1 mL) under nitrogen was added diphenylcarbamyl chloride (29 mg, 0.13 mmol, 1.2 equiv), triethylamine (22 μΐ, 0.16 mmol, 1.5 equiv) and dimethylaminopyridine ( 3 mg, 0.021 mmol, 0.2 eq). The reaction mixture was stirred overnight. Diphenylcarbamyl chloride (15 mg) and triethylamine (11 μΐ) were added. After 3 hours the mixture was diluted with ethyl acetate, washed with IN aqueous HCl, water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The product was purified by preparative TLC (3% MeOH / methylene chloride) to give 50 mg of 17-ethyl-1,14-dihydroxy-12- [2 * - (4 ').<sup>T</sup>—(l’<sup>,T</sup> - (2 '' '- (diphenylaminocarbonyloxy) -ethyl) indol-5' '-yl' -oxy -3 '' -methoxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19 , 21,27tetramethyl-1,11-28-dioxa-4-aza-tricyclo- [22.3.1. Oh<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraono.
Mass Spectrum (FAB) 1046 {M<sup>+</sup>) .
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1' '- (2' '' - (diethylaminocarbonyloxy) ethyl) indole-5 '' '- ii) -oxy -3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' -hydroxyethyl) indole5 '' '- i1)) - oxy-3 '' -methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -October-18-in-2, 3,
10,16-Tetraone (100 mg, 0.105 mmol, 1 equiv) in methylene chloride (1 mL) under nitrogen was added diethylcarbamyl chloride (16 μΐ, 0.13 mmol, 1.2 equiv), tri214 ethylamine (22 μΐ, 1.5 equiv) and dimethylaminopyridine (3 mg) , 1.0 eq.). The reaction mixture was stirred overnight. The mixture is heated at reflux for 4 days. The mixture was then cooled, diluted with ethyl acetate, washed with IN aqueous HCl, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The product was purified by preparative TLC (3% MeOH / methylene chloride) to give 16 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' '- (2' '' '- ( diethylaminocarbonyloxyethyl) indole-5 '' '- (ii) -oxy-3' '- methoxycyclohexyl) -1'-methyl vinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza -tricyclo- [22.3.1 .O<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone. Mass Spectrum (FAB) 1057 {M<sup>+</sup>+ Li).
EXAMPLE
17-Ethyl-1,14-dihydroxy-12- [2 '- (4'<sup>1</sup> - (1 '' - <2 '' '' - Methanesulfonyloxyethyl) indole-5 '' - ii) -oxy-3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19 , 21,
27-tetramethyl-11,. 28-dioxa-4-aza-tricyclo [22.3.1.0<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '' - hydroxyethyl) indole 5 '' '- ii) - oxy-3 '' -methoxycyclohexyl) -1 '' - methylvinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0.<sup>4,9</sup>] -October-18-in-2, 3,
10,16-Tetraone (500 mg, 0.526 mmol, 1 equiv) in methylene chloride (20 mL) under nitrogen was added triethylamine (147 μΐ, 1.053 mmol, 2 equiv) at 0 ° C followed by methanesulfonyl chloride (54 μΐ, 0.579 mmol, Eq. The reaction mixture is stirred for 10 minutes and the cooling bath is removed. The reaction mixture was stirred at room temperature for 3 hours. The mixture is kept in the refrigerator too
IUI
215 at night. The solvent is removed in vacuo. The product is used without further purification.
EXAMPLE
17-Ethyl-l, 14-dihydroxy-12- [2 '- (4' '- (l'<sup>,,</sup>- (2 '' '- azido-ethyl) indol-5' '' - ii) -oxy-3 '' - methoxycyclohexyl) -1'methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27- tetramethyl, 28-dioxa-4-aza-tricyclo- [22.3.1.O<sup>4,9</sup>] -oktakoz-18en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' '' - (2 '' '))<sup>1</sup>-methanesulfonyloxyethyl) -indole-5 '' '- (ii) -oxy-3' '-methoxycyclohexyl) -1<sup>1</sup> methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl, 28-dioxa-4-aza-tricyclo- [22.3.1.O<sup>4,9</sup>] -octacos-18en-2, 3, 10, 16-tetraone (0.526 mmol, 1 eq.) and DMF (10 mL) under a nitrogen atmosphere were added sodium azide (171 mg, 2.63 mmol, 5 eq.). The reaction mixture was heated at 60 ° C for 2 hours. The solvent is removed in vacuo. The residue was diluted with ethyl acetate and washed with brine. The aqueous layer was extracted 3 times with ethyl acetate. The organic extract is dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The product was purified by flash chromatography on silica gel (2: 1 hexane / acetone) to give 310 mg of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '(1' '' - (2 ''))).<sup>T</sup>'-azidoethyl) indole-5' '' - ii) -oxy-3 '' - methoxycyclohexyl) -1 '-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa -4-aza-tricyclo [22.3.1. ON<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraono.
Mass Spectrum (FAB) 975 {M<sup>+</sup>) .
IU III UUIIE JI .1 IJ u. nu
216
EXAMPLE *
17-Ethyl-1,4-dihydroxy-12- [2'- (4 '' - (1 '' '- (2' '' - amino-ethyl) indol-5 '' '- yl) -oxy- 3 '' - methoxycyclohexyl) -1 'methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl, 28-dioxa-4-aza-tricyclo- [22.3.1. Oh<sup>4,9</sup>] -oktakoz-18-en2, 3, 10, 16 tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (4' '- (1' - (2 '' '' - azido-ethyl) indole-5 '' '-ii) - oxy-3 '' -methoxycyclohexyl) -1'-methylvinyl] 23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1.0]<sup>4</sup>'<sup>9</sup>] -October-18-in-2, 3,
10,16-Tetraone (260 mg, 0.27 mmol, 1 eq.) And THF (6 mL) were added water (7 drops) followed by triphenylphosphine (87 mg, 0.33 mmol, 1.25 eq.). The reaction mixture was stirred at room temperature for 16 hours. The solvent is removed in vacuo. The product was purified by flash chromatography on silica gel (10% MeOH / methylene chloride) to give 227 mg of 17-ethyl-1,14-dihydroxy-12 '- [2' - (4 '\ - (l' '' - (2 '' '')). -aminoethyl) indole-5 '' '- (ii) -oxy-3' '-methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,19,21,27-tetramethyl-11,28 -dioxa-4-azatricyclo-22.3.1.0<sup>4,9</sup>] -octacos-18-en-2, 3, 10, 16-tetraone. Mass Spectrum (FAB) 956 {M<sup>+</sup> + Li).
exampleSt
17-Ethyl-1 ,. 14-dihydroxy-12- [2 '- (4' '- (1' '-t-butyldimethylsilyloxyethoxyethyl) indol-5' '- ii) -oxy-3' '- methoxy-cyclohexyl) -1'-methylvinyl ] -23, 25-dimethoxy-13, 19, 21, 27 + tetramethyl-11,18-dioxa-4-aza-tricyclo [22.3.1.0<sup>4</sup>'·<sup>9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of tri [1- (2-t-butyldimethylsilyloxyethoxyethyl) indol-5-yl) -indol-5-yl] bismuthine (360 mg, 0.31 mmol) and methylene chloride (3 mL) ) at -177 bar, add peracetic acid (0.05 mL,% solution in acetic acid) and add 17-ethyl-1,14-dihydroxy-12- [2 '- (3' ') to the mixture after 10 minutes.
4 '' - Dihydroxycyclohexy) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-1,11, 28-dioxa-4-azatricyclo- [22.3.1. Oh<sup>4,9</sup>] -oktakoz-18-en-2, 3, 10, 16-tetLT 3533 B ir Cu (OAc)<sub>2</sub> (20 mg). hours. Reaction of suraone (200 mg, 0.25 mmol)
The reaction mixture was stirred for 18 h by the addition of a saturated sodium bicarbonate solution and the mixture was extracted with methylene chloride. The organic extracts were combined, dried over sodium sulfate, filtered and concentrated in vacuo. The product is isolated and purified by preparative silica gel (3: 1, hexane / acetone),
TLC gives 120 mg of the title compound (dark oil)
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (4' '- (1' '- hydroxyethoxythioindol-5' '-ii) -oxy-3' '- methoxycyclohexyl) 1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-11,18-dioxa-4-aza-tricyclo-<sup>r</sup>L 22.3.1. O<sup>4,9</sup>] -octakozo-18-en-2, 3, 10, 16-tetraonas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (tert -butyldimethylsilyloxyethoxyethylindole-5' '' ii) -oxy-3 '' - methoxycyclohexyl) -1 ' -methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo [22.3.1.0<sup>4</sup>'<sup>9</sup>] -octacos-18-en-2, 3, 10, 16tetraone (120 mg) in methylene chloride (3 mL) was added at room temperature in p-toluenesulfonic acid (20 mg) in methanol (3 mL). The reaction mixture was stirred for 3 hours. The reaction is quenched by the addition of a saturated sodium bicarbonate solution and the mixture is extracted with methylene chloride. The extracts were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The product is purified by preparative TLC on silicate 3533 B
218 of silica gel (2: 1, hexane / acetone) to give the title compound (51 mg). Partial<sup>1</sup>NMR Spectrum, (CDCl<sub>3</sub>, 200 MHz), cheminiai poslinkiai: 7.19 (d, J=9Hz, 1H); 7.17 (d, J=2 Hz, 1H); 7.08 (d, J=3.5 Hz, 1H); 6.89 (dd, J=2Hz ir J=9Hz, 1H); 6.34 (d, J=3.5 Hz, 1H) ; 4.22 (t, J=5Hz, 2H) ; 3.73 (t., J=5Hz, 2H) ; 3.57 (t, J=5Hz,
2H); 3.39 (t, J=5Hz, 2H).
EXAMPLE
17-Ethyl-1,4-dihydroxy-12- [2 '- (3' '- methoxy-4' '- (1' '' (1 '' '- oxoprop-3' '' - ii) indole -5 '' '- ii) oxycyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-1,3, 19, 21, 27 tetramethyl-1,11, 28-dioxa-4-aza-tricyclo- [22.3.1.O<sup>4,9</sup>] octacose-18-e n-2, 3, 10, 16-tetronas
To a solution of 17-ethyl-1,14-dihydroxy-12- [2 '(4' '- (1' '' - (3 '' '' -hydroxypropyl) -indol-5 '' '-yl)) -oxy3 '' -methoxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [22.3.1. O<sup>4,9</sup>] -octacos-18-en-2, 3, 10, 16-tetraone (700 mg, 0.726 mmol) and methylene chloride (25 mL), DMSO (2 mL) and diisopropylethylamine (3.7 mL) were added followed by pyridine and sulfur. trioxide complex (650 mg, 4.1 mmol). The mixture was stirred for 20 minutes, then poured into a saturated sodium bicarbonate solution and then extracted with methylene chloride, dried over sodium sulfate, filtered and concentrated in vacuo. The product was purified by column chromatography on silica gel (4: 1, hexane / acetone) to give the title compound (457 mg).
Partial <sup>X</sup>NMR Spectrum, (CDCl<sub>3</sub>, 200 MHz), chemical shifts: 9.77 (s, 1H); 7.19 (d, J = 2 Hz, 1H); 7.15 (d,
J=9 Hz, 1H); 7.04 (d, J=3.5 Hz, 1H); 6.89 (dd, J=2Hz ir
J=9Hz, 1H) ; 6.33 (d, J=3.5 Hz, 1H) ; 4.39 (t, J=5Hz,
2H); 2.94 (t, J=5Hz, 2H).
111110.1
I, VIII. !! .1 II: 1.111111 UIS
219
EXAMPLE
17-Ethyl-1, 14-dihydroxy-12- [2 '- (3' '- methoxy-4' '- (1' '' (1 '' '' - carboxyeth-2 '' '- ii) indole -5 '' '- ii) oxycyclohexyl) -1' -methylvinyl] -23, 25-dimethoxy-1,3, 19, 21, 27 tetramethyl-1,1, 28-dioxa-4-aza-tricyclo- [22.3.1.O<sup>4,9</sup>] octacose-18-en-2, 3, 10, 16-tetraonas
To a stirred solution of 17-ethyl-1,14-dihydroxy-12- [2 '- (3 *' - methoxy-4 '' - (1 '' '- (1' '' '- oxoprop3' '')) '-ii) -indole-5' '' - (ii) oxycyclohexyl) -1'-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo [ 22.3.1.O<sup>4,9</sup>] -October-18-in-2, 3,
10, 16-Tetraone (100 mg), 5-Bromoindole (300 mg) and 2-methyl-2-butene (0.80 mL) in t-butanol (4 mL), a solution of sodium chloride (15 mg) and sodium dihydrogen phosphate (15 mg) were added. ) solution in water (0.15 mL). The reaction mixture was stirred for 0.5 h then concentrated in vacuo. The residue is poured into 10 ml of water containing two drops of 2N HCl and diethyl ether.
The organic extract was dried over sodium sulfate, filtered, and concentrated in vacuo. The product was purified by preparative TLC (2X): initially 2: 1 hexane / acetone followed by 7% methanol in methylene chloride and flash chromatography on C<sub>18</sub> columns with 60% acetonitrile in water. 11 mg of the title compound are obtained. Mass Spectrum (FAB) 1001 {M<sup>+</sup> + Na).
Using the general procedures described in Examples 1-73, the following compounds of formula I (where R<sup>4</sup> is hydrogen, R<sup>5</sup> is methyl, ethyl, propyl, or allyl; R<sup>10</sup> is hydrogen and n = 2).
220
EXAMPLE NO. R<sup>1</sup>
R'
R<sup>5</sup>
<img file="LT3533B_D0059.tif" />
OH
OH
OH
CHjCHj
CH<sub>3</sub>CH<sub>2</sub>
CKjCHj
<img file="LT3533B_D0060.tif" />
OH
OH
OH
OH
<img file="LT3533B_D0061.tif" />
6h<sub>3</sub>
C H,
OH
ČH,
CHjCfį
CKjCHj
CH<sub>3</sub>CH<sub>2</sub> ch<sub>3</sub>ch<sub>2</sub>
CH<sub>3</sub>CHJ
CHjCHj
I IBIltl Ι.Ι · 11ί H .1 II 9111: 1 IU,
221
EXAMPLE
T-Cell proliferation test
1. Sample preparation
Test compounds are dissolved in absolute alcohol. Concentration of 1 mg / ml.
2. Test
The spleen of mouse C57B1 / 6 is sterile isolated and carefully dissociated in chilled to 0 ° C in RPMI 1640 culture medium (GIBC), Grand Island, NY) containing 10% heat-treated calf embryo serum (GIBO). Cells are tabletted by centrifugation at 1500 rpm for 8 minutes. Adipose red cells are removed by exposure to the tablet in ammonium chloride lysis buffer (GIBO) for 2 minutes at 4 ° C. Chilled medium is added and the cells are centrifuged again at 1500 rpm for 8 minutes. T-lymphocytes are isolated by passing a cell suspension through a nylon fiber column as follows: Prepare a nylon fiber column by washing with a 20 ml plastic syringe and rinsing the nylon fiber. The columns are sterilized by autoclaving for 30 minutes at 25 ° F. Nylon fiber columns are moistened with warm (37 ° C) culture medium and washed with the same medium. The washed spleen cells are resuspended in warmed medium and slowly applied to the column. The columns are then incubated for 1 hour at 37 ° C in an upright position. Unabsorbed T-lymphocytes are eluted from the columns by treatment with warmed culture medium and the cell suspension is centrifuged as described above.
Purified T - lymphocytes are resuspended (2.5 χ 10<sup>5 </sup>cells / ml) in complete culture medium consisting of RPMI 1640 medium with 10% heat inactivated
UII įaugi ii ι i ... uju ji. j.
222 calf embryo serum, 100 mM glutamine, 1 mM sodium pyruvate, 2 x 10 <sup>5</sup> M 2-mercaptoethanol and 50 µg / ml gentamicin. Ionomycin (250 ng / ml) and PMA 10 ng / ml are added. The cell suspension is then dispensed into 96-well flat-bottom microtiter plates (Kostar), 200 μΐ / well. Test compounds are dispensed at 20 μΐ in wells with three replicates at various dilutions. 17-allyl-1, 14 dihydroxy-12-Γ 2 '- (4' '- hydroxy-3' '- methoxy-cyclohexyl) -1'-methylvinyl] -23, 25-dimethoxy-13, 19, 21 is standard , 27tetramethyl-11,18-dioxa-4-aza-tricyclo- [22.3.1.O<sup>4,9</sup>] octacos-18-en-2, 3, 10, 16-tetraone. The plates are incubated with the cultures for 44 hours at 37 ° C in a humidified atmosphere consisting of 5
COir air. T-Lymphocyte Proliferation was assessed by measuring the uptake of tritium-labeled trimide. After 44 hours, cells were pulsed-labeled with 2 micro-wells of tritiated thymidine (NEN, Cambridge, MA). After a further 4 hours of incubation, cultures are harvested on glass fiber filters using a sample multisector. The radioactivity of the filter disks corresponding to individual wells is measured by standard liquid scintillation techniques (beta-counter). The average number of scintillations per minute per well replicate is calculated and expressed as the concentration of compound required to inhibit the uptake of tritiated thymidine by 50% by T cells.
A number of compounds were tested according to the presented methodology. T-cell proliferation by the above assay was inhibited by the compounds shown in the following
<td>Black, Russian</td><td>boxes</td><td>pava</td><td>Ldin</td><td>in the samples:</td><td> 1,</td>
<td>n,</td><td> 12,</td><td> 13,</td><td> 14,</td><td> 15, 16,</td><td> 17</td>
<td> 31,</td><td> 32,</td><td> 33,</td><td> 34,</td><td> 35, 37,</td><td> 39</td>
<td> 51,</td><td> 52,</td><td> 53,</td><td> 54,</td><td> 57, 58,</td><td> 60</td>
<td> 71,</td><td> 72</td><td>and 73</td><td></td><td></td><td></td>
<td> 3,</td><td> 4,</td><td> 5,</td><td> 6, 7, 8,</td><td> 9,</td><td> 10</td>
<td> 18,</td><td> 19,</td><td> 20,</td><td> 21, 23,</td><td> 26,</td><td> 28</td>
<td> 42,</td><td> 44,</td><td> 46,</td><td> 47, 48,</td><td> 49,</td><td> 50</td>
<td> 61,</td><td> 62,</td><td> 63,</td><td> 64, 65,</td><td> 66,</td><td> 69</td>
UI!
223
The results of this assay reliably demonstrate the immunosuppressive activity of the compounds of the present invention.
To determine antagonistic activity, the above procedure is modified as follows: Dilutions of compounds are incubated. with 17-allyl-1,14-dihydroxy-12 [2'- (4 '' -hydroxy-3 '' -methoxycyclohexyl) -1'-methyl-vinyl] -23,25-dimethoxy-13,19,21,27- tetramethyl-11,28-dioxa-4-aza-tricyclo- [22.3.1.0<sup>4,9</sup>] -oktakoz-16-en-2, 3, 10, 16-tetraone (standard) at a concentration of
1.2 nM, a concentration that 100% inhibits T cell proliferation. The concentration of the compound at which the inhibition caused by the standard itself is reduced by 50% is measured and the ED is determined<sub>50</sub> meaning.
As the foregoing description illustrates the principles of the present invention with the examples provided by way of illustration, it is understood that the practice of the invention includes all possible variations, adaptations, modifications, deletions, or appendices to the methodologies or protocols described herein.
Contents182
61 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61
Every citation, both waysCites: the store holds 19 of 20
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP0184162A2 | Cites | European Patent Office (EPO) | Applicant |
| EP0315978A2 | Cites | European Patent Office (EPO) | Applicant |
| EP0323042A1 | Cites | European Patent Office (EPO) | Applicant |
| EP0356399A2 | Cites | European Patent Office (EPO) | Applicant |
| EP0423714A2 | Cites | European Patent Office (EPO) | Applicant |
| EP0428365A1 | Cites | European Patent Office (EPO) | Applicant |
| EP0437680A2 | Cites | European Patent Office (EPO) | Applicant |
| GB2245891A | Cites | United Kingdom | Applicant |
| GB2247620A | Cites | United Kingdom | Applicant |
| US4894366A | Cites | United States of America | Applicant |
| US4929611A | Cites | United States of America | Applicant |
| US4956352A | Cites | United States of America | Applicant |
| US5110811A | Cites | United States of America | Applicant |
| WO8905304A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO9014826A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO9104025A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO9117754A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| WO9119495A1 | Cites | World Intellectual Property Organization (WIPO) | Applicant |
| JPS6317884A | Cites | Japan | Applicant |
| HIROKAZU TANAKA ET AL.: "Structure of FK506, a novel immunosuppressant isolated from Streptomyces", J. AM. CHEM. SOC., 1987, pages 5031, XP001098103, DOI: doi:10.1021/ja00250a050 | Non-patent | – | Applicant |
| KINO T ET AL.: "FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics", J ANTIBIOT, 1987, pages 1249 | Non-patent | – | Applicant |
| TODD K. JONES ET AL.: "Total synthesis of immunosuppressant (-)-FK-506", J. AM. CHEM. SOC, 1989, pages 1157 | Non-patent | – | Applicant |
| ARITA C ET AL.: "Inhibition by FK506 of established lesions of collagen-induced arthritis in rats", CLIN EXP IMMUNOL., 1990, pages 456 - 461, XP000904902 | Non-patent | – | Applicant |
| INAMURA N, HASHIMOTO M, NAKAHARA K, AOKI H, Y: "Immunosuppressive effect of FK506 on collagen-induced arthritis in rats", CLIN IMMUNOL IMMUNOPATHOL., 1988, pages 82 - 90, XP026197664, DOI: doi:10.1016/0090-1229(88)90008-6 | Non-patent | – | Applicant |
| KAWASHIMA H, FUJINO Y, MOCHIZUKI M.: "Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats", INVEST OPHTHALMOL VIS SCI., 1988, pages 1265 - 1271, XP000856700 | Non-patent | – | Applicant |
| SAKR MF ET AL.: "FK 506 ameliorates the hepatic injury associated with ischemia", LIFE SCI., 1990, pages 687 - 691, XP025566971, DOI: doi:10.1016/0024-3205(90)90623-Y | Non-patent | – | Applicant |
| K. DEGUCHI ET AL.: "Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis", BRAIN AND NERVE, 1990, pages 391 - 397 | Non-patent | – | Applicant |
| MCCAULEY J, TZAKIS AG, FUNG JJ, TODO S, STARZ: "FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood", LANCET., 1990, pages 674 | Non-patent | – | Applicant |
| TAKABAYASHI K. ET AL.: "Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus", CLIN IMMUNOL IMMUNOPATHOL., 1989, pages 110 - 117, XP026189728, DOI: doi:10.1016/0090-1229(89)90211-0 | Non-patent | – | Applicant |
| NAITO M, OH-HARA T, YAMAZAKI A, DANKI T, TSUR: "Reversal of multidrug resistance by an immunosuppressive agent FK-506", CANCER CHEMOTHER PHARMACOL., 1992, pages 195 - 200 | Non-patent | – | Applicant |
34 members in 23 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 75694691 | United States of America | A | |
| 75694691 | United States of America | A | |
| 921851 | – | – | – |
| US19910756946 | – | – | – |
Members34
| Document | Office | Kind | |
|---|---|---|---|
| IL103009D0 | Israel | D0 | |
| CA2077331A1 | Canada | A1 | |
| AU2282992A | Australia | A | |
| EP0532088A1 | European Patent Office (EPO) | A1 | |
| WO9305058A1 | World Intellectual Property Organization (WIPO) | A1 | |
| MX9205137A | Mexico | A | |
| KR930006030A | Republic of Korea | A | |
| ZA926812B | South Africa | B | |
| CN1073443A | China | A | |
| US5252732A | United States of America | A | |
| NO940805D0 | Norway | D0 | |
| AU647665B2 | Australia | B2 | |
| JPH06116274A | Japan | A | |
| FI941085A | Finland | A | |
| FI941085A7 | Finland | A7 | |
| FI941085L | Finland | L | |
| NO940805L | Norway | L | |
| HU9400686D0 | Hungary | D0 | |
| SK26094A3 | Slovakia | A3 | |
| CZ53194A3 | Czechia | A3 | |
| US5349061A | United States of America | A | |
| LTIP495A | Lithuania | A | |
| HUT66855A | Hungary | A | |
| BG98639A | Bulgaria | A | |
| NZ244153A | New Zealand | A | |
| LT3533BThis record | Lithuania | B | |
| YU89792A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| JPH0813819B2 | Japan | B2 | |
| EP0532088B1 | European Patent Office (EPO) | B1 | |
| AT145915T | Austria | T | |
| ATE145915T1 | Austria | T1 | |
| DE69215615D1 | Germany | D1 | |
| DE69215615T2 | Germany | T2 | |
| RO114331B1 | Romania | B1 |
2 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Lapsed patentsLapsedMM9A | MM9A | |
| Rectifications: patents6. JUNGINYS, KURIS PARINKTAS IS GRUPES, KURIOJE YRA:17-ETIL-1,14-DIHIDROKSI-12--2'-(4''-(2-FURANIL)METOKSI-3''-METOKSICIKLOHEKSIL)-1'-METILVINIL -23,25-DIMETOKSI-13,19,21,27-TETRAMETIL-11,28-DIOKSA-4-AZATRICIKLO--22.3.1.04,9 OKTAKOZ-18-EN-2,3,10,16-TETRAONAS;17-ETIL-1,14-DIHIDROKSI-12--2'-(4''-(2-FURANIL)METOKSI-3''-HIDROKSICIKLOHEKSIL)-1'-METILVINIL -23,25-DIMETOKSI-13,19,21,27-TETRAMETIL-11,28-DIOKSA-4-AZATRICIKLO--22.3.1.04,9 OKTAKOZ-18-EN-2,3,10,16-TETRAONAS;17-ETIL-1,14-DIHIDROKSI-12--2'-(4''-HIDROKSI-3''-(2-FURANIL)-METOKSICIKLTK9A | TK9A |
Numbers
- Publication, DOCDB
- 3533
- Publication, EPODOC
- LT3533
- Application
- 495
- Application, DOCDB
- IP495
- Application, EPODOC
- LTIP495
Titles
- English
- O-HEYTEROARYL, O-ALKYLHETEROARYL, O-ALKENYLHETEROARYL AND O-ALKYNYLHETEROARYL MACROLIDES
Classification
- IPC, 2
- C07D
- C07D491 12
